BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adult cns tumor 2005:2010[pubdate] *count=100
514 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adult cns tumor
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 514
1.
Veselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T, Relichova J:
Nestin expression in the cell lines derived from glioblastoma multiforme.
BMC Cancer
; 2006;6:32
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Nestin is a protein belonging to class VI of intermediate filaments that is produced in stem/progenitor cells in the mammalian
CNS
during development and is consecutively replaced by other intermediate filament proteins (neurofilaments, GFAP).
Down-regulated nestin may be re-expressed in the
adult
organism under certain pathological conditions (brain injury, ischemia, inflammation, neoplastic transformation).
Our work focused on a detailed study of the nestin cytoskeleton in cell lines derived from glioblastoma multiforme, because re-expression of nestin together with down-regulation of GFAP has been previously reported in this type of brain
tumor
.
METHODS: Two cell lines were derived from the
tumor
tissue of patients treated for glioblastoma multiforme.
CONCLUSION: Detailed information concerning the pattern of the nestin cytoskeleton in glioblastoma cell lines and especially the demonstration of nestin in the nucleus represent an important background for further studies of nestin re-expression in relationship to
tumor
malignancy and invasive potential.
[MeSH-minor]
Cell Line,
Tumor
. Cytoskeleton / chemistry. Cytoskeleton / ultrastructure. Fluorescent Antibody Technique, Indirect. Glial Fibrillary Acidic Protein / analysis. Humans. Nestin. Vimentin / analysis
Genetic Alliance.
consumer health - Glioblastoma
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):503-15
[
10571412.001
]
[Cites]
Exp Cell Res. 2003 Apr 1;284(2):185-95
[
12651152.001
]
[Cites]
Exp Cell Res. 2000 Feb 1;254(2):269-78
[
10640425.001
]
[Cites]
Mol Biol Cell. 2003 Apr;14(4):1468-78
[
12686602.001
]
[Cites]
Mol Cell Biol. 2003 Jul;23(14):5090-106
[
12832492.001
]
[Cites]
Neoplasia. 2003 Nov-Dec;5(6):520-32
[
14965445.001
]
[Cites]
Exp Mol Med. 2004 Feb 29;36(1):52-6
[
15031671.001
]
[Cites]
J Biol Chem. 2004 Jul 2;279(27):27994-9
[
15117961.001
]
[Cites]
J Neurosci. 1985 Dec;5(12):3310-28
[
4078630.001
]
[Cites]
Cell. 1990 Feb 23;60(4):585-95
[
1689217.001
]
[Cites]
Lab Invest. 1992 Mar;66(3):303-13
[
1538585.001
]
[Cites]
Cancer Res. 1992 Oct 1;52(19):5334-41
[
1382841.001
]
[Cites]
J Cell Sci. 1992 Oct;103 ( Pt 2):589-97
[
1478958.001
]
[Cites]
Cancer Res. 1994 Jan 15;54(2):354-6
[
8275467.001
]
[Cites]
Exp Cell Res. 1994 Oct;214(2):447-58
[
7925640.001
]
[Cites]
Neuron. 1994 Nov;13(5):1071-82
[
7946346.001
]
[Cites]
Brain Res Dev Brain Res. 1995 Jan 14;84(1):109-29
[
7720210.001
]
[Cites]
Lab Invest. 1996 Jan;74(1):188-98
[
8569181.001
]
[Cites]
Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):913-25
[
9353831.001
]
[Cites]
J Struct Biol. 1997 Oct;120(1):61-8
[
9356292.001
]
[Cites]
Pediatr Res. 1998 Mar;43(3):386-92
[
9505279.001
]
[Cites]
Exp Cell Res. 1998 Mar 15;239(2):332-43
[
9521851.001
]
[Cites]
Am J Pathol. 1998 Oct;153(4):1157-68
[
9777947.001
]
[Cites]
J Biol Chem. 1999 Aug 20;274(34):23996-4006
[
10446168.001
]
[Cites]
Histol Histopathol. 2005 Apr;20(2):665-71
[
15736068.001
]
[Cites]
J Cell Sci. 1998 Dec 18;111 ( Pt 24):3573-84
[
9819349.001
]
[Cites]
Curr Opin Cell Biol. 2000 Feb;12(1):79-90
[
10679360.001
]
[Cites]
Exp Neurol. 2000 Feb;161(2):585-96
[
10686078.001
]
[Cites]
Int J Dev Neurosci. 2001 Feb;19(1):101-8
[
11226759.001
]
[Cites]
Am J Pathol. 2001 Mar;158(3):817-23
[
11238030.001
]
[Cites]
J Biol Chem. 2001 May 11;276(19):16456-63
[
11278541.001
]
[Cites]
J Neurosci. 2001 Aug 15;21(16):6147-58
[
11487638.001
]
[Cites]
Stem Cells. 2001;19(5):419-24
[
11553850.001
]
[Cites]
J Histochem Cytochem. 2002 Feb;50(2):147-58
[
11799134.001
]
[Cites]
Exp Neurol. 2002 Mar;174(1):89-95
[
11869037.001
]
[Cites]
Lab Invest. 2002 Mar;82(3):345-51
[
11896213.001
]
[Cites]
Brain Res. 2002 Jul 12;943(2):174-80
[
12101039.001
]
[Cites]
APMIS. 2002 Jun;110(6):499-507
[
12193211.001
]
[Cites]
Cancer. 2002 Aug 1;95(3):641-55
[
12209758.001
]
[Cites]
Int J Oncol. 2002 Oct;21(4):775-85
[
12239616.001
]
[Cites]
Neurosci Res. 2002 Oct;44(2):207-12
[
12354635.001
]
[Cites]
Exp Neurol. 1999 Dec;160(2):348-60
[
10619552.001
]
(PMID = 16457706.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Vimentin
[Other-IDs]
NLM/ PMC1403792
2.
Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, Sugie C, Nomoto Y, Mimura M:
CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.
Int J Radiat Oncol Biol Phys
; 2005 Jul 1;62(3):803-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CNS
germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.
PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in
central nervous system
germinoma remains controversial.
METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with
central nervous system
germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002.
The proportion of HCG-producing
tumors
was higher in the lesions at the basal ganglia than in the lesions at the other sites.
No correlation was found between
tumor
size and HCG level, but there seemed to be a weak correlation between size and beta-HCG.
Also, no other patient-,
tumor
-, or treatment-related factors seemed to influence the prognosis of the patients.
Relationship between
tumor
size and site and HCG level should be investigated further.
[MeSH-major]
Central Nervous System Neoplasms
/ blood. Chorionic Gonadotropin / blood. Germinoma / blood.
Neoplasm
Proteins / blood
[MeSH-minor]
Adolescent.
Adult
. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome
Genetic Alliance.
consumer health - Germinoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15936563.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
3.
Moise D, Madhusoodanan S:
Psychiatric symptoms associated with brain tumors: a clinical enigma.
CNS Spectr
; 2006 Jan;11(1):28-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Psychiatric symptoms associated with brain
tumors
: a clinical enigma.
Patients in psychiatric settings may present with medical conditions, such as brain
tumors
, which may or may not be associated with neurological symptoms.
Brain
tumors
may be detected in patients at their first presentation to mental health services or sometimes in patients with well-established psychiatric diagnoses.
Brain imaging showed the presence of a left thalamic
tumor
, later confirmed as glioblastoma multiforme.
With this we show that in some cases, brain
tumors
can be neurologically silent and only present atypical psychiatric symptoms.
[MeSH-major]
Brain
Neoplasms
/ complications. Depressive Disorder, Major / etiology. Stress Disorders, Post-Traumatic / etiology
[MeSH-minor]
Adult
. Female. Functional Laterality. Humans. Severity of Illness Index. Thalamus / surgery
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Post-Traumatic Stress Disorder
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16400253.001).
[ISSN]
1092-8529
[Journal-full-title]
CNS spectrums
[ISO-abbreviation]
CNS Spectr
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
Advertisement
4.
Yasuda K, Taguchi H, Sawamura Y, Ikeda J, Aoyama H, Fujieda K, Ishii N, Kashiwamura M, Iwasaki Y, Shirato H:
Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Jpn J Clin Oncol
; 2008 Jul;38(7):486-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal
tumors
in
the central nervous system
.
OBJECTIVE: The current study was conducted to evaluate the effects of low-dose craniospinal irradiation (CSI) combined with chemotherapy on non-metastatic embryonal
tumors
in
the central nervous system
(
CNS
), including medulloblastoma and supra-tentorial primitive neuroectodermal
tumors
(ST-PNET).
The dose to the primary
tumor
bed was 39.6-54 Gy.
CONCLUSION: Low-dose CSI and ICE chemotherapy may have a role as a treatment option for a subset of patients with non-metastatic embryonal
tumors
in the
CNS
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain
Neoplasms
/ therapy. Cranial Irradiation. Medulloblastoma / therapy. Neuroectodermal
Tumors
, Primitive / therapy
[MeSH-minor]
Adolescent.
Adult
. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Male. Radiotherapy Dosage. Supratentorial
Neoplasms
/ pathology. Supratentorial
Neoplasms
/ therapy. Survival Analysis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
IFOSFAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18573848.001).
[ISSN]
1465-3621
[Journal-full-title]
Japanese journal of clinical oncology
[ISO-abbreviation]
Jpn. J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
5.
Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM:
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.
J Clin Oncol
; 2005 Apr 1;23(10):2233-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary
CNS
lymphoma of T-cell origin: a descriptive analysis from the international primary
CNS
lymphoma collaborative group.
PURPOSE: To describe the demographic and
tumor
related characteristics and outcomes for patients with primary T-cell
CNS
lymphoma (TPCNSL).
Univariate and multivariate analyses were conducted for age (</= 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the
CNS
(no v yes), and methotrexate (MTX) use in the primary treatment (yes v no).
[MeSH-major]
Central Nervous System Neoplasms
/ pathology. Lymphoma, T-Cell / pathology
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Cohort Studies. Female. Health Status. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15800313.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
6.
Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME:
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
J Clin Oncol
; 2007 Feb 1;25(4):399-404
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain
tumor
therapy
CNS
consortium trial.
PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain
tumors
, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
Tumor
samples were evaluated for AGT levels.
Future trials are required to determine if the inhibition of
tumor
AGT levels results in increased efficacy.
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
Carmustine
.
Hazardous Substances Data Bank.
GUANINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 2000 Aug;6(8):3025-31
[
10955780.001
]
[Cites]
J Clin Oncol. 1998 Nov;16(11):3570-5
[
9817277.001
]
[Cites]
J Clin Oncol. 2005 Oct 1;23(28):7178-87
[
16192602.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):997-1003
[
15758010.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
Cancer Res. 2000 Nov 15;60(22):6307-10
[
11103789.001
]
[Cites]
J Clin Oncol. 2002 May 1;20(9):2277-83
[
11980998.001
]
[Cites]
Neuro Oncol. 2003 Apr;5(2):79-88
[
12672279.001
]
[Cites]
J Clin Oncol. 2003 May 1;21(9):1845-9
[
12721262.001
]
[Cites]
Neuro Oncol. 2004 Jan;6(1):28-32
[
14769137.001
]
[Cites]
Clin Cancer Res. 2004 Mar 15;10(6):1871-4
[
15041700.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72
[
2164681.001
]
[Cites]
Cancer Commun. 1990;2(11):371-7
[
2242301.001
]
[Cites]
J Neurosurg. 1991 Mar;74(3):441-6
[
1993909.001
]
[Cites]
Cancer Res. 1991 Jul 1;51(13):3367-72
[
1647266.001
]
[Cites]
J Neurosurg. 1992 Apr;76(4):640-7
[
1545259.001
]
[Cites]
Cancer Chemother Pharmacol. 1993;32(6):471-6
[
8258196.001
]
[Cites]
Cancer Res. 1994 Oct 1;54(19):5123-30
[
7923129.001
]
[Cites]
Lancet. 1995 Apr 22;345(8956):1008-12
[
7723496.001
]
[Cites]
Prog Nucleic Acid Res Mol Biol. 1995;51:167-223
[
7659775.001
]
[Cites]
Cancer Res. 1996 Feb 15;56(4):783-8
[
8631014.001
]
[Cites]
Br J Cancer. 1996 Oct;74(7):1030-6
[
8855970.001
]
[Cites]
Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9
[
9218294.001
]
[Cites]
J Clin Oncol. 1998 May;16(5):1803-10
[
9586894.001
]
[Cites]
J Clin Oncol. 2000 Oct 15;18(20):3522-8
[
11032594.001
]
(PMID = 17264335.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
[Publication-type]
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
[Other-IDs]
NLM/ NIHMS66419; NLM/ PMC2556256
7.
Ali Y, Rahme R, Moussa R, Abadjian G, Menassa-Moussa L, Samaha E:
Multifocal meningeal melanocytoma: a new pathological entity or the result of leptomeningeal seeding?
J Neurosurg
; 2009 Sep;111(3):488-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Meningeal melanocytoma is a rare benign
CNS tumor
derived from the leptomeningeal melanocytes.
[MeSH-major]
Cerebellar
Neoplasms
/ pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal
Neoplasms
/ pathology.
Neoplasm
Seeding. Spinal Cord
Neoplasms
/ pathology
[MeSH-minor]
Adult
. Humans. Magnetic Resonance Imaging. Male
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19361258.001).
[ISSN]
0022-3085
[Journal-full-title]
Journal of neurosurgery
[ISO-abbreviation]
J. Neurosurg.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
8.
Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ:
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.
J Natl Cancer Inst
; 2009 Jul 1;101(13):946-58
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term outcomes among
adult
survivors of childhood
central nervous system
malignancies in the Childhood Cancer Survivor Study.
BACKGROUND:
Adult
survivors of childhood
central nervous system
(
CNS
) malignancies are at high risk for long-term morbidity and late mortality.
However, patterns of late mortality, the long-term risks of subsequent
neoplasms
and debilitating medical conditions, and sociodemographic outcomes have not been comprehensively characterized for individual diagnostic and treatment groups.
METHODS: We collected information on treatment, mortality, chronic medical conditions, and neurocognitive functioning of
adult
5-year survivors of
CNS
malignancies diagnosed between 1970 and 1986 within the Childhood Cancer Survivor Study.
Using competing risk framework, we calculated cumulative mortality according to cause of death and cumulative incidence of subsequent
neoplasms
according to exposure and dose of cranial radiation therapy (RT).
Neurocognitive impairment and socioeconomic outcomes were assessed with respect to dose of
CNS
radiotherapy to specific brain regions.
Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent
neoplasm
within the
CNS
of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT.
Neurocognitive impairment was high and proportional to radiation dose for specific
tumor
types.
CONCLUSIONS: Survivors of childhood
CNS
malignancies are at high risk for late mortality and for developing subsequent
neoplasms
and chronic medical conditions.
Genetic Alliance.
consumer health - Childhood Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
BMJ. 1994 Jul 16;309(6948):162-6
[
8044095.001
]
[Cites]
J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79
[
18812549.001
]
[Cites]
J Natl Cancer Inst. 2001 Apr 18;93(8):618-29
[
11309438.001
]
[Cites]
J Clin Oncol. 2001 Jul 1;19(13):3163-72
[
11432882.001
]
[Cites]
Med Pediatr Oncol. 2002 Apr;38(4):229-39
[
11920786.001
]
[Cites]
J Neurol. 2002 Aug;249(8):955-60
[
12195437.001
]
[Cites]
Cancer. 2003 Feb 1;97(3):663-73
[
12548609.001
]
[Cites]
Cancer. 2003 Feb 15;97(4):1115-26
[
12569614.001
]
[Cites]
J Neurooncol. 2003 Jul;63(3):279-87
[
12892234.001
]
[Cites]
J Clin Oncol. 2003 Sep 1;21(17):3255-61
[
12947060.001
]
[Cites]
JAMA. 2003 Sep 24;290(12):1583-92
[
14506117.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9
[
14557448.001
]
[Cites]
Pediatr Hematol Oncol. 2003 Dec;20(8):617-25
[
14578032.001
]
[Cites]
Neuropsychology. 2003 Oct;17(4):548-55
[
14599268.001
]
[Cites]
Curr Opin Neurol. 2003 Dec;16(6):677-83
[
14624076.001
]
[Cites]
J Clin Oncol. 2004 Mar 15;22(6):999-1006
[
15020603.001
]
[Cites]
Ann Fam Med. 2004 Jan-Feb;2(1):61-70
[
15053285.001
]
[Cites]
Cancer. 2004 May 15;100(10):2246-52
[
15139071.001
]
[Cites]
J Clin Epidemiol. 2004 Sep;57(9):933-44
[
15504636.001
]
[Cites]
Am J Epidemiol. 1986 Jan;123(1):174-84
[
3509965.001
]
[Cites]
Am J Clin Oncol. 1985 Dec;8(6):472-6
[
3936349.001
]
[Cites]
Arch Dis Child. 1990 Dec;65(12):1356-63
[
2270944.001
]
[Cites]
J Clin Oncol. 1991 Apr;9(4):592-9
[
2066756.001
]
[Cites]
J Clin Oncol. 1992 Sep;10(9):1397-406
[
1517782.001
]
[Cites]
Cancer. 2008 Oct 15;113(8):2188-97
[
18792068.001
]
[Cites]
Int J Epidemiol. 1998 Feb;27(1):91-5
[
9563700.001
]
[Cites]
J Clin Oncol. 1998 May;16(5):1723-8
[
9586884.001
]
[Cites]
Ann Neurol. 1998 Sep;44(3):313-6
[
9749596.001
]
[Cites]
Med Pediatr Oncol. 1998 Dec;31(6):506-11
[
9835903.001
]
[Cites]
Stat Med. 1999 Mar 30;18(6):695-706
[
10204198.001
]
[Cites]
J Neurooncol. 1999 Jan;41(1):47-53
[
10222422.001
]
[Cites]
Br J Cancer. 2004 Nov 29;91(11):1905-10
[
15534607.001
]
[Cites]
J Clin Oncol. 2004 Dec 15;22(24):4979-90
[
15576413.001
]
[Cites]
Pediatr Blood Cancer. 2005 Aug;45(2):155-61
[
15880357.001
]
[Cites]
Pediatr Blood Cancer. 2006 May 1;46(5):637-44
[
16421901.001
]
[Cites]
Pediatr Blood Cancer. 2006 Jul;47(1):83-8
[
16317732.001
]
[Cites]
J Clin Oncol. 2006 Jun 1;24(16):2536-43
[
16735706.001
]
[Cites]
Radiat Res. 2006 Jul;166(1 Pt 2):141-57
[
16808603.001
]
[Cites]
Haematologica. 2006 Aug;91(8):1084-91
[
16870549.001
]
[Cites]
N Engl J Med. 2006 Oct 12;355(15):1572-82
[
17035650.001
]
[Cites]
Eur J Cancer. 2007 Jan;43(2):351-62
[
17141498.001
]
[Cites]
Pediatr Blood Cancer. 2007 Apr;48(4):460-7
[
16767717.001
]
[Cites]
J Clin Oncol. 2007 Apr 20;25(12):1532-8
[
17442996.001
]
[Cites]
Pediatr Blood Cancer. 2007 Jul;49(1):47-51
[
16755550.001
]
[Cites]
Blood. 2008 Apr 15;111(8):4014-21
[
18258798.001
]
[Cites]
Cancer. 2008 May 1;112(9):2071-9
[
18327823.001
]
[Cites]
Pediatr Blood Cancer. 2008 Aug;51(2):245-50
[
18386785.001
]
[Cites]
J Clin Oncol. 2008 Sep 20;26(27):4401-9
[
18802152.001
]
[CommentIn]
J Natl Cancer Inst. 2009 Jul 1;101(13):908-10
[
19549957.001
]
[CommentIn]
J Natl Cancer Inst. 2009 Jul 1;101(13):909
[
19549959.001
]
(PMID = 19535780.001).
[ISSN]
1460-2105
[Journal-full-title]
Journal of the National Cancer Institute
[ISO-abbreviation]
J. Natl. Cancer Inst.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U24-CA55727
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2704230
9.
Strojnik T, Røsland GV, Sakariassen PO, Kavalar R, Lah T:
Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival.
Surg Neurol
; 2007 Aug;68(2):133-43; discussion 143-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: The IF protein nestin and the RNA-binding protein musashi are expressed by neural progenitor cells during
CNS
development.
Their expression in glial
tumors
was evaluated by immunohistochemistry, and the histopathological scores correlated with levels of cysteine cathepsins that are known prognostic markers in several
tumors
.
METHODS: The levels of nestin, musashi, and cathepsins B and L were assessed by immunohistochemical analysis of biopsies from 87 patients with primary
CNS
tumors
.
To confirm the immunohistochemical data, nestin expression was analyzed by real-time PCR in 12 brain
tumor
biopsies.
The total IHC score for nestin was significantly higher in high- than in low-grade
tumors
(P < .0001).
IHC staining of nestin in a xenograft model showed that its expression is localized mainly in the invasive
tumor
cells at the
tumor
periphery.
The presented data links the invasive glioma cells to
CNS
precursor cells, indicating that the most malignant cells in the gliomas may well be closely related to the glioma stem cells.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism. Brain
Neoplasms
/ metabolism. Brain
Neoplasms
/ pathology. Glioma / metabolism. Glioma / pathology. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism
[MeSH-minor]
Adolescent.
Adult
. Aged. Animals. Cathepsin B / metabolism. Cathepsin L. Cathepsins / metabolism. Child. Child, Preschool. Cysteine Endopeptidases / metabolism. Female. Humans. Male. Middle Aged. Nestin. RNA, Messenger / metabolism. RNA-Binding Proteins / metabolism. Rats. Survival Rate
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17537489.001).
[ISSN]
0090-3019
[Journal-full-title]
Surgical neurology
[ISO-abbreviation]
Surg Neurol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / MSI1 protein, human; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L; EC 3.4.22.15 / Ctsl protein, rat
10.
Honda S, Toda K, Tozuka Y, Yasuzawa S, Iwabuchi K, Tomooka Y:
Migration and differentiation of neural cell lines transplanted into mouse brains.
Neurosci Res
; 2007 Oct;59(2):124-35
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In the past few years, the plasticity of the regional specification of the
CNS
has been widely debated on the results from in utero transplantation.
These lines were established from a cerebellum of an
adult
p53-deficient mouse.
Our results showed that transplanted cells migrated into various regions of the
CNS
and supported the independent distribution.
[MeSH-minor]
Animals. Animals, Newborn. Biomarkers / metabolism. Blood Vessels / embryology. Cell Line. Cell Lineage / physiology. Cell Shape / physiology. Cell Survival / physiology. Clone Cells / cytology. Clone Cells / metabolism. Clone Cells / transplantation. Female. Male. Mice. Mice, Knockout. Nerve Tissue Proteins / metabolism. Neurites / ultrastructure. Organ Culture Techniques. Sex Characteristics. Time Factors.
Tumor
Suppressor Protein p53 / genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17651850.001).
[ISSN]
0168-0102
[Journal-full-title]
Neuroscience research
[ISO-abbreviation]
Neurosci. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Biomarkers; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Protein p53
11.
Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, McMullen K, McQuellon R, Naughton M, Rapp S, Stieber V, Shaw EG:
A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
Int J Radiat Oncol Biol Phys
; 2007 Dec 1;69(5):1496-501
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain
tumor
patients receiving radiation therapy.
PURPOSE: The quality of life (QOL) and neurocognitive function of patients with brain
tumors
are negatively affected by the symptoms of their disease and brain radiation therapy (RT).
We assessed the effect of prophylactic d-threo-methylphenidate HCl (d-MPH), a
central nervous system
(
CNS
) stimulant on QOL and cognitive function in patients undergoing RT.
METHODS AND MATERIALS: Sixty-eight patients with primary or metastatic brain
tumors
were randomly assigned to receive d-MPH or placebo.
CONCLUSIONS: Prophylactic use of d-MPH in brain
tumor
patients undergoing RT did not result in an improvement in QOL.
[MeSH-major]
Brain
Neoplasms
/ radiotherapy.
Central Nervous System
Stimulants / therapeutic use. Cognition / drug effects. Fatigue / prevention & control. Methylphenidate / therapeutic use. Quality of Life
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Analysis of Variance. Double-Blind Method. Female. Humans. Least-Squares Analysis. Male. Middle Aged. Patient Dropouts / statistics & numerical data. Prospective Studies
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Fatigue
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
METHYLPHENIDATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17869448.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 1 U10CA81851
[Publication-type]
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
12.
Boman KK, Lindblad F, Hjern A:
Long-term outcomes of childhood cancer survivors in Sweden: a population-based study of education, employment, and income.
Cancer
; 2010 Mar 1;116(5):1385-91
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Studies of different national populations were indispensable for estimating the impact of illness-related disability on social outcomes in
adult
childhood cancer survivors.
RESULTS: Non-
central nervous system
(
CNS
) cancer survivors had similar education, employment, and income as the general population in adjusted models, whereas survivors of
CNS
tumors
more often had no more than basic (< or =9 years) education (relative risk [RR], 1.80 [95% confidence interval (95% CI), 1.45-2.23]), less often attained education beyond secondary school (RR, 0.69 [95% CI, 0.58-0.81]), and less often were employed (RR, 0.85 [95% CI, 0.77-0.94]).
Predicted net income from work was lower in
CNS tumor
survivors (P <.001) than in the general population, even after the exclusion of individuals who received economic disability compensation.
CONCLUSIONS:
CNS tumor
survivors had poorer social outcomes compared with the general population, whereas outcomes for survivors of other childhood cancers were similar to the general population.
Established late effects highlighted the importance of improved, safer pediatric
CNS tumor
treatment protocols and surveillance that identified individual needs for preventive and remedial measures.
[MeSH-major]
Neoplasms
/ therapy. Social Class. Survivors / statistics & numerical data
[MeSH-minor]
Adult
.
Central Nervous System Neoplasms
/ economics. Child. Educational Status. Employment. Female. Follow-Up Studies. Humans. Income. Male. Population Surveillance. Sweden
Genetic Alliance.
consumer health - Childhood Cancer
.
MedlinePlus Health Information.
consumer health - Cancer in Children
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20087961.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
13.
Yavari P, Sadrolhefazi B, Mohagheghi MA, Madani H, Mosavizadeh A, Nahvijou A, Mehrabi Y, Pourhseingholi MA:
An epidemiological analysis of cancer data in an Iranian hospital during the last three decades.
Asian Pac J Cancer Prev
; 2008 Jan-Mar;9(1):145-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The objective of this study was to collect analysis of data and discuss certain epidemiologic features
of neoplasm
using data from hospital.
The tumors
were coded and classified according to the International Classification of Diseases 10th revision and ICD-O.
The ten most frequent cancer sites among patients were breast (13.6%), brain &
CNS
(13.6%), skin(13.5%), haemapoitic
system
(9.7%), lymphoid (7.1%), esophagus (7.1%), colon & rectum (4%), male genital organs (1.3%), bladder (1.3%), lung (1.2%), and stomach (1%).
All
tumors
except the breast, female genital organs, thyroid, gallbladder and kidney cancers, were more frequent in males compared to women.
About 16.6%
of tumors
occurred in children aged 15 years or younger.
More than four fifths (81%) of patients with cancer of haematopoeitic
system
were under age of 15 years.
In conclusion, the results of this study present an important epidemiological understanding of patients with
tumors
.
It emphasizes that gender plays an important role in the frequency of primary
tumors
, and how much the sex ratio varies with some types
of tumors
.
We also noted that certain
tumor
types show a prediction for certain decades of life in our series.
[MeSH-major]
Neoplasms
/ epidemiology
[MeSH-minor]
Adolescent.
Adult
. Aged. Child. Child, Preschool. Female. Hospitals / statistics & numerical data. Humans. Incidence. Infant. Infant, Newborn. Iran / epidemiology. Male. Middle Aged. Risk Factors. Time Factors. Young
Adult
MedlinePlus Health Information.
consumer health - Cancer in Children
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18439094.001).
[ISSN]
2476-762X
[Journal-full-title]
Asian Pacific journal of cancer prevention : APJCP
[ISO-abbreviation]
Asian Pac. J. Cancer Prev.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Thailand
14.
Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED:
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
J Clin Oncol
; 2008 Oct 10;26(29):4814-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Del(6)(q22) and BCL6 rearrangements in primary
CNS
lymphoma are indicators of an aggressive clinical course.
PURPOSE: Primary
CNS
lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking.
Several genetic changes including BCL6 rearrangements and deletion of 6q22, containing the putative
tumor
suppressor gene PTPRK, are potential risk predictors.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neuropathol Exp Neurol. 2006 Aug;65(8):776-82
[
16896311.001
]
[Cites]
Cancer Res. 2003 Feb 15;63(4):737-41
[
12591717.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):447-51
[
12640061.001
]
[Cites]
Am J Surg Pathol. 2003 Apr;27(4):487-93
[
12657933.001
]
[Cites]
Virchows Arch. 2003 Aug;443(2):164-9
[
12802586.001
]
[Cites]
Cerebrovasc Dis. 2004;17(2-3):224-7
[
14707426.001
]
[Cites]
Cell. 2004 Jun 11;117(6):699-711
[
15186772.001
]
[Cites]
Am J Pathol. 2004 Jul;165(1):159-66
[
15215171.001
]
[Cites]
Blood. 1994 Apr 1;83(7):1757-9
[
8142643.001
]
[Cites]
Blood. 1994 May 1;83(9):2423-7
[
8167331.001
]
[Cites]
Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46
[
17057753.001
]
[Cites]
Am J Surg Pathol. 2006 Dec;30(12):1546-53
[
17122510.001
]
[Cites]
J Clin Oncol. 2006 Dec 20;24(36):5711-5
[
17116938.001
]
[Cites]
Blood. 1995 May 15;85(10):2877-84
[
7742550.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20
[
9635710.001
]
[Cites]
Genes Chromosomes Cancer. 1999 Jun;25(2):123-33
[
10337996.001
]
[Cites]
J Clin Oncol. 2005 Mar 1;23(7):1507-13
[
15735126.001
]
[Cites]
J Clin Oncol. 2005 Apr 1;23(10):2233-9
[
15800313.001
]
[Cites]
Anticancer Res. 2005 Sep-Oct;25(5):3179-82
[
16101124.001
]
[Cites]
J Clin Oncol. 2005 Aug 20;23(24):5718-27
[
16009945.001
]
[Cites]
Blood. 2005 Nov 1;106(9):3183-90
[
16046532.001
]
[Cites]
Cancer. 2005 Dec 1;104(11):2466-72
[
16240449.001
]
[Cites]
Am J Surg Pathol. 2005 Dec;29(12):1652-60
[
16327438.001
]
[Cites]
J Clin Oncol. 2006 Mar 10;24(8):1281-8
[
16525183.001
]
[Cites]
Blood. 2006 May 1;107(9):3716-23
[
16418334.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2332-43
[
17625604.001
]
[Cites]
Blood. 2008 Jan 1;111(1):292-301
[
17720884.001
]
[Cites]
Leukemia. 2008 Feb;22(2):400-5
[
17989719.001
]
[Cites]
Leukemia. 2008 Jun;22(6):1268-72
[
17989713.001
]
[Cites]
Nat Rev Immunol. 2005 Jan;5(1):43-57
[
15630428.001
]
[Cites]
Am J Pathol. 1999 Nov;155(5):1445-51
[
10550299.001
]
[Cites]
Am J Surg Pathol. 1999 Nov;23(11):1386-92
[
10555007.001
]
[Cites]
J Neurosurg. 2000 Feb;92(2):261-6
[
10659013.001
]
[Cites]
Brain Pathol. 2000 Jan;10(1):73-84
[
10668897.001
]
[Cites]
Neurosurgery. 2000 Aug;47(2):454-6; discussion 456-7
[
10942021.001
]
[Cites]
J Clin Oncol. 2000 Sep;18(17):3144-50
[
10963643.001
]
[Cites]
Cancer Genet Cytogenet. 2001 Mar;125(2):147-50
[
11369058.001
]
[Cites]
Nat Med. 2002 Jan;8(1):68-74
[
11786909.001
]
[Cites]
Br J Haematol. 2002 May;117(2):322-32
[
11972514.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33
[
12387458.001
]
[Cites]
J Clin Oncol. 2003 Jan 15;21(2):266-72
[
12525518.001
]
[Cites]
Lancet. 2003 Jan 25;361(9354):323-31
[
12559880.001
]
[Cites]
Cancer. 1994 Aug 15;74(4):1383-97
[
8055462.001
]
(PMID = 18645192.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA108961
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / BCL6 protein, human; 0 / DNA-Binding Proteins
[Other-IDs]
NLM/ PMC2653136
15.
Klosky JL, Randolph ME, Navid F, Gamble HL, Spunt SL, Metzger ML, Daw N, Morris EB, Hudson MM:
Sperm cryopreservation practices among adolescent cancer patients at risk for infertility.
Pediatr Hematol Oncol
; 2009 Jun;26(4):252-60
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Utilization of sperm banking was significantly associated with a diagnosis
of central nervous system
(
CNS
) malignancy or non-
CNS
solid
tumor
diagnosis, higher socioeconomic status, and not being a member of an Evangelical religious group.
Genetic Alliance.
consumer health - infertility
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Male Infertility
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Cell Endocrinol. 2000 Nov 27;169(1-2):117-22
[
11155943.001
]
[Cites]
Pediatr Blood Cancer. 2008 Jan;50(1):85-9
[
17514741.001
]
[Cites]
J Clin Oncol. 2002 Apr 1;20(7):1880-9
[
11919248.001
]
[Cites]
J Clin Oncol. 2002 Apr 1;20(7):1890-7
[
11919249.001
]
[Cites]
Arch Dis Child. 2004 Aug;89(8):736-7
[
15269072.001
]
[Cites]
Hum Reprod Update. 2004 Nov-Dec;10(6):525-32
[
15319377.001
]
[Cites]
Cancer. 1992 Dec 1;70(11):2703-12
[
1423201.001
]
[Cites]
Cancer. 1999 Aug 15;86(4):697-709
[
10440699.001
]
[Cites]
Psychooncology. 2004 Oct;13(10):689-99
[
15386645.001
]
[Cites]
Psychooncology. 2004 Dec;13(12):867-81
[
15386796.001
]
[Cites]
J Natl Cancer Inst Monogr. 2005;(34):101-3
[
15784836.001
]
[Cites]
J Clin Oncol. 2006 Jun 20;24(18):2917-31
[
16651642.001
]
[Cites]
J Pediatr Hematol Oncol. 2006 Jun;28(6):350-4
[
16794502.001
]
[Cites]
Hum Reprod. 2007 May;22(5):1384-95
[
17259225.001
]
[Cites]
Cancer. 2007 Sep 1;110(5):1125-9
[
17647219.001
]
[Cites]
Cancer. 2001 Feb 1;91(3):613-21
[
11169946.001
]
(PMID = 19437327.001).
[ISSN]
1521-0669
[Journal-full-title]
Pediatric hematology and oncology
[ISO-abbreviation]
Pediatr Hematol Oncol
[Language]
ENG
[Grant]
None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-31
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents
[Other-IDs]
NLM/ NIHMS162120; NLM/ PMC2801903
16.
Kim B, Myung JK, Seo JH, Park CK, Paek SH, Kim DG, Jung HW, Park SH:
The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma.
J Neurol Sci
; 2010 Jul 15;294(1-2):112-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Glioblastoma (GBM) is a malignant
CNS
neoplasm
.
Stratified by age, resectability and
tumor
size <5 cm were favorable survival factors in young (40<yrs) and old age groups (> or =40 yrs), respectively.
Furthermore, the patients with supratentorial
tumor
lived longer than the patients with infratentorial
tumor
(p<0.05).
[MeSH-major]
Brain
Neoplasms
/ metabolism. Glioblastoma / metabolism
[MeSH-minor]
Adult
. Age Factors. Brain / metabolism. Brain / surgery. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infratentorial
Neoplasms
/ diagnosis. Infratentorial
Neoplasms
/ metabolism. Infratentorial
Neoplasms
/ mortality. Infratentorial
Neoplasms
/ pathology. Male. PTEN Phosphohydrolase / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Prognosis. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Epidermal Growth Factor / metabolism. Supratentorial
Neoplasms
/ diagnosis. Supratentorial
Neoplasms
/ metabolism. Supratentorial
Neoplasms
/ mortality. Supratentorial
Neoplasms
/ pathology. Survival Analysis.
Tumor
Suppressor Protein p53 / metabolism
Genetic Alliance.
consumer health - Glioblastoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier B.V. All rights reserved.
(PMID = 20441994.001).
[ISSN]
1878-5883
[Journal-full-title]
Journal of the neurological sciences
[ISO-abbreviation]
J. Neurol. Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
17.
Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG:
Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha.
Clin Neuropharmacol
; 2010 Jul;33(4):191-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Labile anger during interferon alfa treatment is associated with a polymorphism in
tumor
necrosis factor alpha.
Evidence also indicates a
central nervous system
role for
tumor
necrosis factor alpha (TNF-alpha), whose expression may be increased by interferon alfa.
MedlinePlus Health Information.
consumer health - Hepatitis C
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neuropsychiatry Clin Neurosci. 1991 Spring;3(2):S44-51
[
1821222.001
]
[Cites]
Arch Gen Psychiatry. 1997 Dec;54(12):1081-8
[
9400343.001
]
[Cites]
Acta Psychiatr Scand. 1998 Apr;97(4):309-13
[
9570493.001
]
[Cites]
Psychiatry Res. 1998 Jun 15;79(2):163-73
[
9705054.001
]
[Cites]
N Engl J Med. 1998 Nov 19;339(21):1485-92
[
9819446.001
]
[Cites]
Brain Behav Immun. 1999 Jun;13(2):175-86
[
10373280.001
]
[Cites]
Adv Exp Med Biol. 1999;461:117-27
[
10442171.001
]
[Cites]
J Clin Psychiatry. 2005 Jan;66(1):41-8
[
15669887.001
]
[Cites]
J Affect Disord. 2005 Feb;84(2-3):117-25
[
15708408.001
]
[Cites]
World J Gastroenterol. 2005 Mar 28;11(12):1769-74
[
15793861.001
]
[Cites]
J Clin Psychiatry. 2005 Aug;66(8):1050-7
[
16086622.001
]
[Cites]
Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):215-22
[
16133740.001
]
[Cites]
Neurol Res. 2005 Oct;27(7):679-84
[
16197804.001
]
[Cites]
AIDS. 2005 Oct;19 Suppl 3:S174-8
[
16251815.001
]
[Cites]
J Autoimmun. 2005 Sep;25(2):150-4
[
16046099.001
]
[Cites]
Arch Gen Psychiatry. 2005 Dec;62(12):1377-84
[
16330726.001
]
[Cites]
Obes Res. 2005 Dec;13(12):2122-31
[
16421346.001
]
[Cites]
Curr Opin Psychiatry. 2006 Jan;19(1):1-8
[
16612171.001
]
[Cites]
Nature. 2006 Apr 20;440(7087):1054-9
[
16547515.001
]
[Cites]
J Affect Disord. 2006 May;92(1):19-33
[
16635528.001
]
[Cites]
J Neurosci. 2006 May 24;26(21):5709-19
[
16723527.001
]
[Cites]
J Hum Genet. 2006;51(8):677-85
[
16865291.001
]
[Cites]
Psychosomatics. 2007 May-Jun;48(3):223-9
[
17478591.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2007 Aug;19(8):639-46
[
17625432.001
]
[Cites]
J Psychosom Res. 2007 Aug;63(2):131-5
[
17662748.001
]
[Cites]
Int Rev Neurobiol. 2007;82:247-63
[
17678965.001
]
[Cites]
Biol Psychiatry. 2007 Sep 1;62(5):536-40
[
17300755.001
]
[Cites]
N Engl J Med. 2002 Sep 26;347(13):975-82
[
12324553.001
]
[Cites]
Mol Psychiatry. 2002;7(9):942-7
[
12399946.001
]
[Cites]
Mol Psychiatry. 2002;7(9):1023-9
[
12399958.001
]
[Cites]
Brain Behav Immun. 2002 Oct;16(5):569-74
[
12401470.001
]
[Cites]
Brain Behav Immun. 2002 Dec;16(6):675-84
[
12480498.001
]
[Cites]
Psychosomatics. 2003 Mar-Apr;44(2):104-12
[
12618532.001
]
[Cites]
J Clin Psychiatry. 2003 Jun;64(6):708-14
[
12823087.001
]
[Cites]
Biol Psychiatry. 2003 Jul 1;54(1):34-9
[
12842306.001
]
[Cites]
Psychiatr Genet. 2003 Sep;13(3):179-81
[
12960751.001
]
[Cites]
Psychiatry Res. 2004 Jan 30;125(1):65-8
[
14967554.001
]
[Cites]
Eur J Immunogenet. 2004 Feb;31(1):15-9
[
15009176.001
]
[Cites]
J Affect Disord. 2004 Mar;78(3):273-7
[
15013254.001
]
[Cites]
Psychosomatics. 2004 Mar-Apr;45(2):176
[
15016930.001
]
[Cites]
Hum Immunol. 2004 Apr;65(4):347-51
[
15120189.001
]
[Cites]
Psychoneuroendocrinology. 2004 Oct;29(9):1119-28
[
15219635.001
]
[Cites]
J Affect Disord. 2008 Apr;107(1-3):293-8
[
17850879.001
]
[Cites]
Brain Behav Immun. 2008 May;22(4):573-89
[
18191534.001
]
[Cites]
Psychopharmacology (Berl). 2008 May;197(4):629-35
[
18274729.001
]
[Cites]
Arthritis Rheum. 2008 May;58(5):1258-63
[
18438841.001
]
[Cites]
Neuropsychobiology. 2008;57(1-2):88-94
[
18515978.001
]
[Cites]
Psychopharmacology (Berl). 2008 Aug;199(2):231-44
[
18491079.001
]
[Cites]
Mol Psychiatry. 2008 Aug;13(8):800-12
[
18504423.001
]
[Cites]
Compr Psychiatry. 2008 Sep-Oct;49(5):469-75
[
18702932.001
]
[Cites]
Biol Psychiatry. 2008 Sep 15;64(6):476-83
[
18514165.001
]
[Cites]
Neurobiol Dis. 2008 Oct;32(1):125-32
[
18672064.001
]
[Cites]
HIV Med. 2008 Oct;9(8):677-80
[
18631256.001
]
[Cites]
Neuropsychobiology. 2008;58(2):71-80
[
18832862.001
]
[Cites]
Natl Med J India. 2008 May-Jun;21(3):120-2
[
19004142.001
]
[Cites]
Psychiatry Clin Neurosci. 2006 Oct;60(5):611-5
[
16958946.001
]
[Cites]
J Neurosci. 2006 Sep 20;26(38):9703-12
[
16988041.001
]
[Cites]
Aliment Pharmacol Ther. 2006 Oct 15;24(8):1223-30
[
17014581.001
]
[Cites]
Brain Behav Immun. 2006 Nov;20(6):507-14
[
16938427.001
]
[Cites]
Brain Res. 2006 Nov 20;1120(1):64-73
[
17022949.001
]
[Cites]
Neuropsychopharmacology. 2006 Dec;31(12):2619-26
[
16823390.001
]
[Cites]
J Psychiatr Res. 2007 Apr-Jun;41(3-4):326-31
[
16870211.001
]
[Cites]
J Psychosom Res. 2007 Feb;62(2):207-14
[
17270579.001
]
[Cites]
J Am Acad Child Adolesc Psychiatry. 2007 Mar;46(3):309-22
[
17314717.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G779-84
[
17170025.001
]
[Cites]
Eur Neuropsychopharmacol. 2007 May-Jun;17(6-7):410-6
[
17187964.001
]
[Cites]
Brain Behav Immun. 2007 May;21(4):374-83
[
17360153.001
]
[Cites]
Gastroenterology. 2007 Apr;132(4):1279-86
[
17408646.001
]
[Cites]
Bipolar Disord. 2007 Sep;9(6):596-602
[
17845274.001
]
[Cites]
J Viral Hepat. 2007 Nov;14(11):788-96
[
17927615.001
]
[Cites]
Mol Psychiatry. 2007 Nov;12(11):988-1000
[
17457312.001
]
[Cites]
Br J Dermatol. 2007 Dec;157(6):1275-7
[
17916204.001
]
[Cites]
J Clin Gastroenterol. 2008 Jan;42(1):92-6
[
18097297.001
]
[Cites]
Psychoneuroendocrinology. 2008 Jan;33(1):68-76
[
17988804.001
]
[Cites]
Neurosci Lett. 2008 Jan 17;430(3):264-8
[
18063307.001
]
[Cites]
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):445-50
[
17976882.001
]
[Cites]
Mol Immunol. 2008 Mar;45(6):1682-92
[
17996942.001
]
[Cites]
Parkinsonism Relat Disord. 2008 Dec;14(8):636-40
[
18362084.001
]
[Cites]
Brain Res. 2009 Jan 9;1247:178-81
[
18992723.001
]
[Cites]
Am J Gastroenterol. 2008 Dec;103(12):3132-41
[
18853973.001
]
[Cites]
J Psychiatr Res. 2009 Jan;43(4):471-6
[
18640689.001
]
[Cites]
Psychiatry Clin Neurosci. 2009 Feb;63(1):50-5
[
19154212.001
]
[Cites]
Biol Psychiatry. 2009 Feb 15;65(4):344-8
[
18801474.001
]
[Cites]
Respir Med. 2009 Mar;103(3):386-92
[
19022640.001
]
[Cites]
J Physiol Pharmacol. 2008 Dec;59 Suppl 6:607-14
[
19218687.001
]
[Cites]
J Neurosci. 2009 Apr 1;29(13):4200-9
[
19339614.001
]
[Cites]
Emotion. 2009 Jun;9(3):385-96
[
19485616.001
]
[Cites]
Brain Behav Immun. 2009 Nov;23(8):1109-16
[
19615438.001
]
[Cites]
CNS Spectr. 2009 Aug;14(8):419-25
[
19890236.001
]
[Cites]
Mol Psychiatry. 2009 Dec;14(12):1095-104
[
18458677.001
]
[Cites]
Psychiatry Res. 2010 May 15;177(1-2):240-5
[
20381876.001
]
[Cites]
Am J Med. 1999 Dec 27;107(6B):2S-9S
[
10653448.001
]
[Cites]
Cytokine. 2000 Feb;12(2):110-9
[
10671295.001
]
[Cites]
J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):469-76
[
10761349.001
]
[Cites]
Science. 2000 Jul 28;289(5479):591-4
[
10915615.001
]
[Cites]
Ann N Y Acad Sci. 2000;917:4-18
[
11268367.001
]
[Cites]
Psychiatr Genet. 2000 Dec;10(4):195-8
[
11324946.001
]
[Cites]
Genes Immun. 2001 Apr;2(2):105-9
[
11393654.001
]
[Cites]
Lancet. 2001 Sep 22;358(9286):958-65
[
11583749.001
]
[Cites]
J Viral Hepat. 2002 Mar;9(2):84-100
[
11876790.001
]
[Cites]
Science. 2002 Mar 22;295(5563):2282-5
[
11910117.001
]
[Cites]
Eur J Neurosci. 2002 Mar;15(6):1061-76
[
11918665.001
]
[Cites]
Neuropsychopharmacology. 2002 May;26(5):643-52
[
11927189.001
]
[Cites]
Hum Mol Genet. 2002 May 15;11(11):1281-9
[
12019209.001
]
[Cites]
Genes Immun. 2004 Aug;5(5):315-29
[
14973548.001
]
[Cites]
Psychiatry Clin Neurosci. 2004 Oct;58(5):480-6
[
15482578.001
]
(PMID = 20661026.001).
[ISSN]
1537-162X
[Journal-full-title]
Clinical neuropharmacology
[ISO-abbreviation]
Clin Neuropharmacol
[Language]
ENG
[Grant]
United States / NIMH NIH HHS / MH / K23 MH074012; United States / NIMH NIH HHS / MH / MH074012-05; United States / NIMH NIH HHS / MH / K23 MH074012-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / SLC6A4 protein, human; 0 / Serotonin Plasma Membrane Transport Proteins; 0 / Tumor Necrosis Factor-alpha; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
[Other-IDs]
NLM/ NIHMS203707; NLM/ PMC2911643
18.
Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL:
Protein biomarker identification in the CSF of patients with CNS lymphoma.
J Clin Oncol
; 2008 Jan 1;26(1):96-105
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Protein biomarker identification in the CSF of patients with
CNS
lymphoma.
PURPOSE: Elucidation of the CSF proteome may yield insights into the pathogenesis of
CNS
disease.
We tested the hypothesis that individual CSF proteins distinguish
CNS
lymphoma from benign focal brain lesions.
METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in
CNS
lymphoma and control patients.
ATIII RNA transcripts were identified within
CNS
lymphomas, and ATIII protein was localized selectively to
tumor
neovasculature.
We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in
CNS
lymphoma and brain metastasis.
[MeSH-major]
Biomarkers,
Tumor
/ cerebrospinal fluid. Brain
Neoplasms
/ cerebrospinal fluid. Lymphoma / cerebrospinal fluid.
Neoplasm
Proteins / cerebrospinal fluid
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1999 Feb;17(2):554-60
[
10080599.001
]
[Cites]
Bioinformatics. 2004 Dec 12;20(18):3575-82
[
15284095.001
]
[Cites]
J Clin Oncol. 2005 Aug 1;23(22):5034-43
[
15955902.001
]
[Cites]
Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii
[
16083831.001
]
[Cites]
Mol Cell Proteomics. 2005 Sep;4(9):1341-9
[
15970584.001
]
[Cites]
Dis Markers. 2006;22(1-2):3-26
[
16410649.001
]
[Cites]
Blood. 2006 May 1;107(9):3716-23
[
16418334.001
]
[Cites]
J Biol Chem. 2006 Dec 8;281(49):37302-10
[
17040907.001
]
[Cites]
Expert Rev Mol Med. 2006;8(31):1-19
[
17156576.001
]
[Cites]
Cancer Cell. 2007 Jan;11(1):83-95
[
17222792.001
]
[Cites]
Anal Chem. 2003 Sep 15;75(18):4818-26
[
14674459.001
]
[Cites]
J Clin Oncol. 2003 Jan 15;21(2):266-72
[
12525518.001
]
[Cites]
Am J Pathol. 2002 Dec;161(6):2053-63
[
12466122.001
]
[Cites]
Lancet. 2002 Feb 16;359(9306):572-7
[
11867112.001
]
[Cites]
Curr Opin Neurol. 2000 Dec;13(6):641-8
[
11148663.001
]
[Cites]
J Clin Oncol. 1998 Mar;16(3):864-71
[
9508167.001
]
[Cites]
Clin Chem. 1993 Apr;39(4):561-77
[
8472349.001
]
[Cites]
Br J Haematol. 2004 Jul;126(2):202-8
[
15238140.001
]
[Cites]
Clin Cancer Res. 2004 May 1;10(9):2922-7
[
15131026.001
]
[Cites]
Bioinformatics. 2004 Mar 22;20(5):777-85
[
14751995.001
]
[Cites]
J Neurosurg. 2007 Jan;106(1):72-5
[
17236490.001
]
[CommentIn]
J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4
[
19332721.001
]
(PMID = 18056677.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / K23 CA100291
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
[Other-IDs]
NLM/ NIHMS612770; NLM/ PMC4134101
19.
Kim SH, Cheong JW, Park KH, Kim TS, Yang WI:
Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.
Arch Pathol Lab Med
; 2007 Mar;131(3):457-67
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary
central nervous system
and non-
central nervous system
origin.
In primary
central nervous system
diffuse large B-cell lymphomas (PCNS DLBCLs), the pathogenetic role of ATM mutation has not been investigated.
OBJECTIVE: To investigate ATM protein expression in PCNS DLBCLs, in comparison with that in non-
central nervous system
(non-
CNS
) DLBCLs and to study the relationship of ATM protein loss with several clinicopathologic parameters.
DESIGN: This study included 42 cases of PCNS DLBCL and 33 cases of non-
CNS
DLBCL from immunocompetent patients.
RESULTS: The loss of ATM expression was statistically more frequent in PCNS DLBCLs (21/42 cases [50.0%]) than in non-
CNS
DLBCLs (0/33 cases [0.0%]; P < .001).
CONCLUSIONS: Our results suggest that the ATM protein is more strongly correlated with PCNS DLBCL lymphomagenesis than with non-
CNS
DLBCLs, especially in germinal center B-cell-like subtypes demonstrating low Ki-67 labeling indexes and low Bcl-2 expression.
[MeSH-major]
Cell Cycle Proteins / metabolism.
Central Nervous System Neoplasms
/ metabolism. DNA-Binding Proteins / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Serine-Threonine Kinases / metabolism.
Tumor
Suppressor Proteins / metabolism
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Ataxia Telangiectasia Mutated Proteins. Child. Child, Preschool. Epstein-Barr Virus Infections / diagnosis. Female. Humans. In Situ Hybridization. Male. Middle Aged. Prognosis. RNA, Messenger / analysis. RNA-Binding Proteins / genetics. Ribosomal Proteins / genetics
Genetic Alliance.
consumer health - Ataxia
.
Genetic Alliance.
consumer health - Ataxia Telangiectasia
.
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17516749.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Tumor Suppressor Proteins; 135844-68-7 / RPL22 protein, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
20.
Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K, Zitterbart K, Sterba J:
Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.
BMC Cancer
; 2008;8:300
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Nestin was originally identified as a class VI intermediate filament protein that is expressed in stem cells and progenitor cells in the mammalian
CNS
during development.
This protein is replaced in the
adult
organism by other intermediate filament proteins; however, nestin may be re-expressed under certain pathological conditions such as ischemia, inflammation, brain injury, and neoplastic transformation.
Nestin has been detected in many kinds
of tumors
, especially in
tumors
derived from the
CNS
.
Co-expression of nestin and the CD133 surface molecule is considered to be a marker for cancer stem cells in neurogenic
tumors
.
METHODS: Using immunodetection methods, we examined nestin in
tumor
tissue samples from 18 patients with osteosarcomas.
We also successfully established permanent cell lines from the
tumor
tissue of 4 patients and immunodetection of nestin and CD133 was performed on these cell lines.
RESULTS: Nestin-positive
tumor
cells were immunohistochemically detected in all of the examined osteosarcomas, but the proportion of these cells that were positively stained as well as the intensity of staining varied.
Nestin-positive cells were rarely observed in 2
tumor
samples, and the remaining 16
tumor
samples showed various nestin expression patterns ranging from very sporadic occurrence to an overwhelming proportion of cells with strong positive staining.
Three of the established osteosarcoma cell lines were demonstrated to be nestin-positive, and only one cell line showed no expression of nestin; this finding corresponds with the rare occurrence of nestin-positive cells in the respective
tumor
sample.
CONCLUSION: Our results represent the first evidence of nestin expression in osteosarcomas and suggest the possible occurrence of cells with a stem-like phenotype in these
tumors
.
[MeSH-minor]
Adolescent.
Adult
. Cell Line,
Tumor
. Child. Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Male. Middle Aged. Nestin
Genetic Alliance.
consumer health - Osteosarcoma
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Histopathology. 2006 Apr;48(5):536-45
[
16623779.001
]
[Cites]
J Neurosci. 1985 Dec;5(12):3310-28
[
4078630.001
]
[Cites]
Acta Neuropathol. 2006 May;111(5):475-82
[
16598485.001
]
[Cites]
Neurosci Lett. 2006 May 29;400(1-2):80-5
[
16529857.001
]
[Cites]
J Pathol. 2006 Jul;209(3):287-97
[
16770755.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Oct;65(10):1004-11
[
17021405.001
]
[Cites]
Indian J Med Res. 2006 Sep;124(3):269-80
[
17085830.001
]
[Cites]
Mol Cancer. 2006;5:67
[
17140455.001
]
[Cites]
Cell Res. 2006 Dec;16(12):909-15
[
17088899.001
]
[Cites]
Mod Pathol. 2007 Jan;20(1):102-7
[
17143262.001
]
[Cites]
Cell Res. 2007 Jan;17(1):3-14
[
17179981.001
]
[Cites]
Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):92-7
[
17287174.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9
[
17307142.001
]
[Cites]
Mol Cancer. 2007;6:26
[
17407576.001
]
[Cites]
Mod Pathol. 2007 Jul;20(7):734-41
[
17464317.001
]
[Cites]
J Clin Pathol. 2008 Apr;61(4):467-73
[
17873113.001
]
[Cites]
Exp Neurol. 1999 Dec;160(2):348-60
[
10619552.001
]
[Cites]
Am J Pathol. 2001 Mar;158(3):817-23
[
11238030.001
]
[Cites]
Stem Cells. 2001;19(5):419-24
[
11553850.001
]
[Cites]
J Histochem Cytochem. 2002 Feb;50(2):147-58
[
11799134.001
]
[Cites]
Exp Neurol. 2002 Mar;174(1):89-95
[
11869037.001
]
[Cites]
APMIS. 2002 Jun;110(6):499-507
[
12193211.001
]
[Cites]
Int J Oncol. 2002 Oct;21(4):775-85
[
12239616.001
]
[Cites]
Neurosci Res. 2002 Oct;44(2):207-12
[
12354635.001
]
[Cites]
Cell. 1990 Feb 23;60(4):585-95
[
1689217.001
]
[Cites]
Cancer Res. 1992 Oct 1;52(19):5334-41
[
1382841.001
]
[Cites]
J Cell Sci. 1992 Oct;103 ( Pt 2):589-97
[
1478958.001
]
[Cites]
Cancer Res. 1994 Jan 15;54(2):354-6
[
8275467.001
]
[Cites]
Neuron. 1994 Jan;12(1):11-24
[
8292356.001
]
[Cites]
Neuron. 1994 Nov;13(5):1071-82
[
7946346.001
]
[Cites]
Brain Res Dev Brain Res. 1995 Jan 14;84(1):109-29
[
7720210.001
]
[Cites]
Lab Invest. 1996 Jan;74(1):188-98
[
8569181.001
]
[Cites]
Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):913-25
[
9353831.001
]
[Cites]
Pediatr Res. 1998 Mar;43(3):386-92
[
9505279.001
]
[Cites]
Curr Opin Cell Biol. 2004 Dec;16(6):708-12
[
15530785.001
]
[Cites]
Lab Invest. 2004 Dec;84(12):1581-92
[
15502861.001
]
[Cites]
J Clin Pathol. 2005 Feb;58(2):222-3
[
15677549.001
]
[Cites]
J Neurooncol. 2005 Aug;74(1):1-8
[
16078101.001
]
[Cites]
Cell Prolif. 2005 Dec;38(6):423-33
[
16300654.001
]
[Cites]
Folia Histochem Cytobiol. 2005;43(4):175-81
[
16382880.001
]
[Cites]
Histopathology. 2006 Mar;48(4):424-30
[
16487364.001
]
[Cites]
BMC Cancer. 2006;6:32
[
16457706.001
]
[Cites]
Am J Surg Pathol. 2003 Jul;27(7):1008-12
[
12826895.001
]
[Cites]
Exp Mol Med. 2004 Feb 29;36(1):52-6
[
15031671.001
]
[Cites]
J Biol Chem. 2004 Jul 2;279(27):27994-9
[
15117961.001
]
[Cites]
Mod Pathol. 2006 May;19(5):659-68
[
16528378.001
]
(PMID = 18925963.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Peptides
[Other-IDs]
NLM/ PMC2588620
21.
Sundaram C, Uppin SG, Uppin MS, Rekha JS, Panigrahi MK, Purohit AK, Rammurti S:
A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas.
J Clin Neurosci
; 2010 Apr;17(4):469-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A clinicopathological and immunohistochemical study
of central nervous system
hemangiopericytomas.
Hemangiopericytomas (HPC) of the
central nervous system
(
CNS
) are uncommon dural-based
tumors
that mimic meningiomas clinically and radiologically.
Because there are few reports about these
tumors
from India, we aimed to study the clinico-pathological and immunohistochemical features of
CNS
HPC.
During 2000 to 2008 all 23 patients diagnosed with HPC of
CNS
at our Institution were reviewed in the study (11 males and 12 females, mean age of 46 years).
There were 14 patients with grade II and nine with grade III
tumors
.
Immunohistochemistry with antibodies to epithelial membrane antigen (EMA), vimentin, S-100, CD34 and Ki-67 was done on routinely processed, paraffin-embedded sections of 20
tumors
.
The mean Ki-67 labeling index was 4.25% in grade II
tumors
and 7.8% in grade III
tumors
.
[MeSH-major]
Central Nervous System Neoplasms
/ pathology. Hemangiopericytoma / pathology
[MeSH-minor]
Adolescent.
Adult
. Aged. Biomarkers,
Tumor
/ analysis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Meningeal
Neoplasms
/ pathology. Meningioma / pathology. Middle Aged. Tomography, X-Ray Computed. Young
Adult
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2009 Elsevier Ltd. All rights reserved.
(PMID = 20167500.001).
[ISSN]
1532-2653
[Journal-full-title]
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
[ISO-abbreviation]
J Clin Neurosci
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Scotland
[Chemical-registry-number]
0 / Biomarkers, Tumor
22.
Kieran MW, Walker D, Frappaz D, Prados M:
Brain tumors: from childhood through adolescence into adulthood.
J Clin Oncol
; 2010 Nov 10;28(32):4783-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Brain
tumors
: from childhood through adolescence into adulthood.
Clinical care is currently divided into
adult
or pediatric care; adolescent patients require specific expertise that most clinical practices do not have.
When illness coincides with the adolescent transition, the health
system
is severely challenged.
Health systems historically have varied widely in the age they choose for allocating an individual to the
adult
model of health care.
Tumors of
the
CNS
complicate the difficult adjustments required in adolescents and young adults by virtue of their morbidity, complex treatment, and prognosis.
Some brain
tumors
are unique to children, some occur predominantly in adults, and others peak in adolescence.
Delays in the diagnosis of brain
tumors
can occur at any age but are particularly common in adolescence because of difficulties of accessing health systems, the difficulties of discriminating pathologic from typical adolescent behavioral characteristics, and changing endocrine function.
This article will discuss the changing brain
tumor
profile of children, adolescents, and adults, with a focus on our limited understanding of the adolescent/young
adult
transition period.
[MeSH-major]
Brain
Neoplasms
/ diagnosis
[MeSH-minor]
Adolescent. Adolescent Medicine.
Adult
. Brain / growth & development. Child. Continuity of Patient Care. Glioma / diagnosis. Glioma / therapy. Humans. Medulloblastoma / diagnosis. Medulloblastoma / therapy.
Neoplasms
, Germ Cell and Embryonal / diagnosis.
Neoplasms
, Germ Cell and Embryonal / therapy
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20458039.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
23.
Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, Braziel RM:
Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1.
Am J Clin Pathol
; 2007 Apr;127(4):633-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant B cells from patients with primary
central nervous system
lymphoma express stromal cell-derived factor-1.
Although the pathogenesis of primary
central nervous system
lymphoma (PCNSL) remains unclear, it is hypothesized that specific chemokine-chemokine receptor interactions may attract malignant B lymphocytes into the
CNS
.
Tumor
cells also stained positively for CXCR4.
[MeSH-major]
B-Lymphocytes / metabolism. Brain
Neoplasms
/ metabolism. Chemokines, CXC / biosynthesis. Lymphoma, B-Cell / metabolism
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Chemokine CCL20. Chemokine CXCL12. Chemokines, CC / biosynthesis. Female. Humans. Immunohistochemistry. Macrophage Inflammatory Proteins / biosynthesis. Male. Middle Aged. Receptors, CXCR4 / biosynthesis
Genetic Alliance.
consumer health - Central Nervous System Lymphoma, Primary
.
Genetic Alliance.
consumer health - Primary malignant lymphoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17369141.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Grant]
United States / NEI NIH HHS / EY / EY014909
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / CCL20 protein, human; 0 / CXCL12 protein, human; 0 / Chemokine CCL20; 0 / Chemokine CXCL12; 0 / Chemokines, CC; 0 / Chemokines, CXC; 0 / Macrophage Inflammatory Proteins; 0 / Receptors, CXCR4
24.
Navas M, Pascual JM, Fraga J, Pedrosa M, Shakur S, Carrasco R, Martínez P, Manzanares R, de Sola RG:
Intracranial intermediate-grade meningeal melanocytoma with increased cellular proliferative index: an illustrative case associated with a nevus of Ota.
J Neurooncol
; 2009 Oct;95(1):105-115
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Solitary primary melanocytic
tumors of the central nervous system
(
CNS
) represent a spectrum of lesions ranging from well-differentiated melanocytoma to melanoma.
Only a minority of melanocytic
tumors
correspond to lesions of intermediate-grade malignancy, whose biological behavior and outcome remain undetermined.
The MIB-1/Ki-67 labeling index may have potential prognostic value in helping the clinician to predict an aggressive clinical behavior and/or malignant progression for primary melanocytic
neoplasms of
the
CNS
.
[MeSH-major]
Melanoma / pathology. Meningeal
Neoplasms
/ pathology. Nevus of Ota / pathology
[MeSH-minor]
Adult
. Humans. Male. Nevus, Pigmented / surgery. Radiography. Tomography Scanners, X-Ray Computed
Genetic Alliance.
consumer health - Nevus
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Surg Neurol. 2003 Mar;59(3):200-10
[
12681556.001
]
[Cites]
J Neurosurg. 2004 Sep;101(3):528-31
[
15352613.001
]
[Cites]
J Neuroradiol. 2005 Jan;32(1):59-62
[
15798616.001
]
[Cites]
Am J Surg Pathol. 1999 Jul;23(7):745-54
[
10403296.001
]
[Cites]
Tumori. 1980 Jun 30;66(3):405-8
[
7445117.001
]
[Cites]
Mt Sinai J Med. 1974 Nov-Dec;41(6):774-91
[
4610369.001
]
[Cites]
J Neurosurg. 2002 Mar;96(3):619-23
[
11883852.001
]
[Cites]
Dermatology. 1992;185(2):146-50
[
1421629.001
]
[Cites]
Magn Reson Med. 1995 Jun;33(6):818-26
[
7651119.001
]
[Cites]
Neurochirurgie. 2001 May;47(2-3 Pt 1):133-6
[
11404684.001
]
[Cites]
Brain Tumor Pathol. 2003;20(1):21-5
[
14604228.001
]
[Cites]
Strahlenther Onkol. 2002 Jun;178(6):336-42
[
12122790.001
]
[Cites]
Cancer. 1983 Jun 15;51(12):2304-10
[
6850510.001
]
[Cites]
Arch Neurobiol (Madr). 1989 Mar-Apr;52(2):93-9
[
2667490.001
]
[Cites]
Neurosurgery. 2005 Jun;56(6):E1376; discussion E1376
[
15918956.001
]
[Cites]
Neurosurgery. 1999 Nov;45(5):1216-21
[
10549940.001
]
[Cites]
J Neurosurg. 1987 Jan;66(1):50-7
[
3783260.001
]
[Cites]
J Neurooncol. 2003 Sep;64(3):259-63
[
14558602.001
]
[Cites]
Oncol Rep. 2008 Jun;19(6):1367-72
[
18497938.001
]
[Cites]
Acta Neurochir (Wien). 2005 Mar;147(3):313-5; discussion 315
[
15618991.001
]
[Cites]
Neurosurgery. 2005 Aug;57(2):E369; discussion E369
[
16094139.001
]
[Cites]
Clin Radiol. 2006 Mar;61(3):294-8
[
16488214.001
]
[Cites]
J Neurosurg Spine. 2007 May;6(5):451-4
[
17542513.001
]
[Cites]
Neurosurgery. 1992 Nov;31(5):945-8
[
1436422.001
]
[Cites]
Childs Nerv Syst. 2006 Jun;22(6):556-61
[
16491422.001
]
[Cites]
Klin Monbl Augenheilkd. 1992 Jun;200(6):665-70
[
1507791.001
]
[Cites]
J Neurosurg. 1992 Apr;76(4):705-9
[
1545267.001
]
[Cites]
Arch Pathol Lab Med. 1995 Jun;119(6):542-6
[
7605172.001
]
[Cites]
Cancer. 1972 Nov;30(5):1286-94
[
4343293.001
]
[Cites]
J Neurosurg. 2001 Oct;95(2 Suppl):225-31
[
11599841.001
]
[Cites]
NMR Biomed. 1996 Apr;9(2):65-71
[
8887370.001
]
[Cites]
Neurology. 1993 Feb;43(2):381-6
[
8437707.001
]
[Cites]
Childs Nerv Syst. 2009 Apr;25(4):407-10
[
19139906.001
]
(PMID = 19449182.001).
[ISSN]
1573-7373
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
25.
Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM:
Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line.
J Neurooncol
; 2007 Aug;84(1):1-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Malignant gliomas are the most common and devastating primary
tumors of
the
adult
central nervous system
.
Dexamethasone, a synthetic glucocorticoid, is commonly co-administered to control edema in the management of brain
tumors
during chemotherapy and radiotherapy.
[MeSH-major]
5'-Nucleotidase / metabolism. Anti-Inflammatory Agents / pharmacology. Brain
Neoplasms
/ enzymology. Dexamethasone / pharmacology. Glioma / enzymology
[MeSH-minor]
Adenosine Monophosphate / metabolism. Animals. Cell Death / drug effects. Cell Line,
Tumor
. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Protein Kinase C / metabolism. Purines / metabolism. Rats. Signal Transduction / drug effects. Time Factors
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
ADENOSINE 5'-PHOSPHATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anticancer Res. 1996 Mar-Apr;16(2):805-9
[
8687132.001
]
[Cites]
Anal Biochem. 1986 Sep;157(2):375-80
[
2946250.001
]
[Cites]
Am J Reprod Immunol. 2005 Mar;53(3):144-52
[
15727569.001
]
[Cites]
Vascul Pharmacol. 2005 Mar;42(4):153-62
[
15820441.001
]
[Cites]
J Cell Physiol. 2001 Jan;186(1):19-23
[
11147810.001
]
[Cites]
J Neurooncol. 2001 Jan;51(2):105-10
[
11386406.001
]
[Cites]
Science. 1968 Jul 26;161(3839):370-1
[
4873531.001
]
[Cites]
Drug Metab Dispos. 2006 Jun;34(6):1063-9
[
16531474.001
]
[Cites]
Pharmacol Rev. 1998 Sep;50(3):413-92
[
9755289.001
]
[Cites]
Pharmacol Ther. 2003 Oct;100(1):31-48
[
14550503.001
]
[Cites]
Neurology. 1997 Jun;48(6):1704-9
[
9191791.001
]
[Cites]
Purinergic Signal. 2006 Jun;2(2):409-30
[
18404480.001
]
[Cites]
Anticancer Res. 1994 Jul-Aug;14(4A):1585-8
[
7979189.001
]
[Cites]
J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82
[
15698542.001
]
[Cites]
Eur J Pharmacol. 1992 Oct 1;227(2):113-22
[
1426027.001
]
[Cites]
Br J Pharmacol. 1997 Jan;120(2):273-81
[
9117120.001
]
[Cites]
J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43
[
16125621.001
]
[Cites]
Genes Dev. 1995 Jul 1;9(13):1608-21
[
7628695.001
]
[Cites]
Neuroscience. 2000;96(2):417-25
[
10683582.001
]
[Cites]
Cell Tissue Res. 2002 Dec;310(3):257-70
[
12457224.001
]
[Cites]
Blood. 2003 Dec 15;102(13):4472-8
[
12947007.001
]
[Cites]
Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32
[
11124130.001
]
[Cites]
Oncogene. 1998 Sep 24;17(12):1567-75
[
9794234.001
]
[Cites]
Trends Pharmacol Sci. 2006 Mar;27(3):166-76
[
16487603.001
]
[Cites]
Apoptosis. 1999 Jun;4(3):197-211
[
14634282.001
]
[Cites]
Melanoma Res. 2006 Jun;16(3):213-22
[
16718268.001
]
[Cites]
BMC Cancer. 2006 Sep 23;6:226
[
16995949.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Trends Pharmacol Sci. 2006 Apr;27(4):211-7
[
16530853.001
]
[Cites]
Nucleic Acids Res. 1992 Feb 25;20(4):825-9
[
1531873.001
]
[Cites]
Cancer Lett. 2003 Aug 20;198(2):211-8
[
12957360.001
]
[Cites]
Biochem J. 1992 Jul 15;285 ( Pt 2):345-65
[
1637327.001
]
(PMID = 17453149.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-Inflammatory Agents; 0 / Purines; 415SHH325A / Adenosine Monophosphate; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.5 / 5'-Nucleotidase
26.
Manitt C, Wang D, Kennedy TE, Howland DR:
Positioned to inhibit: netrin-1 and netrin receptor expression after spinal cord injury.
J Neurosci Res
; 2006 Dec;84(8):1808-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Netrin-1 regulates axon extension during embryonic development and is expressed by neurons and myelinating oligodendrocytes in the
adult CNS
.
To investigate the potential role of netrin-1 after spinal cord injury, we examined the expression of netrin-1 and netrin receptors after sagittal myelotomy in
adult
rats.
[MeSH-major]
Gene Expression Regulation / physiology. Nerve Growth Factors / metabolism. Receptors, Cell Surface / metabolism. Spinal Cord Injuries / metabolism. Spinal Cord Injuries / physiopathology.
Tumor
Suppressor Proteins / metabolism
MedlinePlus Health Information.
consumer health - Spinal Cord Injuries
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16998900.001).
[ISSN]
0360-4012
[Journal-full-title]
Journal of neuroscience research
[ISO-abbreviation]
J. Neurosci. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Glial Fibrillary Acidic Protein; 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / netrin receptors; 158651-98-0 / netrin-1
27.
Rajaram V, Gutmann DH, Prasad SK, Mansur DB, Perry A:
Alterations of protein 4.1 family members in ependymomas: a study of 84 cases.
Mod Pathol
; 2005 Jul;18(7):991-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Ependymomas are common pediatric and
adult CNS
malignancies with a wide biologic spectrum that is often hard to predict using classic prognostic variables.
The majority of cases harbored one or more detectable genetic alterations, but we found that 4.1B gene deletions and 4.1R loss of expression were statistically more common in the pediatric vs
adult
, intracranial vs spinal, and grade III vs grade I/II subsets (P-values of 0.038 to <0.001).
Also, 4.1G deletions were seen in 11/27 (41%) patients who either died of disease or had residual/recurrent
tumor
vs 5/41 patients with no evidence of disease at last follow-up (P=0.009).
We conclude that alterations of Protein 4.1 family members are common in ependymal
tumors
and that specific alterations are associated with distinct clinicopathologic subsets.
[MeSH-minor]
Adolescent.
Adult
. Aged. Blood Proteins / analysis. Blood Proteins / genetics. Brain
Neoplasms
/ genetics. Brain
Neoplasms
/ metabolism. Brain
Neoplasms
/ pathology. Child. Child, Preschool. Cohort Studies. Cytoskeletal Proteins / analysis. Cytoskeletal Proteins / genetics. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Microfilament Proteins. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / genetics. Middle Aged. Neurofibromin 2 / analysis. Neurofibromin 2 / genetics. Spinal Cord
Neoplasms
/ genetics. Spinal Cord
Neoplasms
/ metabolism. Spinal Cord
Neoplasms
/ pathology.
Tumor
Suppressor Proteins / analysis.
Tumor
Suppressor Proteins / genetics
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15731777.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Blood Proteins; 0 / Cytoskeletal Proteins; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / erythrocyte membrane band 4.1 protein
28.
Kabashi S, Muçaj S, Ahmetgjekaj I, Gashi S, Fazliu I, Dreshaj S, Shala N:
Radiological imaging detection of tumors localized in fossa cranii posterior.
Med Arh
; 2008;62(5-6):271-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radiological imaging detection
of tumors
localized in fossa cranii posterior.
Intracranial
tumors
are characterized by a variety imaging aspects and their detection is always a challenge.
Clinical application of Magnetic Resonance Imaging (MRI) and Computerized Tomography has provided an earlier detection and treatment of many
CNS
pathologies.
The aim of this study is to estimate the role of CT and MRI in the determination of posterior fossa
tumors
.
RESULTS: During period 2000-2005 in UCCK-Prishtina, 368 patients were diagnosed with intracranial
tumors
.
Fifty-nine of them were found to have
tumor
localized in fossa crani posterior (FCP) without any significant difference between genders (50.8% female vs. 49.2% male, chi2 test=0.02 p=0.896).
The average age of patients with FCP
tumors
was 33.1 (SD +/- 22.5, rank 1-70).
Tumor
types that more often were found in young's individuals were: Astrocytomas with a peak incidence in teenagers (average age was 12-year-old SD +/- 7.5, rank 3-23), next was Medulloblastomas (average age was 11-years-old, SD +/- 2.9, rank 6-16 years) and ependymomas (average age was 6.8-years-old, SD +/- 4.6, rank 1-12).
Patients with osseous
tumors
are characterized by older age than median (61.0, SD +/- 4.2, rank 58-64), then metastases (53.0, SD +/- 5.3, rank 45-60) and meningiomas (50.8, SD +/- 7.7, rank 38-63).
CONCLUSION: Comparing with other countries, for some types of FCP
tumors
, lower morbidity is shown in Kosova, with mean incidence 0.41/100,000.
The most frequent
tumors
in children were medulloblastomas, brainstem gliomas, astrocytomas and ependymomas whereas meningiomas and metastasis were most often found in adults.
For FCP
tumors
detection, MRI had 100% sensitivity, specificity and predictive positive value, whereas brain CT was characterized by 95% sensitivity, 90.4 % specificity and 91% predictive positive value.
[MeSH-major]
Infratentorial
Neoplasms
/ diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed
[MeSH-minor]
Adolescent.
Adult
. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Young
Adult
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19469268.001).
[Journal-full-title]
Medicinski arhiv
[ISO-abbreviation]
Med Arh
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Bosnia and Herzegovina
29.
Leães CG, Meurer RT, Coutinho LB, Ferreira NP, Pereira-Lima JF, da Costa Oliveira M:
Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells.
Neuropathology
; 2010 Feb 1;30(1):44-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Evidence suggests that sex hormones may play a role in the tumorigenesis of meningiomas, and studies have demonstrated the expression of hormone receptors in these
tumors
.
Aromatase expression has been detected in several normal tissues, including neurons in the
CNS
, and
tumor
tissues.
Behavior pattern differences observed between aromatase expression, present in normal tissues and absent in meningiomas, and estrogen and androgen hormone receptors, absent in normal tissues and present in meningiomas, suggest that there is heterogeneity in modulation by sex steroids in the development of these
tumors
.
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Arachnoid Cysts / enzymology. Arachnoid Cysts / metabolism. Brazil. Cross-Sectional Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Odds Ratio. Sex Characteristics. Young
Adult
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19703265.001).
[ISSN]
1440-1789
[Journal-full-title]
Neuropathology : official journal of the Japanese Society of Neuropathology
[ISO-abbreviation]
Neuropathology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 1.14.14.1 / Aromatase
30.
Lepore AC, Neuhuber B, Connors TM, Han SS, Liu Y, Daniels MP, Rao MS, Fischer I:
Long-term fate of neural precursor cells following transplantation into developing and adult CNS.
Neuroscience
; 2006 Sep 29;142(1):287-304
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term fate of neural precursor cells following transplantation into developing and
adult CNS
.
Successful strategies for transplantation of neural precursor cells for replacement of lost or dysfunctional
CNS
cells require long-term survival of grafted cells and integration with the host
system
, potentially for the life of the recipient.
Few studies have examined the long-term properties of transplanted neural precursor cells in the
CNS
, particularly in non-neurogenic regions of the
adult
.
The aim of the present study was to extensively characterize the fate of defined populations of neural precursor cells following transplantation into the developing and
adult CNS
(brain and spinal cord) for up to 15 months, including integration of graft-derived neurons with the host.
We found that in both developing and
adult CNS
grafted cells showed long-term survival, morphological maturation, extensive distribution and differentiation into all mature
CNS
cell types (neurons, astrocytes and oligodendrocytes).
Graft-derived neurons also formed synapses, as identified by electron microscopy, suggesting that transplanted neural precursor cells integrated with
adult CNS
.
We did not detect
tumor
formation, cells did not localize to unwanted locations and no pronounced immune response was present at the graft sites.
The long-term stability of neuronal-restricted precursors and glial-restricted precursors and the lack of adverse effects suggest that transplantation of lineage-restricted neural precursor cells can serve as an effective and safe replacement therapy for
CNS
injury and degeneration.
[MeSH-major]
Cell Differentiation / physiology.
Central Nervous System
/ physiology. Neurons / physiology. Stem Cell Transplantation / methods. Stem Cells / physiology
MedlinePlus Health Information.
consumer health - Stem Cells
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[RepublishedFrom]
Neuroscience. 2006 May 12;139(2):513-30
[
16458439.001
]
(PMID = 17120358.001).
[ISSN]
0306-4522
[Journal-full-title]
Neuroscience
[ISO-abbreviation]
Neuroscience
[Language]
eng
[Grant]
United States / NINDS NIH HHS / NS / NS 37515; United States / NINDS NIH HHS / NS / NS24707
[Publication-type]
Comparative Study; Corrected and Republished Article; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Gangliosides; 0 / Immunosuppressive Agents; 0 / Nerve Tissue Proteins; 0 / Neural Cell Adhesion Molecules; 0 / ganglioside A2B5
31.
Harter PN, Bunz B, Dietz K, Hoffmann K, Meyermann R, Mittelbronn M:
Spatio-temporal deleted in colorectal cancer (DCC) and netrin-1 expression in human foetal brain development.
Neuropathol Appl Neurobiol
; 2010 Dec;36(7):623-35
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
AIMS: Deleted in colorectal cancer (DCC) and its ligand netrin-1 are known as axonal guidance factors, being involved in angiogenesis, migration and survival of precursor cells in the embryonic mammalian
central nervous system
(
CNS
).
So far, little is known about the distribution of those molecules in human
CNS
development.
Together with the data from animal experiments, our findings might indicate also an important role for DCC and netrin-1 in human foetal
CNS
development.
[MeSH-major]
Brain / embryology. Brain Chemistry / physiology. Nerve Growth Factors / biosynthesis. Receptors, Cell Surface / biosynthesis.
Tumor
Suppressor Proteins / biosynthesis
[MeSH-minor]
Adult
. Brain Stem / metabolism. Cerebellum / metabolism. Cerebral Cortex / metabolism. Choroid Plexus / metabolism. Ependyma / cytology. Ependyma / metabolism. Female. Fetal Development. Fetus / metabolism. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Pregnancy
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Colorectal cancer 1
.
Genetic Alliance.
consumer health - Brain Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© 2010 The Authors. Neuropathology and Applied Neurobiology © 2010 British Neuropathological Society.
(PMID = 20609112.001).
[ISSN]
1365-2990
[Journal-full-title]
Neuropathology and applied neurobiology
[ISO-abbreviation]
Neuropathol. Appl. Neurobiol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / DCC protein, human; 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1
32.
Kushner YB, Brimo F, Schwartzman K, Auger M:
A rare case of pulmonary cryptococcal inflammatory myofibroblastic tumor diagnosed by fine needle aspiration cytology.
Diagn Cytopathol
; 2010 Jun;38(6):447-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A rare case of pulmonary cryptococcal inflammatory myofibroblastic
tumor
diagnosed by fine needle aspiration cytology.
In a recent outbreak in British Columbia (BC), Canada, Cryptococcus gattii, a rare species of Cryptococcus, was noted to affect primarily immunocompetent hosts and cause limited pulmonary or
CNS
disease.
We herein report a rare case of a pulmonary inflammatory myofibroblastic
tumor
caused by a Cryptococcus infection, presumed to be of the gattii species, in a 20-year-old immunocompetent college student from Vancouver, BC who presented with a large lung mass.
Cryptococcal inflammatory myofibroblastic
tumors
have been reported, but neither in the lung nor in the setting of an immunocompetent host.
[MeSH-minor]
Antifungal Agents / therapeutic use. Biopsy, Fine-Needle. Cryptococcus gattii. Female. Fluconazole / therapeutic use. Humans. Young
Adult
Genetic Alliance.
consumer health - Inflammatory myofibroblastic tumor
.
Hazardous Substances Data Bank.
FLUCONAZOLE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2009 Wiley-Liss, Inc.
(PMID = 19937947.001).
[ISSN]
1097-0339
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antifungal Agents; 8VZV102JFY / Fluconazole
33.
Ahmed S:
The culture of neural stem cells.
J Cell Biochem
; 2009 Jan 1;106(1):1-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Neural stem cells (NSCs) are present during embryonic development and in certain regions of the
adult
central nervous system
(
CNS
).
Mobilizing
adult
NSCs to promote repair of injured or diseased
CNS
is a promising approach.
Since NSCs may give rise to brain
tumor
, they represent in vitro models for anti-cancer drug screening.
Important future directions that are highlighted in this review are; identification of markers for NSCs, the use of NSCs in high-throughput screens and the modelling of the
central nervous
development.
There is no doubt that the study of NSCs is crucial if we are to tackle the diseases of the
CNS
such as Parkinson's and Alzheimer's.
[MeSH-minor]
Animals. Cells, Cultured.
Central Nervous System
/ cytology. Humans. Models, Biological
MedlinePlus Health Information.
consumer health - Stem Cells
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2008 Wiley-Liss, Inc.
(PMID = 19021147.001).
[ISSN]
1097-4644
[Journal-full-title]
Journal of cellular biochemistry
[ISO-abbreviation]
J. Cell. Biochem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Number-of-references]
80
34.
Gerber DE, Grossman SA, Batchelor T, Ye X:
Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Cancer Chemother Pharmacol
; 2007 May;59(6):817-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary
central nervous system
lymphoma.
BACKGROUND: High-dose methotrexate (HDMTX) (>or=3 g/m2), the cornerstone of therapy for primary
CNS
lymphoma (PCNSL), is commonly dosed using a measured 24 h creatinine clearance (CrCl) every 2-4 weeks.
METHODS: A retrospective analysis was performed on data from all 287 treatment cycles from the 25 patients with PCNSL who participated in a multi-center phase II clinical trial of HDMTX conducted by the New Approaches to Brain
Tumor
Therapy (NABTT)
CNS
Consortium.
[MeSH-major]
Central Nervous System Neoplasms
/ drug therapy. Creatinine / pharmacokinetics. Kidney Function Tests / methods. Lymphoma / drug therapy. Lymphoma / urine. Methotrexate / administration & dosage
[MeSH-minor]
Adult
. Aged. Female. Humans. Male. Metabolic Clearance Rate. Middle Aged. Retrospective Studies
Genetic Alliance.
consumer health - Central Nervous System Lymphoma, Primary
.
MedlinePlus Health Information.
consumer health - Creatinine
.
MedlinePlus Health Information.
consumer health - Kidney Tests
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16972068.001).
[ISSN]
0344-5704
[Journal-full-title]
Cancer chemotherapy and pharmacology
[ISO-abbreviation]
Cancer Chemother. Pharmacol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
[Publication-country]
Germany
[Chemical-registry-number]
AYI8EX34EU / Creatinine; YL5FZ2Y5U1 / Methotrexate
35.
Kimura N, Yamamoto Y, Kameyama R, Hatakeyama T, Kawai N, Nishiyama Y:
Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor.
Nucl Med Commun
; 2009 Aug;30(8):602-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain
tumor
.
OBJECTIVE: The purpose of this study was to evaluate the efficacy of quantitative imaging of glucose metabolism with positron emission tomography (PET) using kinetic analysis for differentiating between high-grade glioma and
central nervous system
(
CNS
) lymphoma.
METHODS: Dynamic fluorine-18-fluorodeoxyglucose (18F-FDG)-PET scans obtained in 20 patients with high-grade glioma (World Health Organization grade III, five lesions; grade IV, 15 lesions) and in 12 patients with
CNS
lymphoma (16 lesions) were retrospectively reviewed.
Fourteen
CNS
lymphoma lesions showed an increase of K1, 16 of k3, two of k4, and 14 of CMR(Glc).
Both k3 and CMR(Glc) values (mean+/-SD) of
CNS
lymphoma (0.096+/-0.046 and 77.4+/-37.7, respectively) were significantly higher than those of the normal gray matter (0.059+/-0.015 and 41.3+/-9.3, respectively; P<0.007 and P<0.002, respectively).
The k3 value of
CNS
lymphoma was significantly higher than that of grade III (0.058+/-0.022) and grade IV (0.065+/-0.024) gliomas (P<0.03 and P<0.04, respectively).
The CMR(Glc) value of
CNS
lymphoma was significantly higher than that of grade III (33.8+/-7.8) and grade IV (41.5+/-23.1) gliomas (P<0.001 and P<0.004, respectively).
The value of k2 of
CNS
lymphoma was significantly lower than that of grade IV glioma (P<0.05).
CONCLUSION: The direct measurement of the regional rate constants by kinetic analysis might be useful for the delineation of
CNS
lymphoma and for differential diagnosis of high-grade glioma and
CNS
lymphoma.
[MeSH-major]
Brain
Neoplasms
/ metabolism. Brain
Neoplasms
/ radionuclide imaging. Fluorodeoxyglucose F18. Glucose / metabolism
[MeSH-minor]
Adult
. Aged. Diagnosis, Differential. Female. Glioma / metabolism. Glioma / radionuclide imaging. Humans. Kinetics. Lymphoma / metabolism. Lymphoma / radionuclide imaging. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
GLUCOSE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19521265.001).
[ISSN]
1473-5628
[Journal-full-title]
Nuclear medicine communications
[ISO-abbreviation]
Nucl Med Commun
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
36.
Xiong NX, Zhao HY, Zhang FC, He ZQ:
Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.
Neurosci Bull
; 2007 Jan;23(1):41-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Negative correlation of Nogo-A with the malignancy of oligodendroglial
tumor
.
OBJECTIVE: Nogo-A is an axon regeneration inhibitor, and its function in
central nervous system
(
CNS
) is still unknown.
The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial
tumors
in patients.
METHODS:
Tumor
tissue samples with different malignancy grade were obtained from the hospitals.
The samples used for detection had been diagnosed as oligodendroglial
tumors
(oligodendroglioma or anaplastic oligodendroglioma).
The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in
the tumors
) related to the malignancy of
tumor
tissues was performed.
RESULTS: There was significant negative correlation between the Nogo-A expression and the morphological change of
tumor
tissues according to immunohistochemistry.
CONCLUSION: Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial
tumors
.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism. Brain
Neoplasms
/ diagnosis. Brain
Neoplasms
/ metabolism. Myelin Proteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
[MeSH-minor]
Adult
. Down-Regulation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index.
Neoplasm
Invasiveness / diagnosis. Nogo Proteins. Predictive Value of Tests
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosci. 2002 May 1;22(9):3553-67
[
11978832.001
]
[Cites]
J Neurosci. 2003 Jul 2;23 (13):5393-406
[
12843238.001
]
[Cites]
Oncogene. 2001 Jul 5;20(30):3929-36
[
11494121.001
]
[Cites]
J Mol Neurosci. 2005;25(1):1-6
[
15781961.001
]
[Cites]
J Cell Physiol. 2003 Aug;196 (2):312-8
[
12811824.001
]
[Cites]
Nature. 2000 Jan 27;403(6768):434-9
[
10667796.001
]
[Cites]
J Biol Chem. 2003 May 23;278(21):19280-5
[
12639960.001
]
[Cites]
Nature. 2000 Jan 27;403(6768):439-44
[
10667797.001
]
[Cites]
Cancer Res. 1998 Jan 1;58(1):149-58
[
9426071.001
]
[Cites]
J Neurochem. 2004 Sep;90(5):1156-62
[
15312170.001
]
[Cites]
Oncogene. 2003 Mar 6;22(9):1390-9
[
12618765.001
]
[Cites]
Oncogene. 2000 Nov 23;19(50):5736-46
[
11126360.001
]
[Cites]
Biochem J. 2005 Oct 15;391(Pt 2):433-40
[
16095439.001
]
[Cites]
Oncogene. 2004 Apr 15;23(17):2977-87
[
15021917.001
]
[Cites]
Apoptosis. 2003 Jan;8(1):5-9
[
12510146.001
]
(PMID = 17592524.001).
[ISSN]
1673-7067
[Journal-full-title]
Neuroscience bulletin
[ISO-abbreviation]
Neurosci Bull
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Singapore
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / RTN4 protein, human
37.
Kim DS, Na DG, Kim KH, Kim JH, Kim E, Yun BL, Chang KH:
Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Radiology
; 2009 May;251(2):467-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distinguishing tumefactive demyelinating lesions from glioma or
central nervous system
lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
PURPOSE: To determine retrospectively whether unenhanced computed tomographic (CT) images of the brain have added value in distinguishing tumefactive demyelinating lesions (TDLs) from primary glioma or
central nervous system
(
CNS
) lymphoma, compared with conventional contrast material-enhanced magnetic resonance (MR) images only.
Unenhanced CT and MR images in 15 patients with TDLs (seven women, eight men; mean age, 42 years; range, 27-57 years) and 48 patients with primary brain
tumor
(27 women, 21 men; mean age, 48 years; range, 19-70 years; 10 lymphomas, 38 gliomas) were retrospectively reviewed.
The diagnostic accuracy of MR imaging for differentiating TDLs from
tumors
was compared with that of MR imaging plus CT.
RESULTS: The following MR imaging features were found more frequently in patients with TDL than in those with brain
tumor
: incomplete rim enhancement, mixed T2-weighted iso- and hyperintensity of enhanced regions, absence of a mass effect, and absence of cortical involvement (all P values < .05).
CT hypoattenuation of MR enhanced regions was observed in 14 (93%) of 15 patients with TDL but in only two (4%) of 48 patients with
tumor
.
The CT attenuation of MR enhanced regions was significantly lower for patients with TDL than for those with
tumor
(P < .001).
CONCLUSION: Unenhanced CT plus MR imaging was more accurate for distinguishing TDLs from glioma or
CNS
lymphoma than contrast-enhanced MR imaging alone.
[MeSH-major]
Brain
Neoplasms
/ diagnosis. Demyelinating Diseases / diagnosis. Glioma / diagnosis. Image Enhancement / methods. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
[MeSH-minor]
Adult
. Contrast Media. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young
Adult
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19261924.001).
[ISSN]
1527-1315
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Contrast Media
38.
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK, Cintredekin Besudotox Intraparenchymal Study Group:
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
J Clin Oncol
; 2007 Mar 1;25(7):837-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE: Glioblastoma multiforme (GBM) is a devastating brain
tumor
with a median survival of 6 months after recurrence.
PATIENTS AND METHODS: Three phase I clinical studies evaluated intracerebral CED of CB along with
tumor
resection.
All patients underwent
tumor
resection followed by a single intraparenchymal infusion (in addition to the intraparenchymal one following resection), with a portion of patients who had a preresection intratumoral infusion.
The maximum tolerated intraparenchymal concentration was 0.5 microg/mL and
tumor
necrosis was observed at this concentration.
CB- and procedure-related adverse events were primarily limited to the
CNS
.
[MeSH-major]
Drug Delivery Systems / methods. Exotoxins / administration & dosage. Glioma / drug therapy. Immunotoxins / administration & dosage. Interleukin-13 / administration & dosage. Supratentorial
Neoplasms
/ drug therapy
[MeSH-minor]
Adult
. Aged. Catheterization. Convection. Female. Humans. Male. Middle Aged.
Neoplasm
Recurrence, Local. Tissue Distribution
Genetic Alliance.
consumer health - Glioma
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
SciCrunch.
DrugBank: Data: Chemical
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17327604.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13
39.
Gläsker S, Klingler JH, Müller K, Würtenberger C, Hader C, Zentner J, Neumann HP, Velthoven VV:
Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease.
Cent Eur Neurosurg
; 2010 May;71(2):80-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Essentials and pitfalls in the treatment of
CNS
hemangioblastomas and von Hippel-Lindau disease.
Hemangioblastomas are rare
CNS
tumors
, which are mostly located in the posterior fossa or spinal cord and occasionally in spinal nerves.
They can occur sporadically or as a component
tumor
of von Hippel-Lindau (VHL) disease, an autosomal dominant
tumor
syndrome.
[MeSH-major]
Cerebellar
Neoplasms
/ pathology. Cerebellar
Neoplasms
/ surgery. Hemangioblastoma / pathology. Hemangioblastoma / surgery. Neurosurgical Procedures / methods. Spinal Cord
Neoplasms
/ pathology. Spinal Cord
Neoplasms
/ surgery. von Hippel-Lindau Disease / pathology. von Hippel-Lindau Disease / surgery
[MeSH-minor]
Adult
. Humans. Magnetic Resonance Imaging. Male
MedlinePlus Health Information.
consumer health - Von Hippel-Lindau Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright Georg Thieme Verlag KG Stuttgart . New York.
(PMID = 20229452.001).
[ISSN]
1868-4912
[Journal-full-title]
Central European neurosurgery
[ISO-abbreviation]
Cent Eur Neurosurg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
40.
Neder L, Scheithauer BW, Turel KE, Arnesen MA, Ketterling RP, Jin L, Moynihan TJ, Giannini C, Meyer FB:
Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature.
Virchows Arch
; 2009 Apr;454(4):431-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Desmoplastic small round cell
tumor
of the
central nervous system
: report of two cases and review of the literature.
Desmoplastic small round cell
tumor
(DSRCT) is a malignant
tumor
often involving the abdominal and/or pelvic peritoneum.
Only one fully documented example has arisen in
the central nervous system
(
CNS
).
In conclusion,
CNS
DSRCT follows a similar aggressive course as do peritoneal examples.
Although rare, DSRCT warrants consideration in the differential diagnosis of "malignant small blue cell
tumors
" of the
CNS
.
[MeSH-major]
Carcinoma, Small Cell / pathology. Cerebellar
Neoplasms
/ pathology. Cerebellopontine Angle / pathology
[MeSH-minor]
Adult
. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Desmoplastic Small Round Cell Tumor
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Surg Pathol. 1992 Oct;16(10):998-1006
[
1384373.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
[
11895036.001
]
[Cites]
Am J Surg Pathol. 1998 Nov;22(11):1303-13
[
9808123.001
]
[Cites]
Am J Surg Pathol. 1990 Jul;14(7):633-42
[
2356923.001
]
[Cites]
J Clin Oncol. 1998 Sep;16(9):3028-36
[
9738572.001
]
[Cites]
Diagn Mol Pathol. 1998 Feb;7(1):24-8
[
9646031.001
]
[Cites]
Am J Surg Pathol. 1996 Jan;20(1):112-7
[
8540602.001
]
[Cites]
Hum Pathol. 1997 Apr;28(4):502-9
[
9104953.001
]
[Cites]
Cancer Cell. 2002 Dec;2(6):497-505
[
12498718.001
]
[Cites]
Arch Pathol Lab Med. 2006 May;130(5):728-32
[
16683894.001
]
[Cites]
Hum Pathol. 1992 Apr;23(4):454-64
[
1563748.001
]
[Cites]
Arch Pathol Lab Med. 1989 Sep;113(9):1019-29
[
2505732.001
]
[Cites]
Am J Surg Pathol. 2002 Jul;26(7):823-35
[
12131150.001
]
[Cites]
Am J Surg Pathol. 1989 May;13(5):413-21
[
2469334.001
]
[Cites]
Nature. 1990 Jul 12;346(6280):194-7
[
2164159.001
]
[Cites]
Am J Surg Pathol. 1995 Jun;19(6):659-65
[
7755152.001
]
[Cites]
Diagn Mol Pathol. 2005 Mar;14(1):23-8
[
15714060.001
]
[Cites]
Am J Surg Pathol. 1999 Nov;23(11):1408-13
[
10555010.001
]
[Cites]
Cancer Genet Cytogenet. 1993 Aug;69(1):17-21
[
8374894.001
]
[Cites]
Exp Cell Res. 2001 Mar 10;264(1):74-99
[
11237525.001
]
[Cites]
Acta Cytol. 1995 Mar-Apr;39(2):377-8
[
7887076.001
]
[Cites]
J Surg Oncol. 1999 Aug;71(4):269-72
[
10440769.001
]
[Cites]
J Neurosurg. 1996 Jul;85(1):56-65
[
8683283.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):97-109
[
17618441.001
]
[Cites]
Acta Cytol. 1993 Jan-Feb;37(1):77-82
[
7679537.001
]
[Cites]
Semin Diagn Pathol. 1996 Aug;13(3):204-12
[
8875710.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32
[
7862627.001
]
[Cites]
Am J Surg Pathol. 2004 May;28(5):644-50
[
15105654.001
]
[Cites]
Virchows Arch. 1998 Feb;432(2):135-41
[
9504858.001
]
[Cites]
Mod Pathol. 1999 Jul;12(7):729-34
[
10430278.001
]
[Cites]
Ultrastruct Pathol. 2000 Sep-Oct;24(5):333-7
[
11071572.001
]
[Cites]
Hum Pathol. 1999 Apr;30(4):430-5
[
10208465.001
]
[Cites]
Pediatr Pathol. 1989;9(2):177-83
[
2473463.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1991;418(3):207-14
[
1900966.001
]
[Cites]
Cancer Res. 1994 Jun 1;54(11):2837-40
[
8187063.001
]
[Cites]
Am J Surg Pathol. 1991 Jun;15(6):499-513
[
1709557.001
]
[Cites]
Gynecol Oncol. 2000 Oct;79(1):124-8
[
11006044.001
]
[Cites]
Arch Pathol Lab Med. 2002 Oct;126(10):1226-8
[
12296765.001
]
[Cites]
Semin Cancer Biol. 2005 Jun;15(3):197-205
[
15826834.001
]
[Cites]
Semin Diagn Pathol. 2003 Feb;20(1):25-45
[
12693673.001
]
[Cites]
Pediatr Blood Cancer. 2008 Oct;51(4):545-8
[
18561179.001
]
(PMID = 19263077.001).
[ISSN]
1432-2307
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
41.
Küsters-Vandevelde HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA:
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.
Acta Neuropathol
; 2010 Mar;119(3):317-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic
neoplasms of the central nervous system
.
Primary melanocytic
neoplasms of the central nervous system
(
CNS
) are uncommon
neoplasms
derived from melanocytes that normally can be found in the leptomeninges.
Characteristic genetic alterations in this group
of neoplasms
have not yet been identified.
Using direct sequencing, we investigated 19 primary melanocytic lesions of the
CNS
(12 melanocytomas, 3 intermediate-grade melanocytomas, and 4 melanomas) for hotspot oncogenic mutations commonly found in melanocytic
tumors of
the skin (BRAF, NRAS, and HRAS genes) and uvea (GNAQ gene).
Somatic mutations in the GNAQ gene at codon 209, resulting in constitutive activation of GNAQ, were detected in 7/19 (37%)
tumors
, including 6/12 melanocytomas, 0/3 intermediate-grade melanocytomas, and 1/4 melanomas.
These GNAQ-mutated
tumors
were predominantly located around the spinal cord (6/7).
One melanoma carried a BRAF point mutation that is frequently found in cutaneous melanomas (c.1799 T>A, p.V600E), raising the question whether this is a metastatic rather than a primary
tumor
.
We conclude that somatic mutations in the GNAQ gene at codon 209 are a frequent event in primary melanocytic
neoplasms of
the
CNS
.
This finding provides new insight in the pathogenesis of these lesions and suggests that GNAQ-dependent mitogen-activated kinase signaling is a promising therapeutic target in these
tumors
.
The prognostic and predictive value of GNAQ mutations in primary melanocytic lesions of the
CNS
needs to be determined in future studies.
[MeSH-major]
Central Nervous System Neoplasms
/ genetics.
Central Nervous System Neoplasms
/ pathology. GTP-Binding Protein alpha Subunits / genetics. Melanocytes / pathology. Melanoma / pathology. Mutation / genetics
[MeSH-minor]
Adult
. Aged. Codon / genetics. DNA,
Neoplasm
/ genetics. DNA,
Neoplasm
/ isolation & purification. Female. Genes, ras / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins B-raf / genetics. Retrospective Studies. Tissue Fixation
MedlinePlus Health Information.
consumer health - Melanoma
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2009 May 1;27(13):2290-1
[
19349541.001
]
[Cites]
Br J Cancer. 2009 Sep 1;101(5):813-5
[
19654573.001
]
[Cites]
PLoS One. 2009;4(8):e6833
[
19718445.001
]
[Cites]
Nature. 1999 Dec 2;402(6761):496-501
[
10591209.001
]
[Cites]
Annu Rev Biochem. 2000;69:795-827
[
10966476.001
]
[Cites]
Clin Cancer Res. 2002 Nov;8(11):3468-74
[
12429636.001
]
[Cites]
Cancer Res. 2003 Sep 15;63(18):5761-6
[
14522897.001
]
[Cites]
Leukemia. 2003 Dec;17(12):2257-317
[
14671650.001
]
[Cites]
J Invest Dermatol. 2003 Nov;121(5):1160-2
[
14708620.001
]
[Cites]
Int J Cancer. 2004 Sep 20;111(5):705-10
[
15252839.001
]
[Cites]
Nat Genet. 2004 Sep;36(9):961-8
[
15322542.001
]
[Cites]
Nat Genet. 2004 Sep;36(9):935-6
[
15340429.001
]
[Cites]
Neurosurgery. 1981 Jan;8(1):26-30
[
7207769.001
]
[Cites]
J Invest Dermatol. 1984 Mar;82(3):235-8
[
6699426.001
]
[Cites]
J Neurosurg. 1987 Jun;66(6):948
[
3572529.001
]
[Cites]
Annu Rev Biochem. 1987;56:779-827
[
3304147.001
]
[Cites]
Cancer. 1988 May 1;61(9):1926-34
[
3355984.001
]
[Cites]
J Am Acad Dermatol. 1991 May;24(5 Pt 1):747-55
[
1869648.001
]
[Cites]
Neurology. 1993 Feb;43(2):381-6
[
8437707.001
]
[Cites]
Science. 1993 Dec 17;262(5141):1895-901
[
8266082.001
]
[Cites]
Neurosurgery. 1994 Mar;34(3):533-7; discussion 637
[
8190231.001
]
[Cites]
Pathologica. 1997 Apr;89(2):168-74
[
9411364.001
]
[Cites]
Am J Surg Pathol. 1999 Jul;23(7):745-54
[
10403296.001
]
[Cites]
Acta Neurochir (Wien). 2005 Mar;147(3):313-5; discussion 315
[
15618991.001
]
[Cites]
Melanoma Res. 2006 Apr;16(2):97-103
[
16567964.001
]
[Cites]
Melanoma Res. 2006 Aug;16(4):267-73
[
16845322.001
]
[Cites]
Cell Oncol. 2007;29(1):19-24
[
17429138.001
]
[Cites]
Hum Mutat. 2007 Jun;28(6):578-88
[
17295241.001
]
[Cites]
Curr Opin Oncol. 2008 Mar;20(2):183-9
[
18300768.001
]
[Cites]
J Neurosurg Spine. 2008 Jul;9(1):48-54
[
18590410.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4
[
18719078.001
]
[Cites]
Nature. 2009 Jan 29;457(7229):599-602
[
19078957.001
]
(PMID = 19936769.001).
[ISSN]
1432-0533
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Codon; 0 / DNA, Neoplasm; 0 / GNAQ protein, human; 0 / GTP-Binding Protein alpha Subunits; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
42.
Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V:
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
Breast Cancer Res
; 2006;8(4):R36
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Central nervous system
relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult
tumor
cells and with the HER2/neu status.
INTRODUCTION: To evaluate the incidence
of central nervous system
(
CNS
) involvement in patients with breast cancer treated with a taxane-based chemotherapy regimen and to determine predictive factors for
CNS
relapse.
METHODS: The medical files of patients with early breast cancer (n = 253) or advanced stage breast cancer (n = 239) as well of those with other solid
tumors
(n = 336) treated with or without a taxane-based chemotherapy regimen during a 42-month period were reviewed.
HER2/neu overexpression was identified by immunohistochemistry, whereas cytokeratin 19 (CK-19) mRNA-positive circulating
tumor
cells (CTCs) in the peripheral blood were identified by real-time PCR.
RESULTS: The incidence of
CNS
relapse was similar in patients suffering from breast cancer or other solid
tumors
(10.4% and 11.4%, respectively; P = 0.517).
The incidence of
CNS
relapse was significantly higher in breast cancer patients with advanced disease (P = 0.041), visceral disease and bone disease (P = 0.036), in those who were treated with a taxane-containing regimen (P = 0.024), in those with HER2/neu-overexpressing
tumors
(P = 0.022) and, finally, in those with detectable CK-19 mRNA-positive CTCs (P = 0.008).
Multivariate analysis revealed that the stage of disease (odds ratio, 0.23; 95% confidence interval, 0.007-0.23; P = 0.0001), the HER2/neu status (odds ratio, 29.4; 95% confidence interval, 7.51-101.21; P = 0.0001) and the presence of CK-19 mRNA-positive CTCs (odds ratio, 8.31; 95% confidence interval, 3.97-12.84; P = 0.001) were independent predictive factors for
CNS
relapse.
CONCLUSION:
CNS
relapses are common among breast cancer patients treated with a taxane-based chemotherapy regimen, patients with HER2/neu-positive
tumor
and patients with CK-19 mRNA-positive CTCs.
[MeSH-major]
Breast
Neoplasms
/ pathology. Breast
Neoplasms
/ physiopathology.
Central Nervous System Neoplasms
/ physiopathology. Neoplastic Cells, Circulating
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Keratin-19. Middle Aged.
Neoplasm
Staging. Predictive Value of Tests. RNA, Messenger. Receptor, ErbB-2 / biosynthesis. Taxoids / therapeutic use
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2000 Feb 24;342(8):525-33
[
10684910.001
]
[Cites]
Ann Oncol. 2005 Nov;16(11):1772-7
[
16150805.001
]
[Cites]
N Engl J Med. 2001 Mar 15;344(11):783-92
[
11248153.001
]
[Cites]
Ann Oncol. 2001 Mar;12(3):353-6
[
11332148.001
]
[Cites]
CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
[
11814064.001
]
[Cites]
Lancet Oncol. 2002 Jan;3(1):53-7
[
11905606.001
]
[Cites]
J Clin Oncol. 2002 Aug 15;20(16):3404-12
[
12177100.001
]
[Cites]
J Clin Oncol. 2002 Oct 1;20(19):4130-3
[
12351617.001
]
[Cites]
J Clin Invest. 2002 Nov;110(9):1309-18
[
12417570.001
]
[Cites]
Cancer. 2003 Jun 15;97(12):2972-7
[
12784331.001
]
[Cites]
Ann Oncol. 2003 Jun;14(6):849-55
[
12796021.001
]
[Cites]
Ann Oncol. 2003 Jul;14(7):1072-7
[
12853349.001
]
[Cites]
Clin Cancer Res. 2003 Nov 1;9(14):5145-51
[
14613993.001
]
[Cites]
Br J Cancer. 2004 Aug 16;91(4):639-43
[
15266327.001
]
[Cites]
Adv Neurol. 1978;19:579-92
[
570349.001
]
[Cites]
Cancer. 1979 Nov;44(5):1913-8
[
498057.001
]
[Cites]
Cancer. 1981 Feb 1;47(3):554-60
[
7226005.001
]
[Cites]
Eur J Cancer. 1981 Apr;17(4):449-53
[
7308254.001
]
[Cites]
Cancer. 1983 Dec 15;52(12):2349-54
[
6640506.001
]
[Cites]
Cancer Chemother Pharmacol. 1994;34(6):465-71
[
7923556.001
]
[Cites]
Ann Oncol. 1994 Dec;5(10):951-3
[
7696168.001
]
[Cites]
Cancer. 1995 Jul 15;76(2):232-6
[
8625097.001
]
[Cites]
J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24
[
10393719.001
]
[Cites]
Ann Oncol. 2004 Nov;15(11):1640-4
[
15520065.001
]
[Cites]
Clin Cancer Res. 2004 Dec 15;10(24):8185-94
[
15623593.001
]
[Cites]
QJM. 2000 Sep;93(9):611-5
[
10984556.001
]
(PMID = 16846533.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Keratin-19; 0 / RNA, Messenger; 0 / Taxoids; EC 2.7.10.1 / Receptor, ErbB-2
[Other-IDs]
NLM/ PMC1779464
43.
Brandt-Bohne U, Keene DR, White FA, Koch M:
MEGF9: a novel transmembrane protein with a strong and developmentally regulated expression in the nervous system.
Biochem J
; 2007 Jan 15;401(2):447-57
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MEGF9: a novel transmembrane protein with a strong and developmentally regulated expression in
the nervous system
.
MEGF9 [multiple EGF (epidermal growth factor)-like-domains 9], a novel transmembrane protein with multiple EGF-like repeats, is predominantly expressed in the developing and
adult CNS
(
central nervous system
) and PNS (peripheral
nervous system
).
[MeSH-major]
Central Nervous System
/ metabolism. Gene Expression Regulation, Developmental. Membrane Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Peripheral
Nervous System
/ metabolism
[MeSH-minor]
Amino Acid Sequence. Animals. Epidermal Growth Factor / genetics. Humans. Keratinocytes / metabolism. Mice. Molecular Sequence Data. Protein Processing, Post-Translational. Protein Structure, Tertiary. Rats. Sequence Alignment. Skin / cytology. Tongue / cytology.
Tumor
Cells, Cultured
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 1991 May 25;266(15):9678-86
[
2033060.001
]
[Cites]
Pediatr Res. 2005 May;57(5 Pt 2):104R-109R
[
15817497.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 May 1;90(9):4037-41
[
8483919.001
]
[Cites]
Hum Mutat. 1999;14(5):394-400
[
10533065.001
]
[Cites]
J Biol Chem. 1999 Nov 5;274(45):31751-4
[
10542193.001
]
[Cites]
J Neurosci. 1999 Nov 15;19(22):9900-12
[
10559399.001
]
[Cites]
J Cell Biol. 2000 Oct 16;151(2):221-34
[
11038171.001
]
[Cites]
J Comp Neurol. 2001 Feb 19;430(4):485-500
[
11169482.001
]
[Cites]
Arch Oral Biol. 2001 Aug;46(8):745-57
[
11389866.001
]
[Cites]
Circ Res. 2002 Mar 22;90(5):506-8
[
11909813.001
]
[Cites]
Hum Mol Genet. 2002 Sep 1;11(18):2113-8
[
12189163.001
]
[Cites]
J Biol Chem. 2003 May 2;278(18):15457-60
[
12556455.001
]
[Cites]
Matrix Biol. 1994 Aug;14(4):275-81
[
7827749.001
]
[Cites]
Mol Biol Cell. 2003 Jul;14(7):2665-76
[
12857855.001
]
[Cites]
Neuron. 2003 Sep 25;40(1):113-27
[
14527437.001
]
[Cites]
DNA Res. 2003 Aug 31;10(4):167-80
[
14621295.001
]
[Cites]
Cell Prolif. 2004 Apr;37(2):161-75
[
15030550.001
]
[Cites]
Annu Rev Biochem. 2004;73:491-537
[
15189151.001
]
[Cites]
Int J Biochem Cell Biol. 2004 Oct;36(10):1861-7
[
15203098.001
]
[Cites]
Nature. 1970 Aug 15;227(5259):680-5
[
5432063.001
]
[Cites]
FEBS Lett. 1988 Apr 11;231(1):1-4
[
3282918.001
]
[Cites]
Adv Protein Chem. 1988;39:1-50
[
3149870.001
]
[Cites]
FEBS Lett. 1989 Jul 17;251(1-2):1-7
[
2666164.001
]
[Cites]
Annu Rev Physiol. 1995;57:607-34
[
7778880.001
]
[Cites]
Genomics. 1996 Feb 15;32(1):54-64
[
8786121.001
]
[Cites]
J Lipid Res. 1996 Feb;37(2):368-81
[
9026534.001
]
[Cites]
Genomics. 1998 Jul 1;51(1):27-34
[
9693030.001
]
[Cites]
Dev Biol. 2005 Feb 15;278(2):381-95
[
15680358.001
]
[Cites]
Mol Psychiatry. 2005 Mar;10(3):251-7
[
15583703.001
]
[Cites]
Glia. 1991;4(1):11-24
[
1828781.001
]
(PMID = 16981854.001).
[ISSN]
1470-8728
[Journal-full-title]
The Biochemical journal
[ISO-abbreviation]
Biochem. J.
[Language]
eng
[Databank-accession-numbers]
RefSeq/ NM/ 172694/ XM/ 3769095
[Grant]
United States / NINDS NIH HHS / NS / R01 NS049136
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / MEGF9 protein, human; 0 / MEGF9 protein, mouse; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 62229-50-9 / Epidermal Growth Factor
[Other-IDs]
NLM/ PMC1820795
44.
Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA:
Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
Pediatr Blood Cancer
; 2008 Jul;51(1):17-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Treatment included vincristine, actinomycin D, and cyclophosphamide (VAC) chemotherapy and radiotherapy to the primary
tumor
and up to five metastatic sites/tissues.
Sites of first progression/relapse were distant (55%), local (12%),
CNS
extension (8%), mixed (6%), and uncertain (18%).
Factors indicating likelihood of 10-year FFS included
tumor
arising in "better" versus "worse" sites (FFS 46% vs. 18%, P = 0.02) and embryonal versus other histology (FFS 37% vs. 19%, P = 0.06).
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 Wiley-Liss, Inc.
(PMID = 18266224.001).
[ISSN]
1545-5017
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
45.
Cooper PB, Auerbach A, Aguilera NS, Adair C, Moores L, Geyer D, Rushing EJ:
Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature.
Clin Neuropathol
; 2006 Sep-Oct;25(5):232-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rare primary
CNS
anaplastic large cell lymphoma in an immunocompetent
adult
: a clinical-pathologic case report and review case of the literature.
OBJECTIVE AND IMPORTANCE: Isolated anaplastic large cell lymphoma (ALCL) presenting in the primary
central nervous system
is distinctly uncommon.
The authors describe a case that clinically and radiographically simulated a primary glial
neoplasm
.
There appeared to be a clear demarcation between white matter and
tumor
with no obvious necrosis.
CONCLUSION: Reported in less than 20 patients, primary ALCL in an immunocompetent patient is rarely found intracranially; however, its ability to mimic glial
neoplasms
as well as other pathologies underlines its importance.
[MeSH-major]
Brain
Neoplasms
/ pathology. Lymphoma, Large B-Cell, Diffuse / pathology
[MeSH-minor]
Adult
. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers,
Tumor
/ analysis. Combined Modality Therapy. Diagnosis, Differential. Glioma / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy. Seizures / etiology
Genetic Alliance.
consumer health - Anaplastic Large Cell Lymphoma
.
Genetic Alliance.
consumer health - Lymphoma, large-cell
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Clin Neuropathol. 2007 Jan-Feb;26(1):39-40; author reply 40
[
17290938.001
]
(PMID = 17007446.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor
46.
Selkirk SM, Morrow J, Barone TA, Hoffer A, Lock J, DeChant A, Mangla S, Plunkett RJ, Miller RH:
Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.
J Neurooncol
; 2008 Feb;86(3):285-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Elevation of osteopontin levels in brain
tumor
cells reduces burden and promotes survival through the inhibition of cell dispersal.
Osteopontin (OPN) is a pleotrophic molecule that has been associated with multiple disorders of the
central nervous system
(
CNS
).
Its roles in
CNS
malignancy are unclear but suggest that higher levels of OPN expression correlate with increased
tumor
grade and increased migratory capacity of
tumor
cells.
Implantation of
tumor
cells expressing high levels of OPN into
adult
Fischer rats and nude rats resulted in morphologically distinct
tumors
and prolonged host survival relative to controls.
We propose that local produced, high level OPN expression limits the malignant character of glioma cells and that the downstream mechanisms involved represent pathways that may have therapeutic value in the treatment of human
CNS
malignancy.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
BROMODEOXYURIDINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 1999 Dec 17;274(51):36328-34
[
10593924.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):10024-31
[
17047065.001
]
[Cites]
Exp Cell Res. 2000 Aug 1;258(2):342-51
[
10896785.001
]
[Cites]
J Biol Chem. 2000 Aug 11;275(32):24565-74
[
10835423.001
]
[Cites]
Int J Exp Pathol. 2000 Dec;81(6):373-90
[
11298186.001
]
[Cites]
J Biol Chem. 2001 Jul 27;276(30):28261-7
[
11375993.001
]
[Cites]
Science. 2001 Nov 23;294(5547):1731-5
[
11721059.001
]
[Cites]
J Biol Chem. 2001 Dec 7;276(49):46024-30
[
11590166.001
]
[Cites]
Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85
[
11825687.001
]
[Cites]
QJM. 2002 Jan;95(1):3-13
[
11834767.001
]
[Cites]
Cancer Res. 2002 Sep 15;62(18):5336-43
[
12235004.001
]
[Cites]
Cancer Res. 2002 Nov 1;62(21):6318-22
[
12414663.001
]
[Cites]
Oncogene. 2003 Feb 27;22(8):1198-205
[
12606946.001
]
[Cites]
J Neuroimmunol. 2003 Mar;136(1-2):125-9
[
12620651.001
]
[Cites]
J Biol Chem. 2003 Aug 1;278(31):28593-606
[
12771144.001
]
[Cites]
Mol Cancer Res. 2003 Sep;1(11):810-9
[
14517343.001
]
[Cites]
J Biol Chem. 2004 Mar 19;279(12):11051-64
[
14704150.001
]
[Cites]
J Neuroimmunol. 2004 Oct;155(1-2):155-60
[
15342207.001
]
[Cites]
Cell. 1979 Apr;16(4):885-93
[
88265.001
]
[Cites]
J Biol Chem. 1987 Feb 25;262(6):2900-7
[
3469201.001
]
[Cites]
J Biol Chem. 1987 Jul 15;262(20):9702-8
[
3597437.001
]
[Cites]
J Exp Med. 1989 Jul 1;170(1):145-61
[
2787378.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):426-30
[
1729712.001
]
[Cites]
Am J Pathol. 1994 Sep;145(3):610-23
[
8080043.001
]
[Cites]
Biochem J. 1994 Oct 1;303 ( Pt 1):255-62
[
7945249.001
]
[Cites]
Lab Invest. 1995 Jan;72(1):55-63
[
7837791.001
]
[Cites]
J Clin Invest. 1995 Feb;95(2):713-24
[
7532190.001
]
[Cites]
Lung Cancer. 1996 Nov;15(3):311-23
[
8959677.001
]
[Cites]
J Biol Chem. 1997 Apr 11;272(15):10110-6
[
9092556.001
]
[Cites]
Arch Pathol Lab Med. 1997 Jun;121(6):578-84
[
9199622.001
]
[Cites]
Clin Cancer Res. 1997 Apr;3(4):605-11
[
9815727.001
]
[Cites]
Cancer Res. 1999 Jan 1;59(1):219-26
[
9892210.001
]
[Cites]
J Cell Biochem Suppl. 1998;30-31:92-102
[
9893260.001
]
[Cites]
J Biol Chem. 2005 May 13;280(19):19381-92
[
15757900.001
]
[Cites]
Trends Cell Biol. 2006 Feb;16(2):79-87
[
16406521.001
]
[Cites]
Cancer Res. 2006 Jul 1;66(13):6638-48
[
16818637.001
]
[Cites]
Bioessays. 2006 Sep;28(9):923-34
[
16937364.001
]
[Cites]
Ann N Y Acad Sci. 1999;890:204-22
[
10668427.001
]
(PMID = 17928956.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA10373602; United States / NINDS NIH HHS / NS / R01 NS036674; United States / NINDS NIH HHS / NS / NS030800-14; United States / NINDS NIH HHS / NS / R01 NS030800; United States / NINDS NIH HHS / NS / NS-3080011; United States / NINDS NIH HHS / NS / R37 NS036674; United States / NINDS NIH HHS / NS / R01 NS030800-14; United States / NINDS NIH HHS / NS / NS-36674-08
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD31; 106441-73-0 / Osteopontin; 147336-22-9 / Green Fluorescent Proteins; G34N38R2N1 / Bromodeoxyuridine
[Other-IDs]
NLM/ NIHMS196650; NLM/ PMC2911624
47.
Kuchelmeister K, Nestler U, Siekmann R, Schachenmayr W:
Liponeurocytoma of the left lateral ventricle--case report and review of the literature.
Clin Neuropathol
; 2006 Mar-Apr;25(2):86-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In this location, liponeurocytomas are very exceptional, whereas it is the typical site for classic
central
neurocytomas.
Thus, cerebellar liponeurocytoma is the most frequent neuroepithelial
CNS tumor
with adipose-like cells followed by ependymomas with a lipid component and supratentorial intraventricular liponeurocytoma.
Adipose-like cells in neurocytomas may originate by lipidization of
tumor
cells, metaplastic transformation of neuroectodermal cells into fat cells or by true adipocytic differentiation.
The present case showed also focal glial differentiation with GFAP-positivity of some
tumor
cells as often seen in cerebellar liponeurocytomas but much rarer in
central
neurocytomas.
Future WHO
tumor
classification should consider that liponeurocytomas are not restricted to the cerebellum.
[MeSH-major]
Cerebral Ventricle
Neoplasms
/ pathology. Lipoma / pathology. Neurocytoma / pathology
[MeSH-minor]
Adult
. Cerebellar
Neoplasms
/ pathology. Diagnosis, Differential. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16550742.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Glial Fibrillary Acidic Protein
48.
Lush ME, Li Y, Kwon CH, Chen J, Parada LF:
Neurofibromin is required for barrel formation in the mouse somatosensory cortex.
J Neurosci
; 2008 Feb 13;28(7):1580-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The rodent barrel cortex is a useful
system
to study the role of genes and neuronal activity in the patterning of the
nervous system
.
Neurofibromin is a
tumor
suppressor protein that has Ras GTPase activity, thus attenuating the MAPK (mitogen-activated protein kinase) and and PI-3 kinase (phosphatidylinositol 3-kinase) pathways, and is mutated in humans with the condition neurofibromatosis type 1 (NF1).
Neurofibromin is widely expressed in the developing and
adult
nervous system
, and a common feature of NF1 is deficits in intellectual development.
Thus, NF1 may have important roles in normal
CNS
development and function.
To explore roles for neurofibromin in the development of the
CNS
, we took advantage of a mouse conditional allele.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
The Antibody Registry: Reagent: Antibodies
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Neurosci. 2000 Jul;3(7):661-9
[
10862698.001
]
[Cites]
Nature. 2000 Feb 24;403(6772):895-8
[
10706287.001
]
[Cites]
Genesis. 2000 Nov-Dec;28(3-4):147-55
[
11105057.001
]
[Cites]
Am J Med Genet. 2000 Summer;97(2):119-27
[
11180219.001
]
[Cites]
Nat Neurosci. 2001 Mar;4(3):282-8
[
11224545.001
]
[Cites]
Cell. 2001 Feb 23;104(4):593-604
[
11239415.001
]
[Cites]
Exp Cell Res. 2001 Mar 10;264(1):19-28
[
11237520.001
]
[Cites]
Genet Med. 1999 May-Jun;1(4):136-40
[
11258348.001
]
[Cites]
Genes Dev. 2001 Apr 1;15(7):859-76
[
11297510.001
]
[Cites]
Trends Neurosci. 2001 Oct;24(10):589-95
[
11576673.001
]
[Cites]
Genesis. 2001 Oct;31(2):85-94
[
11668683.001
]
[Cites]
Nat Neurosci. 2002 Feb;5(2):95-6
[
11788835.001
]
[Cites]
Nature. 2002 Jan 31;415(6871):526-30
[
11793011.001
]
[Cites]
Trends Mol Med. 2003 Jan;9(1):19-23
[
12524206.001
]
[Cites]
Neuron. 2003 Mar 6;37(5):751-64
[
12628166.001
]
[Cites]
Am J Med Genet B Neuropsychiatr Genet. 2004 Nov 15;131B(1):43-7
[
15389774.001
]
[Cites]
J Neurosci. 2005 Apr 13;25(15):3774-86
[
15829629.001
]
[Cites]
Cancer Cell. 2005 Aug;8(2):119-30
[
16098465.001
]
[Cites]
Development. 2005 Dec;132(24):5577-88
[
16314489.001
]
[Cites]
J Neurosci. 2006 Feb 1;26(5):1355-65
[
16452659.001
]
[Cites]
Genesis. 2006 Mar;44(3):130-5
[
16496331.001
]
[Cites]
J Neurosci. 2006 Mar 8;26(10):2692-703
[
16525048.001
]
[Cites]
J Neurosci. 2006 Apr 19;26(16):4338-49
[
16624954.001
]
[Cites]
J Neurosci. 2006 May 17;26(20):5393-401
[
16707791.001
]
[Cites]
Neuron. 2007 Oct 25;56(2):339-55
[
17964250.001
]
[Cites]
Neurology. 2003 Dec 23;61(12):1799-801
[
14694053.001
]
[Cites]
Brain Res. 1970 Jan 20;17(2):205-42
[
4904874.001
]
[Cites]
Proc Natl Acad Sci U S A. 1975 Jun;72(6):2165-9
[
1056021.001
]
[Cites]
Proc Natl Acad Sci U S A. 1980 Apr;77(4):2333-7
[
6246540.001
]
[Cites]
Cell. 1990 Jul 13;62(1):187-92
[
1694727.001
]
[Cites]
Cell. 1990 Jul 13;62(1):193-201
[
2114220.001
]
[Cites]
Science. 1990 Jul 13;249(4965):181-6
[
2134734.001
]
[Cites]
Science. 1991 Jun 14;252(5012):1556-60
[
2047863.001
]
[Cites]
Nat Genet. 1994 Jul;7(3):353-61
[
7920653.001
]
[Cites]
Genes Dev. 1994 May 1;8(9):1019-29
[
7926784.001
]
[Cites]
Cell. 1995 Sep 8;82(5):733-42
[
7671302.001
]
[Cites]
Science. 1996 Mar 29;271(5257):1864-7
[
8596955.001
]
[Cites]
Neuron. 1996 Feb;16(2):297-307
[
8789945.001
]
[Cites]
Science. 1997 May 2;276(5313):791-4
[
9115203.001
]
[Cites]
Science. 1997 May 2;276(5313):795-8
[
9115204.001
]
[Cites]
Neuron. 1998 Apr;20(4):683-91
[
9581761.001
]
[Cites]
Neuron. 1998 May;20(5):895-904
[
9620694.001
]
[Cites]
Nat Genet. 1998 Jul;19(3):289-91
[
9662407.001
]
[Cites]
Hum Mol Genet. 1998 Aug;7(8):1261-8
[
9668168.001
]
[Cites]
J Neurosci. 1998 Dec 15;18(24):10420-8
[
9852579.001
]
[Cites]
Nat Genet. 1999 Jan;21(1):70-1
[
9916792.001
]
[Cites]
Am J Med Genet. 1999 Dec 15;88(6):729-32
[
10581497.001
]
[Cites]
Nature. 2000 Aug 17;406(6797):726-31
[
10963597.001
]
(PMID = 18272679.001).
[ISSN]
1529-2401
[Journal-full-title]
The Journal of neuroscience : the official journal of the Society for Neuroscience
[ISO-abbreviation]
J. Neurosci.
[Language]
ENG
[Grant]
United States / NINDS NIH HHS / NS / NS034296-09; United States / NINDS NIH HHS / NS / NS34296; United States / NINDS NIH HHS / NS / R37 NS033199-11; United States / NINDS NIH HHS / NS / R01 NS034296; United States / NINDS NIH HHS / NS / NS033199-11; United States / NINDS NIH HHS / NS / R37NS33199; United States / NINDS NIH HHS / NS / R37 NS033199; United States / NINDS NIH HHS / NS / R01 NS034296-09
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Neurofibromin 1
[Other-IDs]
NLM/ NIHMS149013; NLM/ PMC2760344
49.
Ogata M, Satou T, Kawano R, Takakura S, Goto K, Ikewaki J, Kohno K, Ikebe T, Ando T, Miyazaki Y, Ohtsuka E, Saburi Y, Saikawa T, Kadota J:
Correlations of HHV-6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients.
Bone Marrow Transplant
; 2010 Jan;45(1):129-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Among 111 enrolled subjects, 12 patients developed
central nervous system
(
CNS
) dysfunction.
CNS
dysfunction in four patients was found to have no association with HHV-6.
The remaining eight patients displayed HHV-6 encephalitis (n=3), limbic encephalitis (HHV-6 DNA in cerebrospinal fluid was not examined; n=3) or
CNS
dysfunction because of an unidentified cause (n=2).
Real-time PCR showed
CNS
dysfunction in the latter eight patients, which developed concomitant with the appearance of high plasma levels of HHV-6 DNA (> or =10(4) copies/ml).
Overall, eight of the 24 patients with high-level HHV-6 DNA developed
CNS
dysfunction, whereas no patients developed
CNS
dysfunction potentially associated with HHV-6 infection if peak HHV-6 DNA was <10(4) copies/ml.
We next analyzed plasma concentrations of IL-6, IL-10 and
tumor
necrosis factor-alpha among patients who displayed high-level plasma HHV-6 DNA and found elevated IL-6 concentrations preceding HHV-6 infection in patients who developed
CNS
dysfunction. (Mean+/-s.d.: 865.7+/-1036.3 pg/ml in patients with
CNS
dysfunction; 56.5+/-192.9 pg/ml in others; P=0.01).
[MeSH-minor]
Adolescent.
Adult
. Child. DNA, Viral / blood. Female. Humans. Interleukin-10 / blood. Male. Middle Aged.
Tumor
Necrosis Factor-alpha / blood. Viral Load
Genetic Alliance.
consumer health - HHV-6 encephalitis
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19465942.001).
[ISSN]
1476-5365
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Viral; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
50.
Jayadev S, Yun B, Nguyen H, Yokoo H, Morrison RS, Garden GA:
The glial response to CNS HIV infection includes p53 activation and increased expression of p53 target genes.
J Neuroimmune Pharmacol
; 2007 Dec;2(4):359-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The glial response to
CNS
HIV infection includes p53 activation and increased expression of p53 target genes.
We have also shown that microglia from p53-deficient mice fail to induce neurotoxicity in response to the HIV coat protein gp120 in a coculture
system
, supporting the hypothesis that p53 plays a pathogenic role in the chronic neuroinflammatory component of HIV-associated neurodegeneration.
[MeSH-major]
AIDS Dementia Complex / genetics. AIDS Dementia Complex / metabolism.
Central Nervous System
Infections / metabolism. Gene Expression Regulation, Viral / physiology. Neuroglia / metabolism. Neuroglia / virology.
Tumor
Suppressor Protein p53 / metabolism
[MeSH-minor]
Adult
. Astrocytes / metabolism. Astrocytes / pathology. Astrocytes / virology. Female. Gene Targeting. HeLa Cells. Humans. Male. Microglia / metabolism. Microglia / pathology. Microglia / virology. Middle Aged. Oligodendroglia / metabolism. Oligodendroglia / pathology. Oligodendroglia / virology. Signal Transduction / genetics. Signal Transduction / physiology
Genetic Alliance.
consumer health - HIV
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neuroscience. 2001;103(1):203-18
[
11311801.001
]
[Cites]
Am J Pathol. 1996 Sep;149(3):1027-53
[
8780406.001
]
[Cites]
Neuron. 1996 Mar;16(3):675-86
[
8785064.001
]
[Cites]
Cancer Lett. 2004 Jan 20;203(2):199-207
[
14732228.001
]
[Cites]
N Engl J Med. 1995 Apr 6;332(14):934-40
[
7877652.001
]
[Cites]
J Neurosci Res. 1997 Dec 1;50(5):798-808
[
9418967.001
]
[Cites]
Neurology. 2003 Jan 28;60(2):307-14
[
12552050.001
]
[Cites]
Dev Biol. 2006 May 15;293(2):358-69
[
16581057.001
]
[Cites]
Brain Pathol. 1999 Apr;9(2):209-17
[
10219738.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Jun 10;331(3):851-8
[
15865941.001
]
[Cites]
FASEB J. 2004 Jul;18(10):1141-3
[
15155568.001
]
[Cites]
AIDS. 2000 Sep 8;14(13):1949-54
[
10997399.001
]
[Cites]
Neurology. 1993 Nov;43(11):2230-7
[
8232935.001
]
[Cites]
J Leukoc Biol. 1994 Sep;56(3):389-98
[
8083614.001
]
[Cites]
Ann Neurol. 2001 Jun;49(6):745-52
[
11409426.001
]
[Cites]
Am J Pathol. 2005 Sep;167(3):695-704
[
16127150.001
]
[Cites]
Curr Opin Neurol. 2001 Jun;14(3):375-9
[
11371763.001
]
[Cites]
Brain Res Mol Brain Res. 1999 Jul 23;71(1):78-86
[
10407189.001
]
[Cites]
J Alzheimers Dis. 2001 Feb;3(1):31-40
[
12214070.001
]
[Cites]
Adv Neuroimmunol. 1995;5(3):335-58
[
8748077.001
]
[Cites]
Semin Neurol. 1999;19(2):113-27
[
10718533.001
]
[Cites]
Science. 1990 Dec 14;250(4987):1593-6
[
2148832.001
]
[Cites]
Exp Neurol. 2006 Oct;201(2):349-58
[
16814281.001
]
[Cites]
Nature. 2006 Feb 23;439(7079):988-92
[
16372019.001
]
[Cites]
Glia. 1993 Jan;7(1):102-10
[
8423057.001
]
[Cites]
Nature. 2001 Apr 19;410(6831):988-94
[
11309629.001
]
[Cites]
J Cell Physiol. 2002 Jul;192(1):1-15
[
12115731.001
]
[Cites]
Cell Death Differ. 2005 Aug;12 Suppl 1:855-8
[
15846379.001
]
[Cites]
J Biol Chem. 2000 May 26;275(21):16202-12
[
10821866.001
]
[Cites]
J Cell Physiol. 1999 Nov;181(2):231-9
[
10497302.001
]
[Cites]
Neurobiol Aging. 2005 Mar;26(3):349-54
[
15639313.001
]
[Cites]
J Neurosci. 2003 Sep 24;23(25):8682-91
[
14507967.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12 ):6763-8
[
10823891.001
]
[Cites]
J Neural Transm Suppl. 1999;57:87-97
[
10666670.001
]
[Cites]
J Neurotrauma. 2004 Jun;21(6):754-74
[
15253803.001
]
[Cites]
Biochem Biophys Res Commun. 1992 Feb 14;182(3):1201-7
[
1540165.001
]
[Cites]
Am J Pathol. 1995 May;146(5):1121-30
[
7747806.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):39-44
[
8528731.001
]
[Cites]
Nature. 1997 May 15;387(6630):299-303
[
9153396.001
]
[Cites]
Eur Arch Psychiatry Clin Neurosci. 2001 Aug;251(4):159-69
[
11697580.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2769-73
[
8464887.001
]
[Cites]
Neurochem Res. 2003 Jan;28(1):15-27
[
12587660.001
]
[Cites]
Science. 2004 Feb 13;303(5660):1010-4
[
14963330.001
]
[Cites]
Brain Pathol. 1991 Apr;1(3):143-52
[
1669703.001
]
[Cites]
J Neurosci. 1995 Nov;15(11):7712-26
[
7472522.001
]
[Cites]
Neuropathol Appl Neurobiol. 1999 Apr;25(2):123-33
[
10216000.001
]
[Cites]
Toxicol Lett. 2003 Apr 4;139(2-3):199-206
[
12628755.001
]
[Cites]
Nature. 1997 May 15;387(6630):296-9
[
9153395.001
]
[Cites]
Arch Neurol. 2002 Dec;59(12):1930-6
[
12470182.001
]
[Cites]
Lab Invest. 1998 Apr;78(4):401-11
[
9564885.001
]
[Cites]
Development. 2004 Mar;131(6):1211-20
[
14960496.001
]
[Cites]
Biochem Biophys Res Commun. 1997 Mar 17;232(2):418-21
[
9125193.001
]
[Cites]
Ann Neurol. 1992 Sep;32(3):321-9
[
1416802.001
]
[Cites]
Brain Pathol. 2003 Apr;13(2):195-210
[
12744473.001
]
[Cites]
Am J Pathol. 2004 May;164(5):1717-25
[
15111318.001
]
[Cites]
Ann Neurol. 1993 Jul;34(1):65-70
[
8517682.001
]
[Cites]
Science. 1996 Jul 5;273(5271):59-63
[
8658196.001
]
[Cites]
Nat Neurosci. 2001 Jul;4(7):702-10
[
11426226.001
]
[Cites]
Ann Neurol. 1995 Nov;38(5):755-62
[
7486867.001
]
[Cites]
Mod Pathol. 2000 Oct;13(10):1115-20
[
11048806.001
]
[Cites]
Ann Neurol. 1991 Jun;29(6):651-7
[
1909852.001
]
[Cites]
Cell Mol Life Sci. 2004 Apr;61(7-8):822-42
[
15095006.001
]
[Cites]
J Neurovirol. 2000 May;6 Suppl 1:S38-43
[
10871764.001
]
[Cites]
Oncogene. 1999 Nov 1;18(45):6145-57
[
10557106.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8212-6
[
10393974.001
]
[Cites]
Science. 2006 Jun 16;312(5780):1650-3
[
16728594.001
]
[Cites]
Science. 2000 Apr 21;288(5465):440-2
[
10798979.001
]
[Cites]
Neurobiol Dis. 2000 Dec;7(6 Pt B):613-22
[
11114260.001
]
[Cites]
J Neurovirol. 2004;10 Suppl 1:97-101
[
14982746.001
]
[Cites]
Prog Neurobiol. 2004 Feb;72(2):111-27
[
15063528.001
]
[Cites]
Glia. 2002 Nov;40(2):240-51
[
12379911.001
]
[Cites]
Nature. 2000 Nov 16;408(6810):307-10
[
11099028.001
]
[Cites]
Oncogene. 2001 Mar 8;20(10):1212-9
[
11313865.001
]
[Cites]
Ann Neurol. 1997 Dec;42(6):963-72
[
9403489.001
]
[Cites]
Neurology. 1992 Aug;42(8):1472-6
[
1641138.001
]
[Cites]
Ann Neurol. 2003 Nov;54(5):605-14
[
14595650.001
]
[Cites]
J Clin Invest. 1996 Nov 1;98(9):1979-90
[
8903316.001
]
(PMID = 18040854.001).
[ISSN]
1557-1904
[Journal-full-title]
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
[ISO-abbreviation]
J Neuroimmune Pharmacol
[Language]
eng
[Grant]
United States / NINDS NIH HHS / NS / NS35533; United States / NICHD NIH HHS / HD / P30-HD02774; United States / NIA NIH HHS / AG / T32-AG000268; United States / NINDS NIH HHS / NS / NS45528; United States / NIMH NIH HHS / MH / U01 MH083545; United States / NIMH NIH HHS / MH / N01MH32002
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Tumor Suppressor Protein p53
51.
Sultan I, Qaddoumi I, Rodríguez-Galindo C, Nassan AA, Ghandour K, Al-Hussaini M:
Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.
Pediatr Blood Cancer
; 2010 Jan;54(1):35-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Age, stage, and radiotherapy, but not primary
tumor
site, affects the outcome of patients with malignant rhabdoid
tumors
.
BACKGROUND: Malignant rhabdoid
tumors
(MRTs) are aggressive and often fatal; the Surveillance, Epidemiology, and End Results (SEER) database offers an opportunity to study this rare malignancy.
RESULTS: For the 229 patients included in our data, who were diagnosed from 1986 to 2005, primary
tumors
were located in
the central nervous system
(
CNS
) (35%), kidneys (20%), and extra-renal non-cranial sites (ERNC-MRTs) (45%).
Most patients with renal and
CNS
tumors
were less than 18 years old (87% and 96%, respectively) while more than half of the patients with ERNC-MRTs (61%) were adults.
Among staged
tumors
, 23% were localized, 34% regional, and 43% distant.
Renal
tumors
had significantly more metastatic disease (47%; P = 0.006) than ERNC-MRTs.
Univariate and multivariate analyses showed that age at diagnosis (2-18 years), localized stage
of tumors
, and use of radiotherapy were significantly associated with improved survival.
Adults had a better outcome than young children (<2 years old) but a poorer outcome than older children (2-18 years old);
tumor
stage, but not radiotherapy use, affected outcome in adults.
CONCLUSION: Our population-based study indicates that age at diagnosis,
tumor
stage, and use of radiotherapy favorably impact survival rates of patients with MRTs.
[MeSH-major]
Brain
Neoplasms
/ pathology. Brain
Neoplasms
/ radiotherapy. Kidney
Neoplasms
/ pathology. Kidney
Neoplasms
/ radiotherapy. Rhabdoid
Tumor
/ pathology. Rhabdoid
Tumor
/ radiotherapy
[MeSH-minor]
Adolescent.
Adult
. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged.
Neoplasm
Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Rhabdoid tumor
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Wiley-Liss, Inc.
(PMID = 19798737.001).
[ISSN]
1545-5017
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
52.
Kounin GK, Romansky KV, Traykov LD, Shotekov PM, Stoilova DZ:
Primary spinal melanoma with bilateral papilledema.
Clin Neurol Neurosurg
; 2005 Oct;107(6):525-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A diagnosis of primary
CNS
melanoma was made after dermatological and ophthalmological consultations, ruled out a metastatic lesion.
Primary leptomeningeal melanoma is an extremely rare spinal
tumor
.
[MeSH-major]
Melanoma / diagnosis. Papilledema / etiology. Spinal Cord
Neoplasms
/ diagnosis
[MeSH-minor]
Adult
. Cerebrospinal Fluid / cytology. Cervical Vertebrae / pathology. Diagnosis, Differential. Erythrocyte Count. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging.
Neoplasm
Invasiveness. Spinal Cord / pathology. Spinal Cord Compression / diagnosis. Spinal Cord Compression / surgery. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Papilledema
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16202828.001).
[ISSN]
0303-8467
[Journal-full-title]
Clinical neurology and neurosurgery
[ISO-abbreviation]
Clin Neurol Neurosurg
[Language]
eng
[Publication-type]
Case Reports
[Publication-country]
Netherlands
53.
Vasudevan V, Cheung MC, Yang R, Zhuge Y, Fischer AC, Koniaris LG, Sola JE:
Pediatric solid tumors and second malignancies: characteristics and survival outcomes.
J Surg Res
; 2010 May 15;160(2):184-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pediatric solid
tumors
and second malignancies: characteristics and survival outcomes.
BACKGROUND: To examine the incidence, characteristics, and outcomes for second malignancies following the diagnosis of a primary solid
tumor
in pediatric patients.
Mean age at diagnosis of the primary
tumor
was 7.7 y.
The most common primary malignancies were
CNS
tumors
(22.5%), followed by soft tissue sarcoma (15.8%), retinoblastoma (14.1%), and bone
tumors
(13%).
Hematologic malignancies (35.5%) were the most common second malignancies noted in the cohort, followed by bone
tumors
(18%) and soft tissue sarcomas (15%).
Hematologic malignancies had a shorter latency (3.1 y) compared with solid second
tumors
(11.6 y).
For most
tumor
categories, development of a secondary malignancy was associated with lower 5- and 10-y survival than expected.
CONCLUSIONS:
CNS
tumors
, retinoblastoma, and soft tissue sarcomas in children are the most common solid primary
tumors
, with an increased risk of a second malignancy.
Leukemia is the most common second malignancy seen in pediatric solid
tumors
.
[MeSH-major]
Neoplasms
/ mortality.
Neoplasms
, Second Primary / mortality. SEER Program
[MeSH-minor]
Adolescent. Bone
Neoplasms
/ mortality.
Central Nervous System Neoplasms
/ mortality. Child. Child, Preschool. Female. Follow-Up Studies. Hematologic
Neoplasms
/ mortality. Humans. Incidence. Male. Retinoblastoma / mortality. Sarcoma / mortality. Soft Tissue
Neoplasms
/ mortality. Survival Analysis. Young
Adult
MedlinePlus Health Information.
consumer health - Cancer in Children
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2010 Elsevier Inc. All rights reserved.
(PMID = 19765728.001).
[ISSN]
1095-8673
[Journal-full-title]
The Journal of surgical research
[ISO-abbreviation]
J. Surg. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
54.
Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E:
Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis.
Brain Res
; 2010 May 28;1333:64-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We investigated whether the physiological regulation of cerebrospinal fluid (CSF) levels of
tumor
necrosis factor (TNF)-alpha, epidermal growth factor (EGF), and nerve growth factor (NGF) by cobalamin (Cbl) that is observed in rat and human
central nervous system
(
CNS
) is retained in the CSF of patients with multiple sclerosis (MS).
(b) the decrease in EGF levels in the CSF may be one factor impeding
CNS
remyelination in MS; and (c) the PP clinical course may have different pathogenetic mechanism(s) also on the basis of the molecules investigated in this study.
[MeSH-minor]
Adult
. Aged. Female. Humans. Male. Middle Aged. Radioimmunoassay / methods. Retrospective Studies. Statistics, Nonparametric.
Tumor
Necrosis Factor-alpha / cerebrospinal fluid
Genetic Alliance.
consumer health - Multiple Sclerosis
.
MedlinePlus Health Information.
consumer health - B Vitamins
.
MedlinePlus Health Information.
consumer health - Multiple Sclerosis
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYANOCOBALAMIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2010 Elsevier B.V. All rights reserved.
(PMID = 20347721.001).
[ISSN]
1872-6240
[Journal-full-title]
Brain research
[ISO-abbreviation]
Brain Res.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Tumor Necrosis Factor-alpha; 12001-76-2 / Vitamin B Complex; 62229-50-9 / Epidermal Growth Factor; P6YC3EG204 / Vitamin B 12
55.
Madanat-Harjuoja LM, Malila N, Lähteenmäki PM, Boice JD Jr, Gissler M, Dyba T:
Preterm delivery among female survivors of childhood, adolescent and young adulthood cancer.
Int J Cancer
; 2010 Oct 1;127(7):1669-79
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Site-specific analyses indicated that survivors of germ cell
tumors
and
central nervous system
(
CNS
)
tumors
were at increased risk of preterm delivery, although numbers were small.
In childhood survivors, kidney
tumors
formed the main cause of preterm delivery.
Pediatric, adolescent and young
adult
cancer survivors are at risk for preterm delivery.
Heightened surveillance is recommended especially for Wilms', germ cell and
CNS tumor
survivors.
Genetic Alliance.
consumer health - Childhood Cancer
.
MedlinePlus Health Information.
consumer health - Cancer in Children
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Epidemiol. 2008 Oct;37(5):1109-20
[
18577529.001
]
[Cites]
BMJ. 2008;337:a2312
[
18957469.001
]
[Cites]
Int J Cancer. 2008 Dec 15;123(12):2891-8
[
18798259.001
]
[Cites]
J Clin Oncol. 2009 Jan 20;27(3):334-43
[
19075285.001
]
[Cites]
Fertil Steril. 2009 Feb;91(2):325-30
[
18384780.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):542-52
[
15380591.001
]
[Cites]
JAMA. 1987 Jan 9;257(2):216-9
[
3025465.001
]
[Cites]
Med Pediatr Oncol. 1988;16(4):233-40
[
2843733.001
]
[Cites]
Int J Cancer. 1989 Mar 15;43(3):399-402
[
2538400.001
]
[Cites]
Cancer. 1989 Dec 1;64(11):2335-9
[
2804924.001
]
[Cites]
Duodecim. 1989;105(18):1540-6
[
2680445.001
]
[Cites]
Acta Oncol. 1994;33(4):365-9
[
8018367.001
]
[Cites]
Am J Hum Genet. 1998 Jan;62(1):45-52
[
9443870.001
]
[Cites]
Cancer. 1999 Aug 15;86(4):697-709
[
10440699.001
]
[Cites]
Radiother Oncol. 2004 Nov;73(2):119-31
[
15542158.001
]
[Cites]
J Natl Cancer Inst. 2006 Oct 18;98(20):1453-61
[
17047194.001
]
[Cites]
Pediatr Blood Cancer. 2007 Jul;49(1):47-51
[
16755550.001
]
[Cites]
Paediatr Perinat Epidemiol. 2007 Sep;21(5):441-7
[
17697074.001
]
[Cites]
J Matern Fetal Neonatal Med. 2007 Oct;20(10):719-23
[
17763272.001
]
[Cites]
Obstet Gynecol. 2007 Oct;110(4):849-54
[
17906019.001
]
[Cites]
Cancer. 2007 Nov 15;110(10):2313-20
[
17896787.001
]
[Cites]
BJOG. 2008 Jan;115(1):38-43
[
18053102.001
]
[Cites]
Hum Reprod. 2008 Jan;23(1):178-86
[
18024486.001
]
[Cites]
Health Psychol. 2008 Jan;27(1):43-51
[
18230013.001
]
[Cites]
Arch Pediatr Adolesc Med. 2009 Oct;163(10):879-86
[
19805705.001
]
[Cites]
Eur J Cancer. 2009 Apr;45(6):992-1005
[
19231160.001
]
[Cites]
J Clin Oncol. 2009 May 10;27(14):2319-27
[
19364957.001
]
[Cites]
Br J Obstet Gynaecol. 1999 Dec;106(12):1265-72
[
10609720.001
]
[Cites]
Epidemiology. 2000 Mar;11(2):161-6
[
11021613.001
]
[Cites]
Med Pediatr Oncol. 2002 Apr;38(4):229-39
[
11920786.001
]
[Cites]
J Clin Oncol. 2002 May 15;20(10):2506-13
[
12011129.001
]
[Cites]
Am J Obstet Gynecol. 2002 Oct;187(4):1070-80
[
12389007.001
]
[Cites]
Med Inform Internet Med. 2002 Mar;27(1):33-8
[
12509121.001
]
[Cites]
Pediatrics. 2003 Jun;111(6 Pt 1):1253-61
[
12777538.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1364-8
[
15050311.001
]
[Cites]
J Clin Oncol. 2008 Sep 10;26(26):4340-6
[
18779621.001
]
[Cites]
J Epidemiol Community Health. 2009 Jun;63(6):420-5
[
19211588.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2239-47
[
19661083.001
]
(PMID = 20054856.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA104666; United States / NCI NIH HHS / CA / 1 R01 CA104666
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS180547; NLM/ PMC2919618
56.
Goos M, Lange P, Hanisch UK, Prinz M, Scheffel J, Bergmann R, Ebert S, Nau R:
Fibronectin is elevated in the cerebrospinal fluid of patients suffering from bacterial meningitis and enhances inflammation caused by bacterial products in primary mouse microglial cell cultures.
J Neurochem
; 2007 Sep;102(6):2049-60
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Fibronectin, an extracellular matrix protein, is considered a potent stimulator of the innate immune
system
through TLR4.
For this reason, we hypothesized that these molecules may jointly stimulate the innate immune
system
and increase neuronal damage in bacterial meningitis.
In primary cultures of mouse microglial cells, co-administration of fibronectin at concentrations occurring in the CSF in bacterial meningitis (10 microg/mL) with defined TLR agonists [lipopolysaccharide (TLR4), the synthetic lipopeptide tripalmytoyl-cysteinyl-seryl-(lysyl)3-lysine (TLR2) and single-stranded unmethylated cytosine-guanosine oligodesoxynucleotide (TLR9)] led to an additive release of nitric oxide and
tumor
necrosis factor-alpha when compared with the release elicited by either compound alone.
In conclusion, the inflammatory reaction to bacterial compounds can be aggravated by endogenous fibronectin at elevated levels during bacterial
CNS
infections.
[MeSH-minor]
Adult
. Aged. Animals. Animals, Newborn. Cells, Cultured. Drug Synergism. Female. Humans. Immunity, Innate / immunology. Inflammation Mediators / pharmacology. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Middle Aged. Nerve Degeneration / immunology. Nerve Degeneration / microbiology. Nerve Degeneration / physiopathology. Nitric Oxide / metabolism.
Tumor
Necrosis Factor-alpha / metabolism
Genetic Alliance.
consumer health - Bacterial Meningitis
.
MedlinePlus Health Information.
consumer health - Encephalitis
.
Hazardous Substances Data Bank.
NITRIC OXIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17561936.001).
[ISSN]
0022-3042
[Journal-full-title]
Journal of neurochemistry
[ISO-abbreviation]
J. Neurochem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Fibronectins; 0 / Inflammation Mediators; 0 / Toll-Like Receptors; 0 / Tumor Necrosis Factor-alpha; 31C4KY9ESH / Nitric Oxide
57.
Alameda F, Lloreta J, Ariza A, Salido M, Espinet B, Baro T, Garcia-Fructoso G, Galito E, Munne A, Cruz Sanchez FF, Sole F, Serrano S:
Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case.
Clin Neuropathol
; 2007 Jan-Feb;26(1):12-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primitive neuroectodermal
tumor
of the
central nervous system
with glial differentiation: a FISH study of an
adult
case.
Primitive neuroectodermal
tumors
(PNETs) of the
central nervous system
(
CNS
), a rare occurrence in adults, may show glial differentiation and can be misinterpreted as pure astrocytic
neoplasms
.
Few fluorescence in situ hybridization (FISH) studies have been carried out on these
tumors
; isochromosome 17q was found to be the major chromosomal abnormality.
We present the case of an
adult
in which we performed a FISH study of both the glial and neuronal components.
[MeSH-major]
Brain
Neoplasms
/ genetics. Brain
Neoplasms
/ pathology. Chromosomes, Human, Pair 17 / genetics. Neuroectodermal
Tumors
, Primitive / genetics. Neuroectodermal
Tumors
, Primitive / pathology. Trisomy / genetics
[MeSH-minor]
Adult
. Humans. In Situ Hybridization, Fluorescence. Male
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17290931.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
58.
Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE:
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
J Clin Oncol
; 2010 Jun 20;28(18):3069-75
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain
Tumor
Consortium study.
Toxicities related to BVZ included grade 1 to 3 fatigue in seven patients, grade 1 to 2 hypertension in seven patients, grade 1
CNS
hemorrhage in four patients, and grade 4
CNS
ischemia in two patients.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain
Neoplasms
/ drug therapy. Brain Stem
Neoplasms
/ drug therapy. Glioma / drug therapy.
Neoplasm
Recurrence, Local / drug therapy
[MeSH-minor]
Adolescent.
Adult
. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Child. Diffusion Magnetic Resonance Imaging. Humans. Phosphorylation. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young
Adult
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
[
17317837.001
]
[Cites]
Cancer Cell. 2007 Jan;11(1):83-95
[
17222792.001
]
[Cites]
Nat Rev Cancer. 2008 Apr;8(4):309-16
[
18337733.001
]
[Cites]
Neuro Oncol. 2008 Aug;10(4):624-30
[
18539884.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9
[
18793954.001
]
[Cites]
Pediatr Blood Cancer. 2008 Dec;51(6):806-11
[
18802947.001
]
[Cites]
Clin Cancer Res. 2008 Oct 15;14(20):6371-5
[
18927275.001
]
[Cites]
J Neurooncol. 2009 Feb;91(3):329-36
[
18953493.001
]
[Cites]
J Clin Oncol. 2009 Feb 10;27(5):740-5
[
19114704.001
]
[Cites]
J Clin Oncol. 2009 Oct 1;27(28):4733-40
[
19720927.001
]
[Cites]
Cancer Res. 2000 Apr 1;60(7):1878-86
[
10766175.001
]
[Cites]
Oncogene. 2000 Nov 20;19(49):5598-605
[
11114740.001
]
[Cites]
Eur J Cancer. 2001 Nov;37(16):2064-72
[
11597385.001
]
[Cites]
NMR Biomed. 2002 Feb;15(1):6-17
[
11840548.001
]
[Cites]
J Neurooncol. 2002 Jul;58(3):237-53
[
12187958.001
]
[Cites]
J Clin Oncol. 2002 Dec 15;20(24):4684-91
[
12488414.001
]
[Cites]
J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543
[
12972536.001
]
[Cites]
N Engl J Med. 1971 Nov 18;285(21):1182-6
[
4938153.001
]
[Cites]
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
[
1688381.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
Cancer. 1993 Jul 1;72(1):271-5
[
8508417.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1516-25
[
10334539.001
]
[Cites]
J Neurooncol. 1999 May;43(1):43-7
[
10448870.001
]
[Cites]
Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6
[
15552623.001
]
[Cites]
J Natl Cancer Inst. 2005 Feb 2;97(3):172-87
[
15687360.001
]
[Cites]
Neurol Res. 2005 Jun;27(4):371-7
[
15949234.001
]
[Cites]
Blood. 2005 Oct 1;106(7):2347-55
[
15985545.001
]
[Cites]
Oncology. 2005;69 Suppl 3:25-33
[
16301833.001
]
[Cites]
Cancer. 2006 Mar 15;106(6):1364-71
[
16463390.001
]
[Cites]
Cancer Cell. 2007 Jan;11(1):69-82
[
17222791.001
]
[Cites]
Cancer. 2007 Oct 1;110(7):1542-50
[
17705175.001
]
(PMID = 20479404.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
[Other-IDs]
NLM/ PMC2903337
59.
Sofo V, Salmeri FM, Di Bella P, Sessa E, D'Aleo G, Trimarchi G, Bramanti P:
Short communication: impairment of membrane markers on peripheral blood mononuclear cells and imbalance of cytokine secretion in the pathogenesis of multiple sclerosis active phases.
J Interferon Cytokine Res
; 2005 Nov;25(11):661-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system
(
CNS
).
In active disease, a transmigration of autoreactive T cells to myelin antigens recruited from the peripheral blood (PBMC) to the
CNS
occurs, and there these cells prolong their survival and contribute to the perpetuation of the inflammation.
The aim of this research is to study on PBMCs and in the serum of stable and active MS subjects (1) the behavior of the CD40/CD40L
system
and the consequent balance of Th1 and Th2 cytokines and (2) the apoptosis marker
system
CD95/CD95L and
tumor
necrosis factor (TNF)- binding receptors, TNFRI and TNFRII.
[MeSH-minor]
Adult
. Antigens, CD40 / biosynthesis. Antigens, CD95 / biosynthesis. Apoptosis. Cell Movement. Fas Ligand Protein. Female. Humans. Inflammation. Magnetic Resonance Imaging. Male. Membrane Glycoproteins / biosynthesis. Middle Aged. Myelin Sheath / chemistry. T-Lymphocytes / metabolism. Th1 Cells. Th2 Cells.
Tumor
Necrosis Factors / biosynthesis
Genetic Alliance.
consumer health - Multiple Sclerosis
.
MedlinePlus Health Information.
consumer health - Multiple Sclerosis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16318579.001).
[ISSN]
1079-9907
[Journal-full-title]
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
[ISO-abbreviation]
J. Interferon Cytokine Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD40; 0 / Antigens, CD95; 0 / Cytokines; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors
60.
Guan YG, Wang TH, Ni W, Li L, Lu YC, Gao ZY:
[Distribution of Fas and FasL in the central nervous system of adult rhesus].
Sichuan Da Xue Xue Bao Yi Xue Ban
; 2005 May;36(3):322-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Distribution of Fas and FasL in
the central nervous system
of
adult
rhesus].
OBJECTIVE: To investigate the distribution of Fas and FasL in the
CNS
of
adult
rhesus.
CONCLUSION: The distribution profiles of Fas and FasL in various areas of
CNS
indicate that they may fill some roles in the immune and physical function of the aforesaid anatomic
[MeSH-major]
Antigens, CD95 / metabolism. Brain Chemistry. Membrane Glycoproteins / metabolism.
Tumor
Necrosis Factors / metabolism
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15931857.001).
[ISSN]
1672-173X
[Journal-full-title]
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
[ISO-abbreviation]
Sichuan Da Xue Xue Bao Yi Xue Ban
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors
61.
Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA:
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Neuro Oncol
; 2010 Aug;12(8):855-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain
Tumor
Consortium Study 06-02).
Grade 3/4 toxicities included leukopenia (n = 1), lymphopenia (n = 2), thrombocytopenia (n = 1), ALT elevation (n = 3), AST elevation (n = 1),
CNS
hemorrhage (n = 1), fatigue (n = 1), and thrombotic/embolic events (n = 3); 8 patients required dose reduction.
Two patients had a partial radiographic response by standard bidimensional measurements, whereas 9 patients (6 at the 8-week point and 3 only within the first month of treatment) had decreased contrast enhancement, vasogenic edema, and mass effect but <50% reduction in
tumor
.
[MeSH-major]
Angiogenesis Inhibitors / administration & dosage. Brain
Neoplasms
/ drug therapy. Glioblastoma / drug therapy.
Neoplasm
Recurrence, Local / drug therapy. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage
[MeSH-minor]
Administration, Oral.
Adult
. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Treatment Outcome
Genetic Alliance.
consumer health - Glioblastoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1999 Aug;17(8):2572-8
[
10561324.001
]
[Cites]
J Clin Oncol. 2009 Oct 1;27(28):4733-40
[
19720927.001
]
[Cites]
Am J Pathol. 2003 Apr;162(4):1083-93
[
12651601.001
]
[Cites]
Clin Cancer Res. 2003 Apr;9(4):1399-405
[
12684411.001
]
[Cites]
J Clin Invest. 2003 May;111(9):1287-95
[
12727920.001
]
[Cites]
J Neurosurg. 1977 Sep;47(3):329-35
[
894339.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 Oct;85(20):7748-52
[
2845420.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
Cancer Res. 1992 Jun 1;52(11):3213-9
[
1317261.001
]
[Cites]
Nature. 1992 Oct 29;359(6398):845-8
[
1279432.001
]
[Cites]
Science. 1998 Jan 23;279(5350):577-80
[
9438854.001
]
[Cites]
Science. 2005 Jan 7;307(5706):58-62
[
15637262.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
Cancer Res. 2005 Jul 1;65(13):5523-34
[
15994924.001
]
[Cites]
Cancer Cell. 2006 Apr;9(4):287-300
[
16616334.001
]
[Cites]
Cancer Cell. 2006 May;9(5):391-403
[
16697959.001
]
[Cites]
Clin Cancer Res. 2006 Aug 15;12(16):4899-907
[
16914578.001
]
[Cites]
N Engl J Med. 2007 Jan 11;356(2):115-24
[
17215529.001
]
[Cites]
Cancer Cell. 2007 Jan;11(1):83-95
[
17222792.001
]
[Cites]
Cell Oncol. 2007;29(5):399-408
[
17726262.001
]
[Cites]
Neuro Oncol. 2008 Apr;10(2):162-70
[
18356283.001
]
[Cites]
N Engl J Med. 2008 Jul 31;359(5):492-507
[
18669428.001
]
[Cites]
J Clin Oncol. 2008 Oct 1;26(28):4659-65
[
18824712.001
]
[Cites]
Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35
[
19037839.001
]
[Cites]
J Clin Oncol. 2009 Feb 10;27(5):740-5
[
19114704.001
]
[Cites]
Cancer Cell. 2009 Mar 3;15(3):220-31
[
19249680.001
]
[Cites]
PLoS One. 2009;4(4):e5123
[
19352490.001
]
[Cites]
J Clin Oncol. 2009 May 20;27(15):2542-52
[
19332720.001
]
[Cites]
J Clin Oncol. 2009 Jul 1;27(19):3126-32
[
19451427.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63
[
19167838.001
]
[Cites]
Neoplasia. 2000 Jul-Aug;2(4):306-14
[
11005565.001
]
(PMID = 20200024.001).
[ISSN]
1523-5866
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00459381
[Grant]
United States / NCI NIH HHS / CA / U01 CA062421-12; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCRR NIH HHS / RR / M01RR03186; United States / NCI NIH HHS / CA / CA62399
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
[Other-IDs]
NLM/ PMC2940686
62.
Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, Hallene K, Diglaw T, Franic L, Najm I, Janigro D:
Seizure-promoting effect of blood-brain barrier disruption.
Epilepsia
; 2007 Apr;48(4):732-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE: It is generally accepted that blood-brain barrier (BBB) failure occurs as a result of
CNS
diseases, including epilepsy.
The contribution of
tumor
or chemotherapy to acute seizures was therefore excluded.
Acute vascular failure is sufficient to cause seizures in the absence of
CNS
pathologies or chemotherapy.
MedlinePlus Health Information.
consumer health - Seizures
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
METHOTREXATE
.
Hazardous Substances Data Bank.
D-MANNITOL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Epilepsy Res. 1999 Dec;37(3):223-32
[
10584972.001
]
[Cites]
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1278-86
[
16256779.001
]
[Cites]
J Child Neurol. 2002 Mar;17(3):227-30
[
12026242.001
]
[Cites]
World J Surg. 2002 Oct;26(10):1251-5
[
12205550.001
]
[Cites]
J Neurosci. 2003 Mar 1;23(5):1949-55
[
12629200.001
]
[Cites]
Epilepsia. 2003;44 Suppl 10:11-7
[
14511389.001
]
[Cites]
Restor Neurol Neurosci. 2003;21(3-4):109-21
[
14530574.001
]
[Cites]
Clin Chem Lab Med. 2003 Oct;41(10):1320-2
[
14580159.001
]
[Cites]
Cell Mol Life Sci. 2004 Feb;61(3):369-85
[
14770299.001
]
[Cites]
Clin Chim Acta. 2004 Apr;342(1-2):1-12
[
15026262.001
]
[Cites]
Ann Thorac Surg. 2004 Jul;78(1):46-52; discussion 52-3
[
15223400.001
]
[Cites]
J Neurosci. 2004 Sep 8;24(36):7829-36
[
15356194.001
]
[Cites]
Life Sci. 1980 Jul 21;27(3):239-43
[
6772908.001
]
[Cites]
AJR Am J Roentgenol. 1983 Oct;141(4):829-35
[
6412531.001
]
[Cites]
Ann Neurol. 1983 Sep;14(3):316-24
[
6195955.001
]
[Cites]
Ann Neurol. 1987 Jan;21(1):59-63
[
3493728.001
]
[Cites]
Cancer Chemother Pharmacol. 1990;25(5):320-5
[
2306791.001
]
[Cites]
J Clin Oncol. 1991 Sep;9(9):1580-90
[
1875220.001
]
[Cites]
AJNR Am J Neuroradiol. 1991 Sep-Oct;12(5):885-90
[
1950917.001
]
[Cites]
N Engl J Med. 1993 Oct 7;329(15):1057-64
[
8371727.001
]
[Cites]
J Neurotrauma. 1993 Winter;10(4):415-30
[
8145265.001
]
[Cites]
AJNR Am J Neuroradiol. 1994 Mar;15(3):581-90
[
8197962.001
]
[Cites]
J Comput Assist Tomogr. 1994 Sep-Oct;18(5):731-6
[
8089321.001
]
[Cites]
Glia. 1998 Apr;22(4):390-400
[
9517571.001
]
[Cites]
Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100
[
9588554.001
]
[Cites]
Epilepsy Res. 1998 Sep;32(1-2):275-85
[
9761327.001
]
[Cites]
Brain. 1949 Sep;72(3):373-81, 3 pl
[
15409268.001
]
[Cites]
Rocz Akad Med Bialymst. 2004;49 Suppl 1:236-8
[
15638435.001
]
[Cites]
Epilepsia. 2005 Jan;46(1):84-90
[
15660772.001
]
[Cites]
J Clin Neurophysiol. 2005 Jan-Feb;22(1):1-9
[
15689708.001
]
[Cites]
Ann Neurol. 2005 Mar;57(3):310-26
[
15732097.001
]
[Cites]
J Neurophysiol. 2005 Aug;94(2):907-18
[
15728766.001
]
[Cites]
Cancer. 2005 Aug 15;104(4):817-24
[
15971200.001
]
[Cites]
Am J Hematol. 2005 Sep;80(1):35-7
[
16138356.001
]
[Cites]
Brain Res. 2002 Jun 14;940(1-2):102-4
[
12020881.001
]
(PMID = 17319915.001).
[ISSN]
0013-9580
[Journal-full-title]
Epilepsia
[ISO-abbreviation]
Epilepsia
[Language]
ENG
[Grant]
United States / NINDS NIH HHS / NS / NS38195; United States / NINDS NIH HHS / NS / NS43284; United States / NINDS NIH HHS / NS / R01 NS046513; United States / NINDS NIH HHS / NS / NS46513; United States / NINDS NIH HHS / NS / R01 NS043284; United States / NHLBI NIH HHS / HL / HL51614; United States / NHLBI NIH HHS / HL / R01 HL051614; United States / NINDS NIH HHS / NS / NS049514; United States / NINDS NIH HHS / NS / R01 NS049514; United States / NINDS NIH HHS / NS / R01 NS038195
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biomarkers; 0 / S100 Proteins; 3OWL53L36A / Mannitol; YL5FZ2Y5U1 / Methotrexate
[Other-IDs]
NLM/ NIHMS608611; NLM/ PMC4135474
63.
Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, Stuerenburg HJ, Selle H:
Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme.
Eur J Surg Oncol
; 2010 Feb;36(2):201-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CONCLUSION: The study showed that peptidomics technology is able to identify possible biomarkers of neoplastic
CNS
disease.
[MeSH-major]
Biomarkers,
Tumor
/ cerebrospinal fluid. Glioblastoma / cerebrospinal fluid. Peptides / cerebrospinal fluid. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Supratentorial
Neoplasms
/ cerebrospinal fluid
[MeSH-minor]
Adult
. Aged. Albumins / cerebrospinal fluid. Chromatography, High Pressure Liquid. Female. Humans. Male. Middle Aged. Osteopontin / cerebrospinal fluid. Peptide Fragments. Prealbumin / cerebrospinal fluid. Proteomics / methods. alpha 1-Antichymotrypsin / cerebrospinal fluid
Genetic Alliance.
consumer health - Glioblastoma
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
(PMID = 19674866.001).
[ISSN]
1532-2157
[Journal-full-title]
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
[ISO-abbreviation]
Eur J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Albumins; 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Peptides; 0 / Prealbumin; 0 / alpha 1-Antichymotrypsin; 106441-73-0 / Osteopontin
64.
Hoffman S, Propp JM, McCarthy BJ:
Temporal trends in incidence of primary brain tumors in the United States, 1985-1999.
Neuro Oncol
; 2006 Jan;8(1):27-37
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Temporal trends in incidence of primary brain
tumors
in the United States, 1985-1999.
A number of reports have indicated an increasing incidence of primary brain
tumors
over the past few decades.
The purpose of this study was to describe incidence rate trends in a population-based series of newly diagnosed primary nonmalignant and malignant brain and other
CNS
tumors
, contributing five additional years to previously published incidence trends.
Data for the years 1985 through 1999 from six collaborating state cancer registries of the
Central
Brain
Tumor
Registry of the United States were used to determine incidence trends in the broad age groups 0-19, 20-64, and >or=65 years, overall and for selected histologies.
Specific histologies that were increasing included anaplastic astrocytomas in individuals aged >or=65 years, microscopically confirmed gliomas in both
adult
age groups, and microscopically confirmed glioma, not otherwise specified (NOS), in children.
Increases that were not specific to any population subgroup were seen for oligodendrogliomas, ependymomas, meningiomas, and nerve sheath
tumors
.
Decreases were noted for astrocytoma, NOS, nonmicroscopically confirmed gliomas, and pituitary
tumors
.
However, increases in meningiomas and nerve sheath
tumors
deserve further attention.
[MeSH-major]
Brain
Neoplasms
/ epidemiology
[MeSH-minor]
Adult
. Aged. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Registries
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neuroepidemiology. 2004 May-Jun;23(3):101-9
[
15084778.001
]
[Cites]
Neuro Oncol. 2006 Jan;8(1):1-11
[
16443943.001
]
[Cites]
N Engl J Med. 1985 Oct 3;313(14):859-64
[
3897866.001
]
[Cites]
AJR Am J Roentgenol. 1986 Sep;147(3):453-5
[
3488645.001
]
[Cites]
J Natl Cancer Inst. 1990 Oct 17;82(20):1621-4
[
2213902.001
]
[Cites]
Am J Ind Med. 1991;19(4):421-31
[
2035544.001
]
[Cites]
CMAJ. 1991 Dec 15;145(12):1583-91
[
1742695.001
]
[Cites]
J Natl Cancer Inst. 1991 Nov 20;83(22):1679-81
[
1749021.001
]
[Cites]
Cancer. 1992 Mar 1;69(5):1300-6
[
1739929.001
]
[Cites]
J Natl Cancer Inst. 1992 Mar 18;84(6):442-5
[
1538422.001
]
[Cites]
Neurosurgery. 1992 Jul;31(1):78-82
[
1641113.001
]
[Cites]
Brain Pathol. 1993 Jul;3(3):255-68
[
8293185.001
]
[Cites]
Br J Cancer. 1994 Nov;70(5):973-9
[
7947107.001
]
[Cites]
Cancer. 1995 Jan 1;75(1 Suppl):330-7
[
8001004.001
]
[Cites]
Ann Neurol. 1995 Jan;37(1):67-73
[
7818260.001
]
[Cites]
Eur J Cancer. 1994;30A(10):1498-511
[
7833109.001
]
[Cites]
IARC Sci Publ. 1994;(128):1-302
[
7698823.001
]
[Cites]
Cancer. 1995 Nov 1;76(9):1634-42
[
8635069.001
]
[Cites]
Cancer. 1996 Aug 1;78(3):532-41
[
8697401.001
]
[Cites]
Paediatr Perinat Epidemiol. 1996 Jul;10(3):319-38
[
8822774.001
]
[Cites]
Int J Epidemiol. 1995 Dec;24(6):1078-85
[
8824847.001
]
[Cites]
Stat Med. 2000 Feb 15;19(3):335-51
[
10649300.001
]
[Cites]
Cancer. 2000 May 15;88(10):2342-9
[
10820357.001
]
[Cites]
N Engl J Med. 2001 Jan 11;344(2):79-86
[
11150357.001
]
[Cites]
J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62
[
11245209.001
]
[Cites]
Neuro Oncol. 2001 Jul;3(3):141-51
[
11465394.001
]
[Cites]
Neuro Oncol. 1999 Jan;1(1):14-25
[
11554386.001
]
[Cites]
Brain Pathol. 2002 Apr;12(2):257-9
[
11958379.001
]
[Cites]
Neurology. 2002 Apr 23;58(8):1304-6
[
11971109.001
]
[Cites]
Cancer. 2002 Jul 1;95(1):193-202
[
12115333.001
]
[Cites]
J Neurooncol. 2002 Oct;60(1):61-9
[
12416547.001
]
[Cites]
J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26
[
12578221.001
]
[Cites]
Neuroepidemiology. 2003 Mar-Apr;22(2):124-9
[
12629278.001
]
[Cites]
Int J Cancer. 2004 Jan 20;108(3):450-5
[
14648713.001
]
[Cites]
Neuroepidemiology. 2004 Jan-Apr;23(1-2):85-93
[
14739573.001
]
[Cites]
Am J Epidemiol. 2004 Feb 1;159(3):277-83
[
14742288.001
]
[Cites]
Cancer. 1997 Apr 1;79(7):1381-93
[
9083161.001
]
[Cites]
J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77
[
9731733.001
]
[Cites]
J Natl Cancer Inst. 1999 Apr 7;91(7):648-9
[
10203289.001
]
[Cites]
AIDS. 1999 Jan 14;13(1):103-8
[
10207551.001
]
[Cites]
Cancer. 1999 May 1;85(9):2077-90
[
10223251.001
]
[Cites]
J Natl Cancer Inst. 1999 Jun 2;91(11):973-4
[
10359552.001
]
[Cites]
J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90
[
10451443.001
]
[Cites]
Neurology. 1999 Sep 22;53(5):1141-3
[
10496285.001
]
[Cites]
Cancer. 2004 Nov 15;101(10):2293-9
[
15476282.001
]
[Cites]
Epidemiology. 2004 Nov;15(6):653-9
[
15475713.001
]
(PMID = 16443945.001).
[ISSN]
1522-8517
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC1871920
65.
Nuttall RK, Silva C, Hader W, Bar-Or A, Patel KD, Edwards DR, Yong VW:
Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia.
Glia
; 2007 Apr 01;55(5):516-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Microglia are resident immune cells within
the central nervous system
(
CNS
).
Also elevated in
CNS
injuries are proteases, including matrix metalloproteinases (MMPs) and A disintegrin and metalloproteinases (ADAMs).
The spectrum of metalloproteinase members expressed by microglia and by the systemic leukocytes that infiltrate the injured
CNS
is unknown, as are their functions.
Activation of microglia also resulted in increased levels of
tumor
necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-10 protein in the conditioned media of cells.
The results have implications for the regulation of neuroinflammation and its outcomes following
CNS
injuries.
[MeSH-minor]
Adult
. Cells, Cultured.
Central Nervous System
/ injuries. Humans. Inflammation. Interleukin-10 / immunology. Interleukin-10 / metabolism. Interleukin-1beta / immunology. Interleukin-1beta / metabolism. Lipopolysaccharides / immunology. RNA / analysis. RNA, Messenger / analysis.
Tumor
Necrosis Factor-alpha / immunology.
Tumor
Necrosis Factor-alpha / metabolism. Up-Regulation / physiology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley-Liss, Inc.
(PMID = 17216595.001).
[ISSN]
0894-1491
[Journal-full-title]
Glia
[ISO-abbreviation]
Glia
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0100250
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cytokines; 0 / Interleukin-1beta; 0 / Lipopolysaccharides; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 63231-63-0 / RNA; EC 3.4.- / Metalloproteases; EC 3.4.24.- / ADAM Proteins
66.
Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R:
The diagnostic dilemma of primary central nervous system melanoma.
J Clin Neurosci
; 2010 Aug;17(8):1014-1017
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The diagnostic dilemma of primary
central nervous system
melanoma.
Melanomas are malignant
neoplasms of
melanocytes developing predominantly in the skin, but occasionally arising from eyes, mucous membranes, and
the central nervous system
(
CNS
).
The
CNS
can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign
neoplasm
(melanocytoma), and to an overtly malignant
tumor
(melanoma).
Primary melanocytic lesions involving the
CNS
are typically concentrated in the perimedullary and high cervical region.
Primary
CNS
melanoma cannot be reliably distinguished from metastatic melanoma on neuroimaging and histopathological characteristics alone: its diagnosis is established only after exclusion of secondary metastatic disease from a cutaneous, mucosal or retinal primary.
We present two patients with primary
CNS
melanoma and discuss relevant issues, available treatment options, and expected outcomes.
Awareness of disease spectrum and clinico-biological differences may be used to guide therapeutic decision-making for a patient with a proven or suspected primary
CNS
melanoma.
[MeSH-major]
Brain
Neoplasms
/ pathology. Cerebellopontine Angle / pathology. Melanoma / pathology. Parietal Lobe / pathology
[MeSH-minor]
Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Prognosis. Young
Adult
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20627582.001).
[ISSN]
1532-2653
[Journal-full-title]
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
[ISO-abbreviation]
J Clin Neurosci
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Scotland
67.
Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL:
Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
Pediatr Blood Cancer
; 2010 Jul 15;55(1):42-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment of primary
CNS
germinomatous germ cell
tumors
with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary
central nervous system
(
CNS
) germinomas.
Initial
tumor
markers for beta-human chorionic gonadotrophin (HCGbeta) and alpha-fetoprotein (AFP) were evaluated in serum and lumbar cerebrospinal fluid (CSF).
RESULTS: Eighteen of 20 patients are without evidence of residual or recurrent
tumor
.
Both relapsing patients were subsequently determined to harbor malignant non-germinomatous germ cell
tumor
(NGGCT).
CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure
CNS
germinoma with evidence of preservation of neurocognitive function.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain
Neoplasms
/ therapy.
Central Nervous System Neoplasms
/ therapy. Germinoma / therapy.
Neoplasms
, Germ Cell and Embryonal / therapy
[MeSH-minor]
Adolescent.
Adult
. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young
Adult
. alpha-Fetoproteins / analysis
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20222020.001).
[ISSN]
1545-5017
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
68.
Hosono A, Makimoto A, Kawai A, Takaue Y:
Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors.
Bone Marrow Transplant
; 2008 Jun;41(12):1067-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Segregated graft-versus-
tumor
effect between
CNS
and non-
CNS
lesions of Ewing's sarcoma family
of tumors
.
[MeSH-major]
Central Nervous System Neoplasms
/ secondary. Graft vs
Tumor
Effect. Hematopoietic Stem Cell Transplantation / methods.
Neoplasm
Recurrence, Local / therapy. Sarcoma, Ewing / therapy
[MeSH-minor]
Adult
. Female. Humans. Siblings. Transplantation, Homologous
Genetic Alliance.
consumer health - Ewing's Sarcoma
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18332914.001).
[ISSN]
0268-3369
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
69.
Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T:
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
J Neurooncol
; 2008 Jan;86(2):211-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Topotecan as salvage therapy for relapsed or refractory primary
central nervous system
lymphoma.
Treatment for patients with refractory or relapsed primary
CNS
lymphoma (PCNSL) remains unsatisfactory.
All 15 patients had measurable, contrast-enhancing
tumor
on cranial MRI at the time of relapse.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Brain
Neoplasms
/ drug therapy. Lymphoma, Non-Hodgkin / drug therapy.
Neoplasm
Recurrence, Local / drug therapy. Salvage Therapy. Topotecan / therapeutic use
[MeSH-minor]
Adult
. Aged. Disease-Free Survival. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome
Genetic Alliance.
consumer health - Central Nervous System Lymphoma, Primary
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
Topotecan
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2005 Mar 1;23(7):1507-13
[
15735126.001
]
[Cites]
Clin Cancer Res. 2004 Sep 1;10(17):5643-6
[
15355887.001
]
[Cites]
Neurology. 2004 Sep 14;63(5):901-3
[
15365145.001
]
[Cites]
J Clin Oncol. 1990 Jul;8(7):1277-80
[
2358840.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1992;23(1):9-17
[
1572835.001
]
[Cites]
Bull Cancer. 2004 Feb;91(2):189-92
[
15047459.001
]
[Cites]
Neurology. 2000 Apr 25;54(8):1707-8
[
10762527.001
]
[Cites]
J Neurooncol. 1989 Sep;7(3):249-54
[
2610754.001
]
[Cites]
Eur J Cancer. 2004 Jul;40(11):1682-8
[
15251157.001
]
[Cites]
Cancer Res. 1994 Oct 1;54(19):5118-22
[
7923128.001
]
[Cites]
Ann Oncol. 2006 Jul;17(7):1141-5
[
16603598.001
]
[Cites]
J Clin Oncol. 2003 Mar 15;21(6):1044-9
[
12637469.001
]
[Cites]
Oncologist. 2004;9(1):68-79
[
14755016.001
]
[Cites]
Leuk Lymphoma. 2003 Apr;44(4):627-33
[
12769339.001
]
(PMID = 17896078.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 7M7YKX2N15 / Topotecan
70.
Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D:
Metabotropic glutamate receptors: new targets for the control of tumor growth?
Trends Pharmacol Sci
; 2007 May;28(5):206-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metabotropic glutamate receptors: new targets for the control of
tumor
growth?
Cancer stem cells are currently a target for the treatment of malignant
tumors
.
Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain
tumors
in adults and children, respectively.
The proliferation of neural stem-progenitor cells is regulated by metabotropic glutamate (mGlu) receptors, which are G-protein-coupled receptors that are activated by glutamate, the major excitatory neurotransmitter of the
CNS
.
At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain
tumor
cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant
tumors
, including brain
tumors
.
[MeSH-major]
Antineoplastic Agents / pharmacology. Brain
Neoplasms
/ drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
[MeSH-minor]
Adult
. Animals. Cell Proliferation. Child. Colorectal
Neoplasms
/ drug therapy. Colorectal
Neoplasms
/ physiopathology. Drug Resistance,
Neoplasm
. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin
Neoplasms
/ drug therapy. Skin
Neoplasms
/ physiopathology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17433452.001).
[ISSN]
0165-6147
[Journal-full-title]
Trends in pharmacological sciences
[ISO-abbreviation]
Trends Pharmacol. Sci.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
71.
Mao XC, Su ZP, Yu WQ, Zheng WM, Zeng YJ:
Familial and genetic researches on three Chinese families with von Hippel-Lindau disease.
Neurol Res
; 2009 Sep;31(7):743-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: Hemangioblastoma of the
central nervous system
(
CNS
) occur as sporadic
tumors
or as a part of von Hippel-Lindau (VHL) disease, an autosomal dominant hereditary
tumor
syndrome caused by germline mutation of the VHL
tumor
suppressor gene.
Twenty VHL disease patients in the three families have the most common manifestation of
CNS
hemangioblastoma.
The
CNS
hemangioblastoma is the early manifestation in VHL disease.
It is recommended that every patient with
CNS
hemangioblastoma should be screened for VHL gene mutation.
[MeSH-major]
Genetic Predisposition to Disease. Mutation / genetics. Von Hippel-Lindau
Tumor
Suppressor Protein / genetics. von Hippel-Lindau Disease / genetics
[MeSH-minor]
Adolescent.
Adult
. Asian Continental Ancestry Group / ethnology. Brain
Neoplasms
/ etiology. Brain
Neoplasms
/ genetics. DNA Mutational Analysis. Female. Genetic Testing. Genotype. Hemangioblastoma / etiology. Hemangioblastoma / genetics. Humans. Male. Middle Aged. Phenotype. Retrospective Studies. Severity of Illness Index. Young
Adult
MedlinePlus Health Information.
consumer health - Von Hippel-Lindau Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19133167.001).
[ISSN]
0161-6412
[Journal-full-title]
Neurological research
[ISO-abbreviation]
Neurol. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
72.
Marinovic T, Grahovac G, Habek M, Lambasa S, Tomac D:
Simultaneous conus medullaris ependymoma and cerebellar astrocytoma in the same patient.
Clin Neuropathol
; 2009 May-Jun;28(3):173-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Multiple primary
tumors
in
the central nervous system
of different histological cell types are uncommon.
The suggested mechanism of this association is that primitive multipotent cells might have been displaced in the different
CNS
areas and developed in different
tumor
cells.
Multiplicity of primary
CNS
tumors
should be considered in certain occasions, when clinical symptoms and signs are pointing in that direction.
[MeSH-major]
Astrocytoma / pathology. Cerebellar
Neoplasms
/ pathology. Ependymoma / pathology.
Neoplasms
, Multiple Primary / pathology. Spinal Cord
Neoplasms
/ pathology
[MeSH-minor]
Adult
. Cauda Equina / pathology. Cauda Equina / surgery. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures
Genetic Alliance.
consumer health - Ependymoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19537133.001).
[ISSN]
0722-5091
[Journal-full-title]
Clinical neuropathology
[ISO-abbreviation]
Clin. Neuropathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
73.
Varghese M, Olstorn H, Berg-Johnsen J, Moe MC, Murrell W, Langmoen IA:
Isolation of human multipotent neural progenitors from adult filum terminale.
Stem Cells Dev
; 2009 May;18(4):603-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Isolation of human multipotent neural progenitors from
adult
filum terminale.
Stem cells have been isolated from several
CNS
regions, including the spinal cord.
We show for the first time that progenitor cells exhibiting the hallmarks of stem cells can be isolated from
adult
human filum terminale (FTNPs).
Significantly, no
tumor
formation or aberrant cell morphology was seen in or adjacent to the graft area.
Thus, filum terminale provides a novel source of
adult
human neural progenitor cells that develop into functional neurons with possible clinical applications.
[MeSH-minor]
Adult
. Animals. Biopsy. Cell Differentiation / physiology. Cell Proliferation. Cells, Cultured. Child. Humans. Membrane Potentials / physiology. Middle Aged. Patch-Clamp Techniques. Rats. Stem Cell Transplantation. Young
Adult
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18652547.001).
[ISSN]
1557-8534
[Journal-full-title]
Stem cells and development
[ISO-abbreviation]
Stem Cells Dev.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
74.
Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group:
The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
Blood
; 2005 Feb 1;105(3):948-58
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell
neoplasms
: a report of the BFM Group Study NHL-BFM95.
In the Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster 95 (NHL-BFM95) study, we tested by randomization whether for patients with B-cell
neoplasms
methotrexate as intravenous infusion over 4 hours (MTX-4h) is not inferior to, but less toxic than, a 24-hour intravenous infusion (MTX-24h).
Second, we investigated against the historical control of study NHL-BFM90, whether for patients with moderate
tumor
mass MTX can be reduced from 5 g/m(2) to 1 g/m(2).
Patients received 2 5-day therapy courses in risk group R1 (resected), 4 in R2 (lactate dehydrogenase [LDH] < 500 U/L), 5 in R3 (LDH > 500 to < 1000 U/L) and 6 in R4 (LDH > 1000 U/L and/or
central nervous system
[
CNS
] disease).
[MeSH-minor]
Adolescent.
Adult
. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Survival Analysis. Time Factors
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
METHOTREXATE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15486066.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
YL5FZ2Y5U1 / Methotrexate
75.
Kim YJ, Kim YS, Kim MS, Ryu JC:
The inhibitory mechanism of methylmercury on differentiation of human neuroblastoma cells.
Toxicology
; 2007 May 5;234(1-2):1-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Methylmercury (MeHg) is a ubiquitous environmental toxicant and shows neurotoxicity to
central
nerve
system
(
CNS
) or neuronal cells.
It has been known that MeHg has more influence to developing or differentiating
CNS
/neuronal cells than
adult
or differentiated
CNS
/neuronal cells.
[MeSH-minor]
Blotting, Western. Cell Line,
Tumor
. Cell Survival / drug effects. Comet Assay. DNA Damage. Dose-Response Relationship, Drug. Drug Synergism. Flavonoids / pharmacology. Flow Cytometry. Humans. Indoles / pharmacology. Interphase / drug effects. Maleimides / pharmacology. Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 3 / metabolism. Neuroblastoma / genetics. Neuroblastoma / metabolism. Neuroblastoma / pathology. Phosphorylation / drug effects. Protein Kinase C-alpha / antagonists & inhibitors. Protein Kinase C-alpha / metabolism. Time Factors. Tretinoin / pharmacology
Genetic Alliance.
consumer health - Neuroblastoma
.
Hazardous Substances Data Bank.
ALL-TRANS-RETINOIC ACID
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17350151.001).
[ISSN]
0300-483X
[Journal-full-title]
Toxicology
[ISO-abbreviation]
Toxicology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
[Chemical-registry-number]
0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Flavonoids; 0 / Indoles; 0 / Maleimides; 0 / Methylmercury Compounds; 133052-90-1 / bisindolylmaleimide I; 5688UTC01R / Tretinoin; EC 2.7.11.13 / Protein Kinase C-alpha; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
76.
Hurst LA, Bunning RA, Couraud PO, Romero IA, Weksler BB, Sharrack B, Woodroofe MN:
Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment.
J Neuroimmunol
; 2009 May 29;210(1-2):108-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of ADAM-17, TIMP-3 and fractalkine in the human
adult
brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment.
ADAM-17 expression is localised to endothelial cells in the human
central nervous system
(
CNS
) and is increased in multiple sclerosis (MS) white matter, suggesting a role in MS pathogenesis.
Fractalkine shedding may regulate immune cell trafficking into the
CNS
, however, this does not appear to be directly controlled by ADAM-17 activity.
[MeSH-minor]
Cell Line. Chemotaxis, Leukocyte / immunology. Encephalitis / immunology. Encephalitis / metabolism. Encephalitis / physiopathology. Gene Expression / drug effects. Gene Expression / physiology. Humans. RNA, Messenger / analysis. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Tissue Inhibitor of Metalloproteinase-3 / genetics. Tissue Inhibitor of Metalloproteinase-3 / metabolism.
Tumor
Necrosis Factor-alpha / metabolism.
Tumor
Necrosis Factor-alpha / pharmacology. Up-Regulation / drug effects. Up-Regulation / immunology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19324423.001).
[ISSN]
1872-8421
[Journal-full-title]
Journal of neuroimmunology
[ISO-abbreviation]
J. Neuroimmunol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / CX3CL1 protein, human; 0 / Chemokine CX3CL1; 0 / Cytokines; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Tumor Necrosis Factor-alpha; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
77.
Katz J, Keenan B, Snyder EY:
Culture and manipulation of neural stem cells.
Adv Exp Med Biol
; 2010;671:13-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Both murine and human neural stem cells (NSCs) have been shown to migrate through
the central nervous system
(
CNS
) and infiltrate
tumors
and other pathological disease states of the brain.
Genetic modification of NSCs to produce cytotoxic or immunomodulatory agents in the vicinity of a primary
tumor
and/or satellite lesion or has proven instrumental to the reduction of
tumor
bulk in murine models.
Although the use of stem cells proves to be a volatile social topic, scientists have discovered that NSCs are present in the
adult
brain and continue to propagate and differentiate.
These cells may be isolated and cultured to produce clonal NSC lines that are capable of self renewal and differentiation when introduced into the
CNS
.
In this chapter, we describe protocols currently used in ourlab for the successful maintenance of NSCs in vitro advancing the role of neural stem cells in the treatment of brain
tumors
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20455492.001).
[ISSN]
0065-2598
[Journal-full-title]
Advances in experimental medicine and biology
[ISO-abbreviation]
Adv. Exp. Med. Biol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Prodrugs
78.
Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H, Takahashi H, Onda K, Takahashi H, Tanaka R:
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Ann Hematol
; 2005 Jul;84(7):447-55
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary
CNS
lymphoma.
The object of this study was to assess the estimation of 2- and 5-year overall survival and
tumor
response and the frequency and severity of treatment morbidity with a modified ProMACE-MOPP hybrid protocol in patients with primary
CNS
lymphoma (PCNSL).
Eighteen patients were followed up with neuroimaging and neuropsychological assessments for evidence of
CNS
toxicity.
[MeSH-major]
Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Central Nervous System Neoplasms
/ therapy. Cranial Irradiation. Lymphoma / therapy. Methotrexate / administration & dosage
[MeSH-minor]
Adult
. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Etoposide / administration & dosage. Etoposide / toxicity. Female. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / administration & dosage. Mechlorethamine / toxicity. Middle Aged. Pneumonia / etiology. Pneumonia / mortality. Prednisone / administration & dosage. Prednisone / toxicity. Procarbazine / administration & dosage. Procarbazine / toxicity. Retrospective Studies. Sepsis / etiology. Sepsis / mortality. Vincristine / administration & dosage. Vincristine / toxicity
MedlinePlus Health Information.
consumer health - Lymphoma
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
MECHLORETHAMINE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
MECHLORETHAMINE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
METHOTREXATE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15747120.001).
[ISSN]
0939-5555
[Journal-full-title]
Annals of hematology
[ISO-abbreviation]
Ann. Hematol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol
79.
Propp JM, McCarthy BJ, Davis FG, Preston-Martin S:
Descriptive epidemiology of vestibular schwannomas.
Neuro Oncol
; 2006 Jan;8(1):1-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Vestibular schwannomas, commonly termed acoustic neuromas, arise from the vestibular branch of the eighth cranial nerve (acoustic nerve) and are benign, slow-growing brain
tumors
that negatively impact patient quality of life.
They are thought to account for the majority of intracranial nerve sheath
tumors
.
To describe incidence rate patterns and trends of primary nerve sheath
tumors of
the brain/
CNS
and the subset of vestibular schwannomas in two population-based incidence registries, data were obtained from 11
Central
Brain
Tumor
Registry of the United States (CBTRUS) collaborating state registries and the Los Angeles County Cancer Surveillance Program (LACCSP) (1975-1998).
Multiplicative Poisson regression models were used to compare trends in primary nerve sheath
tumors of
the brain/
CNS
overall and in subgroups, including vestibular schwannomas, controlling for age, gender, race, microscopic confirmation, and region.
The overall incidence of primary nerve sheath
tumors of
the brain/
CNS
was 1.1 per 100,000 person-years (CBTRUS, 1995-1999 and LACCSP, 1995-1998).
Moreover, the incidence of primary nerve sheath
tumors of
the brain/
CNS
overall (CBTRUS, 1985-1999 and LACCSP, 1975-1998) and of vestibular schwannomas (CBTRUS, 1992-1999 and LACCSP, 1992-1998) increased over time.
[MeSH-minor]
Adolescent.
Adult
. Aged. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Acoustic Neuroma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Epidemiol. 1992 Jun 15;135(12):1349-57
[
1510081.001
]
[Cites]
J Natl Cancer Inst. 1992 Mar 18;84(6):442-5
[
1538422.001
]
[Cites]
Ann Neurol. 1995 Jan;37(1):67-73
[
7818260.001
]
[Cites]
Laryngoscope. 1999 May;109(5):736-40
[
10334223.001
]
[Cites]
Stat Med. 2000 Feb 15;19(3):335-51
[
10649300.001
]
[Cites]
Am J Otol. 2000 Sep;21(5):690-4
[
10993460.001
]
[Cites]
N Engl J Med. 2001 Jan 11;344(2):79-86
[
11150357.001
]
[Cites]
J Natl Cancer Inst. 2001 Feb 7;93(3):203-7
[
11158188.001
]
[Cites]
Neuro Oncol. 2001 Jul;3(3):141-51
[
11465394.001
]
[Cites]
Neurology. 2002 Apr 23;58(8):1304-6
[
11971109.001
]
[Cites]
Neuroepidemiology. 2003 Mar-Apr;22(2):124-9
[
12629278.001
]
[Cites]
Am J Epidemiol. 2004 Feb 1;159(3):277-83
[
14742288.001
]
[Cites]
J Toxicol Environ Health B Crit Rev. 2004 Sep-Oct;7(5):351-84
[
15371240.001
]
[Cites]
Epidemiology. 2004 Nov;15(6):653-9
[
15475713.001
]
[Cites]
Health Care Financ Rev. 1984 Winter;6(2):1-29
[
10310949.001
]
[Cites]
N Engl J Med. 1988 Oct 20;319(16):1033-9
[
3173432.001
]
[Cites]
Br J Cancer. 1989 May;59(5):783-6
[
2736213.001
]
[Cites]
Neuroepidemiology. 1989;8(6):283-95
[
2586698.001
]
[Cites]
Cancer. 1992 Mar 1;69(5):1300-6
[
1739929.001
]
[Cites]
Brain Pathol. 1993 Jul;3(3):255-68
[
8293185.001
]
(PMID = 16443943.001).
[ISSN]
1522-8517
[Journal-full-title]
Neuro-oncology
[ISO-abbreviation]
Neuro-oncology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC1871924
80.
Kamoshima Y, Sawamura Y, Ikeda J, Shirato H, Aoyama H:
Late recurrence and salvage therapy of CNS germinomas.
J Neurooncol
; 2008 Nov;90(2):205-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Late recurrence and salvage therapy of
CNS
germinomas.
Central nervous system
(
CNS
) germinoma is a curable
tumor
and its recurrence rate after initial therapy may be approximately 10% or higher.
All patients had been
tumor
-free for at least 6 months after the initial treatment.
Seventeen patients (68%) were salvaged and were
tumor
-free at the final observation.
At first recurrence, 11 patients were treated using radiation therapy with or without surgery and 7 out of the 11 patients died due to the recurrent
tumor
.
On the other hand, 13 patients who received salvage chemotherapy and radiotherapy were
tumor
-free at the last follow-up.
In conclusion, late recurrence is not a rare event in patients with
CNS
germinoma.
[MeSH-major]
Central Nervous System Neoplasms
/ prevention & control. Germinoma / prevention & control. Salvage Therapy / methods
[MeSH-minor]
Adolescent.
Adult
. Child. Female. Follow-Up Studies. Humans. Male. Remission Induction. Retrospective Studies. Secondary Prevention. Time Factors. Young
Adult
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2006 Dec 10;24(35):5503-11
[
17158535.001
]
[Cites]
J Neurosurg. 1998 Jan;88(1):66-72
[
9420074.001
]
[Cites]
Int J Urol. 2005 Sep;12(9):855-8
[
16201988.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9
[
7607968.001
]
[Cites]
J Clin Oncol. 2002 Feb 1;20(3):857-65
[
11821471.001
]
[Cites]
Pediatr Blood Cancer. 2004 Aug;43(2):126-33
[
15236278.001
]
[Cites]
J Neurosurg. 1997 Aug;87(2):262-6
[
9254091.001
]
[Cites]
Cancer. 2006 Nov 1;107(9):2228-36
[
17019739.001
]
[Cites]
J Urol. 2005 Mar;173(3):824-9
[
15711278.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):204-9
[
9440744.001
]
[Cites]
J Clin Oncol. 2004 May 15;22(10):1934-43
[
15143087.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2585-92
[
10561326.001
]
[Cites]
Cancer. 1994 Aug 1;74(3):940-4
[
8039122.001
]
[Cites]
Radiology. 2001 Feb;218(2):452-6
[
11161161.001
]
[Cites]
Childs Nerv Syst. 2007 Oct;23(10):1155-61
[
17610071.001
]
[Cites]
Br J Neurosurg. 1999 Aug;13(4):376-81
[
10616563.001
]
[Cites]
Br J Cancer. 2006 Mar 27;94(6):820-7
[
16508636.001
]
[Cites]
Cancer. 2002 Aug 1;95(3):520-30
[
12209744.001
]
[Cites]
Eur J Cancer. 1998 Jan;34(1):104-10
[
9624246.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):214-7
[
15337558.001
]
[Cites]
Urol Int. 2004;73(1):84-6
[
15263799.001
]
[Cites]
J Clin Oncol. 1996 Nov;14(11):2908-15
[
8918487.001
]
[Cites]
Neurosurgery. 1999 Dec;45(6):1292-7; discussion 1297-8
[
10598695.001
]
[Cites]
Acta Oncol. 2006;45(4):476-83
[
16760185.001
]
[Cites]
J Pediatr Hematol Oncol. 2006 Jan;28(1):36-9
[
16394891.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):291-7
[
3403312.001
]
[Cites]
J Neurooncol. 2001 Sep;54(3):311-6
[
11767296.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6
[
10725628.001
]
[Cites]
J Clin Oncol. 1999 Mar;17(3):933-40
[
10071287.001
]
[Cites]
Am J Clin Oncol. 2007 Apr;30(2):205-10
[
17414472.001
]
[Cites]
J Neurooncol. 2007 May;83(1):71-9
[
17245622.001
]
(PMID = 18604473.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
81.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD:
IDH1 and IDH2 mutations in gliomas.
N Engl J Med
; 2009 Feb 19;360(8):765-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such
tumors
, most frequently in
tumors
that were known to have evolved from lower-grade gliomas (secondary glioblastomas).
METHODS: We determined the sequence of the IDH1 gene and the related IDH2 gene in 445
central nervous system
(
CNS
)
tumors
and 494 non-
CNS
tumors
.
Tumors
without mutations in IDH1 often had mutations affecting the analogous amino acid (R172) of the IDH2 gene.
Tumors
with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics, and patients with such
tumors
had a better outcome than those with wild-type IDH genes.
Genetics Home Reference.
consumer health - IDH1 gene
.
Genetics Home Reference.
consumer health - IDH2 gene
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Pharmacogenomics Knowledge Base.
meta-databases - Pharmacogenomic Annotation 827855335 for PMID:19228619 [PharmGKB]
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
SciCrunch.
OMIM: Data: Gene Annotation
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2009 Massachusetts Medical Society
[Cites]
Cancer Res. 1996 Jan 1;56(1):150-3
[
8548755.001
]
[Cites]
Oncogene. 1996 Sep 5;13(5):983-94
[
8806688.001
]
[Cites]
Am J Pathol. 1994 Nov;145(5):1175-90
[
7977648.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9
[
1557402.001
]
[Cites]
Science. 1997 Mar 28;275(5308):1943-7
[
9072974.001
]
[Cites]
Biochemistry. 1997 Nov 4;36(44):13743-7
[
9354646.001
]
[Cites]
Am J Pathol. 1999 Aug;155(2):375-86
[
10433931.001
]
[Cites]
N Engl J Med. 2005 Mar 10;352(10):987-96
[
15758009.001
]
[Cites]
Science. 2006 Oct 13;314(5797):268-74
[
16959974.001
]
[Cites]
Am J Pathol. 2007 May;170(5):1445-53
[
17456751.001
]
[Cites]
Genes Dev. 2007 Nov 1;21(21):2683-710
[
17974913.001
]
[Cites]
Free Radic Res. 2008 Jul;42(7):618-24
[
18608518.001
]
[Cites]
N Engl J Med. 2008 Jul 31;359(5):492-507
[
18669428.001
]
[Cites]
Science. 2008 Sep 26;321(5897):1807-12
[
18772396.001
]
[Cites]
Nature. 2008 Oct 23;455(7216):1061-8
[
18772890.001
]
[Cites]
Cancer Res. 2008 Nov 1;68(21):8673-7
[
18974108.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94
[
14970324.001
]
[Cites]
J Biol Chem. 2004 Aug 6;279(32):33946-57
[
15173171.001
]
[Cites]
Cancer Res. 2004 Oct 1;64(19):6892-9
[
15466178.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903
[
3477813.001
]
[Cites]
Nature. 1989 Dec 7;342(6250):705-8
[
2531845.001
]
[CommentIn]
N Engl J Med. 2009 May 21;360(21):2248; author reply 2249
[
19458374.001
]
[CommentIn]
N Engl J Med. 2009 May 21;360(21):2248-9; author reply 2249
[
19469031.001
]
[CommentIn]
N Engl J Med. 2009 Feb 19;360(8):813-5
[
19228626.001
]
(PMID = 19228619.001).
[ISSN]
1533-4406
[Journal-full-title]
The New England journal of medicine
[ISO-abbreviation]
N. Engl. J. Med.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R01CA118822; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / 2P30-CA-14236; United States / NCI NIH HHS / CA / 5P50-CA-108786; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / CA062924-150012; United States / NCI NIH HHS / CA / R37 CA043460-26; United States / NCI NIH HHS / CA / 5R37-CA-11898; United States / NCI NIH HHS / CA / R37CA11898-34; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043460-26; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NINDS NIH HHS / NS / NS20023-21; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / P50 CA062924-150012; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA118822; United States / NINDS NIH HHS / NS / 5P50-NS-20023; United States / NCI NIH HHS / CA / R37 CA011898
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human
[Other-IDs]
NLM/ NIHMS107443; NLM/ PMC2820383
82.
Klosky JL, Tyc VL, Lawford J, Ashford J, Lensing S, Buscemi J:
Predictors of non-participation in a randomized intervention trial to reduce environmental tobacco smoke (ETS) exposure in pediatric cancer patients.
Pediatr Blood Cancer
; 2009 May;52(5):644-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Medical features that significantly associated with study non-participation included
CNS tumor
diagnosis (P = 0.030), no history of chemotherapy (P = 0.012), history of surgery prior to study recruitment (P = 0.036), and having future radiation therapy planned post study recruitment (P = 0.009).
Multivariable logistic regression modeling revealed that study non-participation was associated with the primary caregiver being a smoker (OR = 6.48, P = 0.002) or female (OR = 8.56, P = 0.023), and patient
CNS tumor
diagnosis (OR = 4.63, P = 0.021).
[MeSH-major]
Neoplasms
. Patient Participation. Pediatrics. Randomized Controlled Trials as Topic. Tobacco Smoke Pollution / adverse effects
[MeSH-minor]
Adult
. Child. Female. Humans. Male
MedlinePlus Health Information.
consumer health - Cancer in Children
.
MedlinePlus Health Information.
consumer health - Children's Health
.
MedlinePlus Health Information.
consumer health - Secondhand Smoke
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2009 Wiley-Liss, Inc.
[Cites]
Pediatrics. 2001 Mar;107(3):540-2
[
11230596.001
]
[Cites]
Am J Public Health. 2005 Apr;95(4):652-9
[
15798126.001
]
[Cites]
Pediatrics. 2002 Nov;110(5):946-56
[
12415035.001
]
[Cites]
Pediatrics. 2003 Jan;111(1):140-5
[
12509567.001
]
[Cites]
J Pediatr Psychol. 2003 Dec;28(8):519-28
[
14602842.001
]
[Cites]
J Child Health Care. 2004 Dec;8(4):288-300
[
15507466.001
]
[Cites]
Thorax. 1982 Mar;37(3):175-80
[
6285541.001
]
[Cites]
N Engl J Med. 1990 Aug 9;323(6):378-82
[
2370889.001
]
[Cites]
N Engl J Med. 1991 Mar 21;324(12):808-15
[
1997853.001
]
[Cites]
N Engl J Med. 1991 Nov 7;325(19):1330-6
[
1922234.001
]
[Cites]
Hematol Oncol Clin North Am. 1993 Apr;7(2):401-15
[
8468273.001
]
[Cites]
Curr Probl Pediatr. 1993 Mar;23(3):102-31
[
8513680.001
]
[Cites]
Health Psychol. 1993 Nov;12(6):443-50
[
8293727.001
]
[Cites]
Pediatrics. 1996 Apr;97(4):560-8
[
8632946.001
]
[Cites]
Pediatrics. 1998 Feb;101(2):E8
[
9445518.001
]
[Cites]
BMJ. 1999 May 29;318(7196):1456-9
[
10346773.001
]
[Cites]
Thorax. 1999 Apr;54(4):357-66
[
10092699.001
]
[Cites]
Chest. 2001 Nov;120(5):1709-22
[
11713157.001
]
(PMID = 19156856.001).
[ISSN]
1545-5017
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA085406; United States / NCI NIH HHS / CA / R01 CA085406-05
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Tobacco Smoke Pollution
[Other-IDs]
NLM/ NIHMS124032; NLM/ PMC2733242
83.
Gabrovski N, Poptodorov G, Velinov N, Gabrovski S:
[Late metastases from breast cancer--report of two cases].
Khirurgiia (Sofiia)
; 2010;(1):62-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Due to complain of headache and nausea CT scan was performed showing a
tumor
lesion in the right frontal lobe.
Metastasis in
CNS
should be taken into consideration in patients treated for breast cancer no matter the time from the initial diagnosis when clinical symptoms appear.
[MeSH-major]
Brain / pathology. Brain / surgery. Brain
Neoplasms
/ secondary. Brain
Neoplasms
/ surgery. Breast
Neoplasms
/ pathology. Carcinoma, Ductal, Breast / pathology
[MeSH-minor]
Adult
. Breast / pathology. Breast / surgery. Female. Follow-Up Studies. Humans. Mastectomy. Middle Aged
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21972709.001).
[ISSN]
0450-2167
[Journal-full-title]
Khirurgii︠a︡
[ISO-abbreviation]
Khirurgiia (Sofiia)
[Language]
bul
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Bulgaria
84.
Schittenhelm J, Thiericke J, Nagel C, Meyermann R, Beschorner R:
WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy.
Cancer Biomark
; 2010;7(2):73-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: Wilms'
tumor
protein (WT1) expression is usually absent in normal glial cells of the
CNS
but is highly upregulated in brain
tumor
cells and its expression correlates with
tumor
grade.
However, knowledge on WT1 expression in
tumors of
the peripheral nerve
system
(PNS) is limited.
METHODS: We analyze the immunohistochemical expression of WT1 in 101 samples consisting of 13 normal nerves, 10 neurofibromas, 69 schwannomas and 9 malignant peripheral nerve sheath
tumors
(MPNST).
Tumor
samples included 14 specimen from patients with a proven neurocutaneous disorder (neurofibromatosis type 1 and 2) and 3 cases of schwannomatosis.
In 50 vestibular schwannomas
tumor
growth extension was correlated to WT1 expression.
In peripheral nerve sheath
tumors
, cytoplasmic WT1 protein is expressed in the cytoplasm of the neoplastic cells in all
tumors
, including MPNST, neurofibromas and schwannomas.
The WT1 expression is independent of
tumor
malignancy or
tumor
growth extension and is not associated with a neurocutaneous disorder.
CONCLUSION: WT1 expression in normal and neoplastic tissue differs in the peripheral and
the central nervous system
.
These findings may point to a different functional role of WT1 in the PNS and the
CNS
.
[MeSH-major]
Cranial Nerve
Neoplasms
/ metabolism. Cranial Nerves / metabolism. Nerve Sheath
Neoplasms
/ metabolism. Peripheral Nerves / metabolism. WT1 Proteins / metabolism
[MeSH-minor]
Adolescent.
Adult
. Aged. Case-Control Studies. Child. Female. Humans. Male. Middle Aged. Neurilemmoma / metabolism. Neurofibroma / metabolism. Young
Adult
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21178265.001).
[ISSN]
1875-8592
[Journal-full-title]
Cancer biomarkers : section A of Disease markers
[ISO-abbreviation]
Cancer Biomark
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / WT1 Proteins
85.
Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Kocełak P, Janowska J, Semik-Grabarczyk E, Wikarek T, Gruszka W, Dabrowski P:
Is chronic inflammation a possible cause of obesity-related depression?
Mediators Inflamm
; 2009;2009:439107
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Adult
obesity has been associated with depression, especially in women.
[MeSH-minor]
Age Factors. Body Mass Index. Enzyme-Linked Immunosorbent Assay. Female. Humans. Interleukin-6 / blood. Leptin / blood. Middle Aged. Receptors,
Tumor
Necrosis Factor / blood. Sex Factors.
Tumor
Necrosis Factor-alpha / blood
Genetic Alliance.
consumer health - Depression
.
Genetic Alliance.
consumer health - Obesity
.
Genetic Alliance.
consumer health - Dysthmia
.
MedlinePlus Health Information.
consumer health - Depression
.
MedlinePlus Health Information.
consumer health - Obesity
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neuropsychobiology. 1999 Nov;40(4):171-6
[
10559698.001
]
[Cites]
Physiol Behav. 2007 Jul 24;91(4):449-58
[
17543357.001
]
[Cites]
Arch Intern Med. 2000 May 22;160(10):1495-500
[
10826464.001
]
[Cites]
Arch Intern Med. 2000 Jun 26;160(12):1761-8
[
10871968.001
]
[Cites]
Am J Epidemiol. 2000 Jul 15;152(2):163-70
[
10909953.001
]
[Cites]
Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S80-5
[
10997616.001
]
[Cites]
Int J Obes Relat Metab Disord. 2000 Nov;24(11):1392-5
[
11126333.001
]
[Cites]
Diabetes Care. 2001 Jun;24(6):1069-78
[
11375373.001
]
[Cites]
Int J Obes Relat Metab Disord. 2001 Jul;25(7):1047-56
[
11443505.001
]
[Cites]
Pediatrics. 2002 Sep;110(3):497-504
[
12205250.001
]
[Cites]
JAMA. 2002 Oct 9;288(14):1723-7
[
12365955.001
]
[Cites]
Am J Cardiol. 2002 Dec 15;90(12):1279-83
[
12480034.001
]
[Cites]
Diabetes Care. 2003 Mar;26(3):744-9
[
12610032.001
]
[Cites]
Int J Obes Relat Metab Disord. 2003 Apr;27(4):514-21
[
12664085.001
]
[Cites]
Brain Behav Immun. 2003 Aug;17(4):276-85
[
12831830.001
]
[Cites]
Endocr Regul. 2003 Jun;37(2):51-68
[
12932191.001
]
[Cites]
Am J Psychiatry. 2004 Feb;161(2):271-7
[
14754776.001
]
[Cites]
Metabolism. 2004 Oct;53(10):1268-73
[
15375781.001
]
[Cites]
Semin Vasc Med. 2004 May;4(2):161-5
[
15478037.001
]
[Cites]
J Affect Disord. 1993 Oct-Nov;29(2-3):183-92
[
8300977.001
]
[Cites]
N Engl J Med. 1996 Feb 1;334(5):292-5
[
8532024.001
]
[Cites]
Obes Res. 2005 Feb;13(2):320-5
[
15800290.001
]
[Cites]
Eur Cytokine Netw. 2006 Mar;17(1):4-12
[
16613757.001
]
[Cites]
Endokrynol Pol. 2006 Sep-Oct;57(5):487-93
[
17133313.001
]
[Cites]
Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):145-54
[
17346438.001
]
[Cites]
Aust N Z J Psychiatry. 2007 Mar;41(3):266-73
[
17464708.001
]
[Cites]
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1044-53
[
17433516.001
]
[Cites]
Clin Cardiol. 2007 Jun;30(6):295-300
[
17551966.001
]
[Cites]
Arch Intern Med. 2000 May 8;160(9):1261-8
[
10809028.001
]
(PMID = 19587822.001).
[ISSN]
1466-1861
[Journal-full-title]
Mediators of inflammation
[ISO-abbreviation]
Mediators Inflamm.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Interleukin-6; 0 / Leptin; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha
[Other-IDs]
NLM/ PMC2705765
86.
Ifergan I, Kébir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, Arbour N, Prat A:
The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells.
Brain
; 2008 Mar;131(Pt 3):785-99
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Trafficking of antigen-presenting cells into the
CNS
is essential for lymphocyte reactivation within the
CNS
compartment.
Our data support the notion that functional perivascular myeloid
CNS
dendritic cells arise as a consequence of migration of CD14+ monocytes across the human BBB, through the concerted actions of BBB-secreted transforming growth factor-beta and granulocyte-macrophage colony-stimulating factor.
[MeSH-minor]
Adult
. Antigen Presentation / immunology. Antigens, CD14 / analysis. CD4-Positive T-Lymphocytes / immunology. Cell Movement / immunology. Cells, Cultured. Chemokines / biosynthesis. Endothelium / immunology. Humans. Interferon-gamma / immunology. Interleukin-17 / biosynthesis. Lymphocyte Culture Test, Mixed. Middle Aged. Phagocytosis / immunology. Phenotype.
Tumor
Necrosis Factor-alpha / immunology
MedlinePlus Health Information.
consumer health - Multiple Sclerosis
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18156156.001).
[ISSN]
1460-2156
[Journal-full-title]
Brain : a journal of neurology
[ISO-abbreviation]
Brain
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD14; 0 / Chemokines; 0 / Interleukin-17; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
87.
López M O:
[Three-year survival of a patient with HIV and chagasic meningoencephalitis: case report].
Rev Chilena Infectol
; 2010 Apr;27(2):160-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Central nervous system
(
CNS
) evolvement (cerebral
tumor
or chagoma and diffuse meningoencephalitis) is similar to other opportunistic infections that present with cerebral expansive processes like toxoplasmosis or
CNS
primary lymphoma.
[MeSH-minor]
Adult
. Antiretroviral Therapy, Highly Active. Disease-Free Survival. Humans. Male. Nifurtimox / therapeutic use. Treatment Outcome. Trypanocidal Agents / therapeutic use
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Chagas Disease
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20556321.001).
[ISSN]
0716-1018
[Journal-full-title]
Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
[ISO-abbreviation]
Rev Chilena Infectol
[Language]
spa
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Chile
[Chemical-registry-number]
0 / Trypanocidal Agents; M84I3K7C2O / Nifurtimox
88.
Reardon DA, Zalutsky MR, Bigner DD:
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
Expert Rev Anticancer Ther
; 2007 May;7(5):675-87
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Most of these
tumors
recur at or adjacent to the site of origin, which indicates that failure to eradicate local
tumor
growth is a major factor contributing to poor outcome.
Malignant gliomas selectively express several factors that are not present on normal
CNS
tissue.
Regional administration of radiolabeled monoclonal antibodies targeting
tumor
-specific antigens expressed by malignant gliomas offers an innovative therapeutic strategy that has recently demonstrated encouraging antitumor activity and acceptable toxicity in clinical trials at a number of centers.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Brain
Neoplasms
/ radiotherapy. Glioma / radiotherapy. Radioimmunotherapy. Tenascin / immunology
[MeSH-minor]
Administration, Topical.
Adult
. Humans
Genetic Alliance.
consumer health - Glioma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17492931.001).
[ISSN]
1744-8328
[Journal-full-title]
Expert review of anticancer therapy
[ISO-abbreviation]
Expert Rev Anticancer Ther
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Tenascin
[Number-of-references]
97
89.
Kino T, Jaffe H, Amin ND, Chakrabarti M, Zheng YL, Chrousos GP, Pant HC:
Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor.
Mol Endocrinol
; 2010 May;24(5):941-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Glucocorticoids, major end effectors of the stress response, play an essential role in the homeostasis of the
central nervous system
(
CNS
) and contribute to memory consolidation and emotional control through their intracellular receptors, the glucocorticoid and mineralocorticoid receptors.
Cyclin-dependent kinase 5 (CDK5), on the other hand, plays important roles in the morphogenesis and functions of the
central nervous system
, and its aberrant activation has been associated with development of neurodegenerative disorders.
COS Scholar Universe.
author profiles
.
Gene Ontology.